

# Management of Immune-Related Adverse Events in Patient with Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

Journal of Clinical Oncology

36, 1714-1768

DOI: [10.1200/jco.2017.77.6385](https://doi.org/10.1200/jco.2017.77.6385)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Excellent treatment response with pembrolizumab in a lung cancer patient who developed immune-mediated acute motor/sensory axonal polyneuropathy. <i>Lung Cancer</i> , 2018, 120, 149-151.	2.0	1
2	Top Ten Tips for Palliative Care Clinicians Caring for Cancer Patients Receiving Immunotherapies. <i>Journal of Palliative Medicine</i> , 2018, 21, 694-699.	1.1	9
3	Avelumab: A Review of Its Application in Metastatic Merkel Cell Carcinoma. <i>Annals of Pharmacotherapy</i> , 2018, 52, 928-935.	1.9	10
4	Kidney Cancer: Toxicity Management, Symptom Control, and Palliative Care. <i>Journal of Clinical Oncology</i> , 2018, 36, 3632-3638.	1.6	2
6	Full Issue PDF Volume 33, Issue 6. <i>Oncology Issues</i> , 2018, 33, 1-84.	0.1	0
7	Cardio-toxicity of checkpoint inhibitors. <i>Journal of Thoracic Disease</i> , 2018, 10, S4400-S4404.	1.4	19
8	Modern concepts in cardio-oncology. <i>Journal of Thoracic Disease</i> , 2018, 10, S4386-S4390.	1.4	13
9	Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity. <i>Journal of Thoracic Disease</i> , 2018, 10, S4282-S4295.	1.4	69
10	Cancer treatment of today in view of the Nobel Prize. <i>Upsala Journal of Medical Sciences</i> , 2018, 123, 205-206.	0.9	0
11	Taking the bull by the horn: the frontline use of infliximab for the treatment of immune checkpoint inhibitor-induced enterocolitis. , 2018, 6, 154.		3
12	Severe pneumonitis refractory to steroids following anti-PD-1 immunotherapy. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2018-225937.	0.5	20
13	Rheumatic immune-related adverse events secondary to anti-“programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series. <i>European Journal of Cancer</i> , 2018, 105, 88-102.	2.8	53
14	Pneumonitis in Patients with Lung Cancer Following Treatment: the Effects of Chemotherapy, Immunotherapy, and Tyrosine Kinase Inhibitors. <i>Current Pulmonology Reports</i> , 2018, 7, 214-219.	1.3	0
15	Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma. , 2018, 6, 124.		89
16	Immune-Related Adverse Events of Immune Checkpoint Inhibitors: A Brief Review. <i>Current Oncology</i> , 2018, 25, 342-347.	2.2	98
17	Checkpoint Inhibitor Pneumonitis “ Real-World Incidence and Risk. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1812-1814.	1.1	10
18	Management of immunotherapy toxicities in older adults. <i>Seminars in Oncology</i> , 2018, 45, 226-231.	2.2	25
19	Review of Immune Therapies Targeting Ovarian Cancer. <i>Current Treatment Options in Oncology</i> , 2018, 19, 74.	3.0	48

#	ARTICLE	IF	CITATIONS
20	Cytokines, Chemokines, and Other Biomarkers of Response for Checkpoint Inhibitor Therapy in Skin Cancer. <i>Frontiers in Medicine</i> , 2018, 5, 351.	2.6	67
21	Recurrent Episodes of Nivolumab-Induced Pneumonitis after Nivolumab Discontinuation and the Time Course of Carcinoembryonic Antigen Levels: A Case of a 58-Year-Old Woman with Non-Small Cell Lung Cancer. <i>Chemotherapy</i> , 2018, 63, 272-277.	1.6	13
22	Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing. <i>Journal of Hematology and Oncology</i> , 2018, 11, 142.	17.0	95
23	Infliximab for treatment-refractory transverse myelitis following immune therapy and radiation. , 2018, 6, 153.		29
24	Skin Reactions to Immune Checkpoint Inhibitors. <i>Advances in Experimental Medicine and Biology</i> , 2018, 995, 117-129.	1.6	15
26	Évaluation, prévention et gestion des toxicités de la chimiothérapie, des anti-angiogéniques et de l'immunothérapie. <i>Revue Des Maladies Respiratoires Actualites</i> , 2018, 10, 398-407.	0.0	0
28	Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study. , 2018, 6, 142.		146
29	Thromboembolic Events Related to Treatment with Checkpoint Inhibitors: Report of Two Cases. <i>Case Reports in Oncology</i> , 2018, 11, 648-653.	0.7	24
31	Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. , 2018, 6, 95.		146
32	Defective DNA repair in hereditary ovarian cancers: Implications for therapy. <i>American Journal of Health-System Pharmacy</i> , 2018, 75, 1697-1707.	1.0	4
33	Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma. <i>Frontiers in Oncology</i> , 2018, 8, 351.	2.8	71
34	Mechanism and Management of Cancer Chemotherapy-Induced Atherosclerosis. <i>Journal of Atherosclerosis and Thrombosis</i> , 2018, 25, 994-1002.	2.0	29
35	Thyroid disorders induced by checkpoint inhibitors. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2018, 19, 325-333.	5.7	87
36	Searching for Oncology-Related Information. <i>Seminars in Oncology Nursing</i> , 2018, 34, 354-360.	1.5	0
37	Liver Toxicity with Cancer Checkpoint Inhibitor Therapy. <i>Seminars in Liver Disease</i> , 2018, 38, 366-378.	3.6	31
38	Current State of Immunotherapy for HCC—Supporting Data and Toxicity Management. <i>Current Hepatology Reports</i> , 2018, 17, 434-443.	0.9	2
39	Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement. , 2018, 6, 108.		16
40	Immune-related adverse events are linked with improved progression-free survival in patients receiving anti-PD-1/PD-L1 therapy. <i>Seminars in Oncology</i> , 2018, 45, 156-163.	2.2	57

#	ARTICLE	IF	CITATIONS
41	Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 2108-2121.	27.0	3,097
42	A man with recurrent hypovolemic shock on anti-“programmed cell death protein 1 treatment: Immune-related protein-losing enteropathy. <i>European Journal of Cancer</i> , 2018, 104, 104-107.	2.8	2
43	Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report. , 2018, 6, 82.		30
44	Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma. <i>Drugs</i> , 2018, 78, 1443-1457.	10.9	70
45	Management of challenging immune-related gastrointestinal adverse events associated with immune checkpoint inhibitors. <i>Future Oncology</i> , 2018, 14, 3187-3198.	2.4	9
46	A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice. <i>Gynecologic Oncology</i> , 2018, 151, 374-380.	1.4	1
47	Complete Clinical Remission of Stage IV Triple-Negative Breast Cancer Lung Metastasis Administering Low-Dose Immune Checkpoint Blockade in Combination With Hyperthermia and Interleukin-2. <i>Integrative Cancer Therapies</i> , 2018, 17, 1297-1303.	2.0	27
48	T lymphocytes as therapeutic arsenal for patients with hematological malignancies. <i>Current Opinion in Oncology</i> , 2018, 30, 425-434.	2.4	4
49	Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases. , 2018, 6, 83.		45
50	Rheumatic immune-related adverse events from cancer immunotherapy. <i>Nature Reviews Rheumatology</i> , 2018, 14, 569-579.	8.0	162
51	Role of Anti-PD-1 Antibodies in Advanced Melanoma: The Era of Immunotherapy. <i>Cureus</i> , 2018, 10, e3700.	0.5	25
52	The ASH Agenda for Hematology Research: a roadmap for advancing scientific discovery and cures for hematologic diseases. <i>Blood Advances</i> , 2018, 2, 2430-2432.	5.2	4
53	Recurrent Pericardial Effusion While Receiving Nivolumab for Metastatic Lung Adenocarcinoma: Case Report and Review of the Literature. <i>Clinical Lung Cancer</i> , 2018, 19, e717-e720.	2.6	16
54	Immune Checkpoint Inhibitor Toxicity Review for the Palliative Care Clinician. <i>Journal of Pain and Symptom Management</i> , 2018, 56, 460-472.	1.2	14
55	Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action. <i>Oncologist</i> , 2018, 23, 874-878.	3.7	89
56	Severe recalcitrant morbilliform eruption from dual immune checkpoint blockade. <i>JAAD Case Reports</i> , 2018, 4, 593-595.	0.8	3
57	Neurosarcoidosis following Immune Checkpoint Inhibition. <i>Case Reports in Oncology</i> , 2018, 11, 521-526.	0.7	30
58	Nivolumab-Induced Hemophilia A Presenting as Gastric Ulcer Bleeding in a Patient With NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, e239-e241.	1.1	17

#	ARTICLE	IF	CITATIONS
59	Management of adverse events related to checkpoint inhibition therapy. Memo - Magazine of European Medical Oncology, 2018, 11, 132-137.	0.5	22
60	Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC. Cancer Immunology Research, 2018, 6, 1093-1099.	3.4	258
61	Defining success with cellular therapeutics: the current landscape for clinical end point and toxicity analysis. Blood, 2018, 131, 2630-2639.	1.4	9
62	ASCO guidelines for AEs due to immune checkpoint inhibitors. Reactions Weekly, 2018, 1691, 4-4.	0.0	0
63	Immune-Related Thyroiditis with Immune Checkpoint Inhibitors. Thyroid, 2018, 28, 1243-1251.	4.5	160
64	Rituximab in the treatment of pembrolizumab-induced myasthenia gravis. European Journal of Cancer, 2018, 102, 49-51.	2.8	18
65	Annals for Hospitalists Inpatient Notes - Clinical Pearlsâ€”A Young Man With Lung Cancer and Diarrhea. Annals of Internal Medicine, 2018, 169, HO2.	3.9	1
66	Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade. Oncologist, 2018, 23, 991-997.	3.7	86
67	Safety of combining radiotherapy with immune-checkpoint inhibition. Nature Reviews Clinical Oncology, 2018, 15, 477-494.	27.6	208
68	Immune checkpoint-mediated myositis and myasthenia gravis: A case report and review of evaluation and management. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2018, 39, 642-645.	1.3	33
69	Myocarditis with tremelimumab plus durvalumab combination therapy for endometrial cancer: A case report. Gynecologic Oncology Reports, 2018, 25, 74-77.	0.6	42
70	Adverse Effects of Immune Checkpoint Therapy in Cancer Patients Visiting the Emergency Department of a Comprehensive Cancer Center. Annals of Emergency Medicine, 2019, 73, 79-87.	0.6	68
71	Checkpoint inhibitors and arthritis: seeking balance between victories and defeats. Annals of the Rheumatic Diseases, 2019, 78, e91-e91.	0.9	4
72	Strategies for Recognizing and Managing Immune-Mediated Adverse Events in the Treatment of Hodgkin Lymphoma with Checkpoint Inhibitors. Oncologist, 2019, 24, 86-95.	3.7	11
73	Response to: â€”Checkpoint inhibitors and arthritis: seeking balance between victories and defeatsâ€” by Moura and Moura. Annals of the Rheumatic Diseases, 2019, 78, e92-e92.	0.9	4
74	Immune checkpoint inhibitor therapy-induced hypophysitis âˆ¼ a case series of Taiwanese patients. Journal of the Formosan Medical Association, 2019, 118, 524-529.	1.7	11
75	Immunotherapy and targeted therapies in older patients with advanced melanoma; Young International Society of Geriatric Oncology review paper. Journal of Geriatric Oncology, 2019, 10, 389-397.	1.0	20
76	Cancer immunotherapy-associated hypophysitis. Future Oncology, 2019, 15, 3159-3169.	2.4	24

#	ARTICLE	IF	CITATIONS
77	Review article: immune checkpoint inhibitors and the liver, from therapeutic efficacy to side effects. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 872-884.	3.7	31
78	A Case of Immunotherapy-Induced Colitis Complicated by Perforation and Treated with Infliximab Postoperatively. <i>Case Reports in Oncological Medicine</i> , 2019, 2019, 1-6.	0.3	8
79	Cancer Therapy-Related Cardiac Dysfunction: An Overview for the Clinician. <i>Clinical Medicine Insights: Cardiology</i> , 2019, 13, 117954681986644.	1.8	98
80	Review of systemic agents in the treatment of advanced cutaneous squamous cell carcinoma. <i>Future Oncology</i> , 2019, 15, 3171-3184.	2.4	11
81	Melanoma Immunology and Immunotherapy. , 2019, , 651-665.		0
82	Immune checkpoint inhibitorsâ€”induced neuromuscular toxicity: From pathogenesis to treatment. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, S74-S85.	3.1	42
83	Fatal Acute Motor Axonal Neuropathy Induced by Nivolumab: A Case Report and Literature Review. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e1104-e1107.	1.9	8
84	Elevated Adenosine Deaminase Levels in the Cerebrospinal Fluid in Immune Checkpoint Inhibitor-induced Autoimmune Encephalitis. <i>Internal Medicine</i> , 2019, 58, 2871-2874.	0.7	18
85	Letter: immune checkpoint inhibitorâ€”induced colitisâ€”shouldn't we be checking more often?. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 472-473.	3.7	1
86	A Review of Immune-Mediated Adverse Events in Melanoma. <i>Oncology and Therapy</i> , 2019, 7, 101-120.	2.6	23
87	Do biomarkers play a predictive role for response to novel immunotherapeutic agents in metastatic renal cell carcinoma?. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 1107-1110.	3.1	6
88	Current state of melanoma diagnosis and treatment. <i>Cancer Biology and Therapy</i> , 2019, 20, 1366-1379.	3.4	462
89	Immune checkpoint inhibitors in non-small cell lung cancer: A bird's eye view. <i>Life Sciences</i> , 2019, 233, 116713.	4.3	42
90	Is Immune Checkpoint Inhibitor Treatment an Option for Patients With Rheumatic Diseases and Cancer?. <i>Arthritis and Rheumatology</i> , 2019, 71, 1971-1973.	5.6	4
91	Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations. <i>Frontiers in Pharmacology</i> , 2019, 10, 726.	3.5	20
92	To treat or not to treat: Patient exclusion in immune oncology clinical trials due to preexisting autoimmune disease. <i>Cancer</i> , 2019, 125, 3506-3513.	4.1	24
93	Diagnosis of immune checkpoint inhibitor-associated myocarditis: A systematic review. <i>International Journal of Cardiology</i> , 2019, 296, 113-121.	1.7	34
94	Emerging trends in immunotherapy for pediatric sarcomas. <i>Journal of Hematology and Oncology</i> , 2019, 12, 78.	17.0	59

#	ARTICLE	IF	CITATIONS
95	Kidney Complications of Immune Checkpoint Inhibitors: A Review. American Journal of Kidney Diseases, 2019, 74, 529-537.	1.9	55
96	Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners. , 2019, , .		0
97	Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: A Bayesian network meta-analysis. Critical Reviews in Oncology/Hematology, 2019, 142, 16-25.	4.4	28
98	Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition. , 2019, 7, 169.		28
100	Acquired Hemophilia A After Nivolumab Therapy in a Patient With Metastatic Squamous Cell Carcinoma of the Lung Successfully Managed With Rituximab. Clinical Lung Cancer, 2019, 20, e560-e563.	2.6	14
101	Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance. , 2019, 7, 165.		135
102	Colitis after checkpoint blockade: A retrospective cohort study of melanoma patients requiring admission for symptom control. Cancer Medicine, 2019, 8, 4986-4999.	2.8	27
103	Pembrolizumab for the treatment of head and neck squamous cell cancer. Expert Opinion on Biological Therapy, 2019, 19, 879-885.	3.1	8
104	Ipilimumab-induced hypophysitis, a single academic center experience. Pituitary, 2019, 22, 488-496.	2.9	28
105	The Impact and Toxicity of Checkpoint Inhibitors in Management of Lung Cancer. , 2019, , 65-84.		0
106	Liver injury is most commonly due to hepatic metastases rather than drug hepatotoxicity during pembrolizumab immunotherapy. Alimentary Pharmacology and Therapeutics, 2019, 50, 800-808.	3.7	60
107	Neurologic Autoimmunity in the Era of Checkpoint Inhibitor Cancer Immunotherapy. Mayo Clinic Proceedings, 2019, 94, 1865-1878.	3.0	49
108	Immunotherapy in Hodgkin Lymphoma: Present Status and Future Strategies. Cancers, 2019, 11, 1071.	3.7	32
109	Outcomes and Quality of Life of Systemic Therapy in Advanced Hepatocellular Carcinoma. Cancers, 2019, 11, 861.	3.7	25
110	Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan Endocrine Society. Endocrine Journal, 2019, 66, 581-586.	1.6	63
111	Rapid temporal improvement of pembrolizumab-induced pneumonitis using the anti-TNF-Î± antibody infliximab. Drug Discoveries and Therapeutics, 2019, 13, 164-167.	1.5	14
112	Immunotherapy Summit: Proceedings and Identified Priorities for Safe Administration and Care. , 2019, 23, E60-E65.		1
113	Noncellular Immune Therapies for Non-Hodgkin Lymphoma. Hematology/Oncology Clinics of North America, 2019, 33, 707-725.	2.2	7

#	ARTICLE	IF	CITATIONS
114	Immune Checkpoint Inhibitor Toxicities. Mayo Clinic Proceedings, 2019, 94, 1321-1329.	3.0	105
115	Immune Checkpoint Inhibitor Therapy: Key Principles When Educating Patients. , 2019, 23, 271-280.		15
116	Pembrolizumab-Induced Obstructive Bronchiolitis in a Patient With Stage IV Non-Small-Cell Lung Cancer. Current Oncology, 2019, 26, 571-573.	2.2	13
117	Exploiting autoimmunity unleashed by low-dose immune checkpoint blockade to treat advanced cancer. Scandinavian Journal of Immunology, 2019, 90, e12821.	2.7	20
118	The mechanisms of acute interstitial nephritis in the era of immune checkpoint inhibitors in melanoma. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591987554.	3.2	21
119	Diagnosis and Management of Immune Related Adverse Events (irAEs) in Cancer Immunotherapy. Biomedicine and Pharmacotherapy, 2019, 120, 109437.	5.6	45
120	Immune checkpoint inhibitors for treatment of thymic epithelial tumors: how to maximize benefit and optimize risk?. Mediastinum, 2019, 3, 35-35.	1.1	38
121	The Relative Risk of Immune-Related Liver Dysfunction of PD-1/PD-L1 Inhibitors Versus Chemotherapy in Solid Tumors: A Meta-Analysis of Randomized Controlled Trials. Frontiers in Pharmacology, 2019, 10, 1063.	3.5	7
122	The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 1692-1700.	4.5	193
123	Budesonide treatment for microscopic colitis from immune checkpoint inhibitors. , 2019, 7, 292.		63
124	Immune Checkpoint Inhibitor Toxicity in Head and Neck Cancer: From Identification to Management. Frontiers in Pharmacology, 2019, 10, 1254.	3.5	21
125	Adverse Events of Concurrent Immune Checkpoint Inhibitors and Antiangiogenic Agents: A Systematic Review. Frontiers in Pharmacology, 2019, 10, 1173.	3.5	35
126	Increased reporting of fatal hepatitis associated with immune checkpoint inhibitors. European Journal of Cancer, 2019, 123, 112-115.	2.8	17
129	Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?. European Journal of Cancer, 2019, 122, 72-90.	2.8	97
130	Closing the survivorship gap in children and adolescents with Hodgkin lymphoma. British Journal of Haematology, 2019, 187, 573-587.	2.5	15
131	Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab. BMC Cancer, 2019, 19, 974.	2.6	104
132	Study on the Rule of Concrete Corrosion in Harsh Environment. IOP Conference Series: Earth and Environmental Science, 2019, 304, 052002.	0.3	1
133	High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer. Thoracic Cancer, 2019, 10, 2006-2012.	1.9	52



#	ARTICLE	IF	CITATIONS
134	Editorial: liver test abnormalities in oncology patients in the age of the checkpoint inhibitors. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 831-832.	3.7	0
135	Challenge of Rechallenge: When to Resume Immunotherapy Following an Immune-Related Adverse Event. <i>Journal of Clinical Oncology</i> , 2019, 37, 2714-2718.	1.6	23
137	Myasthenia gravis and myopathy after nivolumab treatment for non-small cell lung carcinoma: A case report. <i>Thoracic Cancer</i> , 2019, 10, 2045-2049.	1.9	12
138	Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know?. <i>Annals of Intensive Care</i> , 2019, 9, 25.	4.6	46
139	Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy. <i>Seminars in Cancer Biology</i> , 2019, 59, 290-297.	9.6	78
140	Checkpoint Inhibition and Infectious Diseases: A Good Thing?. <i>Trends in Molecular Medicine</i> , 2019, 25, 1080-1093.	6.7	37
141	C-reactive protein as an early marker of immune-related adverse events. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2625-2631.	2.5	59
142	Non-canonical Expression of Cardiac Troponin-T in Neuroendocrine Ethmoid Sinus Carcinoma Following Immune Checkpoint Blockade. <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 124.	2.4	5
143	Best Practice in Systemic Therapy for Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 815.	2.8	53
144	The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481986976.	3.2	31
145	Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective study. <i>European Journal of Cancer</i> , 2019, 120, 122-131.	2.8	76
146	Cardiotoxicity from immune checkpoint inhibitors. <i>IJC Heart and Vasculature</i> , 2019, 25, 100420.	1.1	79
147	Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor-related Pneumonitis. An Official American Thoracic Society Research Statement. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, e31-e43.	5.6	97
148	Erosive Deforming Inflammatory Arthritis in a Patient With Cervical Adenocarcinoma. <i>JAMA Oncology</i> , 2019, 5, 1628.	7.1	5
149	Cardiovascular Toxicities of Immune Checkpoint Inhibitors. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1714-1727.	2.8	124
150	Cerebrospinal fluid lymphocytosis: a hallmark of neurological complications during checkpoint inhibition. <i>European Journal of Cancer</i> , 2019, 121, 1-3.	2.8	2
151	Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies. <i>Neurology</i> , 2019, 93, e1093-e1103.	1.1	107
152	Immune-Mediated Therapies in Lymphoma. <i>Seminars in Oncology Nursing</i> , 2019, 35, 150925.	1.5	0

#	ARTICLE	IF	CITATIONS
153	Acute and Long-term Adverse Events Associated With Checkpoint Blockade. <i>Seminars in Oncology Nursing</i> , 2019, 35, 150926.	1.5	7
154	Immune Checkpoint Inhibitors in Lung Cancer and Melanoma. <i>Seminars in Oncology Nursing</i> , 2019, 35, 150932.	1.5	34
155	Eltrombopag treatment for severe refractory thrombocytopenia caused by pembrolizumab. <i>European Journal of Cancer</i> , 2019, 121, 4-6.	2.8	13
156	Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 947-951.	3.1	58
157	Case Series of Ventricular Tachycardia and Myocarditis From Programmed Cell-Death Protein-1 Inhibitor Treated With Infliximab. <i>JACC: Clinical Electrophysiology</i> , 2019, 5, 989-992.	3.2	5
158	Pericardial effusion due to pembrolizumab-induced immunotoxicity: A case report and literature review. <i>Current Problems in Cancer</i> , 2019, 43, 504-510.	2.0	16
159	Addressing immune-related adverse events of cancer immunotherapy: how prepared are rheumatologists?. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 860-862.	0.9	14
160	The Risks and Benefits of Immune Checkpoint Blockade in Anti-AChR Antibody-Seropositive Non-Small Cell Lung Cancer Patients. <i>Cancers</i> , 2019, 11, 140.	3.7	18
161	Further Considerations of the Need for Integrated Mental Health Treatment in Rheumatoid Arthritis Patients: Comment on the Review by Matcham et al. <i>Arthritis and Rheumatology</i> , 2019, 71, 1024-1025.	5.6	4
162	Immunotherapy Toxicity. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 275-290.	2.2	23
163	Biological Effects of Nanoparticles on Macrophage Polarization in the Tumor Microenvironment. <i>Nanotheranostics</i> , 2019, 3, 66-88.	5.2	121
164	Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports. <i>Clinical Diabetes and Endocrinology</i> , 2019, 5, 1.	2.7	125
165	Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor-induced inflammatory arthritis. <i>Clinical Rheumatology</i> , 2019, 38, 1513-1519.	2.2	44
166	Gastrointestinal Bleeding in Critically Ill Cancer Patients. , 2019, , 1-12.		1
167	Cardiovascular toxicities associated with immune checkpoint inhibitors. <i>Cardiovascular Research</i> , 2019, 115, 854-868.	3.8	311
168	Nivolumab-induced Myocarditis Successfully Treated with Corticosteroid Therapy: A Case Report and Review of the Literature. <i>Internal Medicine</i> , 2019, 58, 2367-2372.	0.7	16
169	Unexpected serious aplastic anemia from PD-1 inhibitors: beyond what we know. <i>Tumori</i> , 2019, 105, NP48-NP51.	1.1	8
170	Checkpoint Inhibitors. <i>Deutsches A&amp;#x0308;rzblatt International</i> , 2019, 116, 119-126.	0.9	83

#	ARTICLE	IF	CITATIONS
171	Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019. <i>European Urology</i> , 2019, 76, 368-380.	1.9	48
172	Mechanisms of immune-related adverse events associated with immune checkpoint blockade: using germline genetics to develop a personalized approach. <i>Genome Medicine</i> , 2019, 11, 39.	8.2	62
173	Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer. <i>JAMA Oncology</i> , 2019, 5, 1310.	7.1	268
174	Cardiotoxicity of Immune Checkpoint Inhibitors. Current Treatment Options in Cardiovascular Medicine, 2019, 21, 32.	0.9	42
175	Targeting Tumors with IL-10 Prevents Dendritic Cell-Mediated CD8+ T Cell Apoptosis. <i>Cancer Cell</i> , 2019, 35, 901-915.e4.	16.8	98
176	Cascade of immunologic adverse events related to pembrolizumab treatment. <i>BMJ Case Reports</i> , 2019, 12, e229149.	0.5	17
177	Pediatric Cardio-Oncology: Development of Cancer Treatment-Related Cardiotoxicity and the Therapeutic Approach to Affected Patients. <i>Current Treatment Options in Oncology</i> , 2019, 20, 56.	3.0	17
178	Three cases of immune cholangitis related to anti-CD137 programmed cell death and programmed cell death ligand agents for the treatment of non-small cell lung cancer. <i>European Journal of Cancer</i> , 2019, 115, 107-110.	2.8	20
179	New oncologic emergencies: What is there to know about immunotherapy and its potential side effects?. <i>European Journal of Internal Medicine</i> , 2019, 66, 1-8.	2.2	19
180	Immunotherapy, cancer and rheumatic diseases. <i>Reumatologia Clínica (English Edition)</i> , 2019, 15, 249-251.	0.3	0
181	Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2560.	4.1	72
182	Disorder of Coagulation-Fibrinolysis System: An Emerging Toxicity of Anti-PD-1/PD-L1 Monoclonal Antibodies. <i>Journal of Clinical Medicine</i> , 2019, 8, 762.	2.4	53
184	Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis. <i>Journal of Clinical Oncology</i> , 2019, 37, 2738-2745.	1.6	138
185	Nivolumab-induced Thyroid Dysfunctions in Patients with Previously Treated Non-small Cell Lung Cancer. <i>Interdisciplinary Sciences, Computational Life Sciences</i> , 2019, 11, 287-291.	3.6	1
186	Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis. <i>New England Journal of Medicine</i> , 2019, 380, 2377-2379.	27.0	296
187	The role of combination chemo-immunotherapy in advanced non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 561-568.	2.4	58
188	Hematological Side Effects of Immune Checkpoint Inhibitors: The Example of Immune-Related Thrombocytopenia. <i>Frontiers in Pharmacology</i> , 2019, 10, 454.	3.5	35
189	Infliximab for the treatment of refractory immune-related hepatitis secondary to checkpoint inhibitors: A case report. <i>JHEP Reports</i> , 2019, 1, 66-69.	4.9	23

#	ARTICLE	IF	CITATIONS
190	Challenge of immune-mediated adverse reactions in the emergency department. <i>Emergency Medicine Journal</i> , 2019, 36, 369-377.	1.0	10
191	Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment. , 2019, 7, 118.		26
192	Pain in Cancer Survivors: How to Manage. <i>Current Treatment Options in Oncology</i> , 2019, 20, 48.	3.0	18
193	The American Cancer Society 2035 challenge goal on cancer mortality reduction. <i>Ca-A Cancer Journal for Clinicians</i> , 2019, 69, 351-362.	329.8	49
194	Evolving Landscape of Systemic Therapy for Hepatocellular Carcinoma: Breakthroughs, Toxicities, and Future Frontiers. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 248-260.	3.8	8
195	Immunotherapy in Older Adults: A Checkpoint to Palliation?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, e110-e120.	3.8	11
196	Managing Immuno-Oncology Toxicity: Top 10 Innovative Institutional Solutions. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 96-104.	3.8	22
197	Recurrent Pneumonitis in Patients with Melanoma Treated with Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2019, 24, 640-647.	3.7	32
198	Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 538-545.	1.5	51
199	Efficacy and safety of immune checkpoint inhibitors in a Danish real life non-small cell lung cancer population: a retrospective cohort study. <i>Acta OncolÃ³gica</i> , 2019, 58, 953-961.	1.8	35
200	The Impact of High-Dose Glucocorticoids on the Outcome of Immune-Checkpoint Inhibitor-Related Thyroid Disorders. <i>Cancer Immunology Research</i> , 2019, 7, 1214-1220.	3.4	44
201	Identification and Management of Immune Checkpoint Inhibitor-Related Myocarditis: Use Troponin Wisely. <i>Journal of Clinical Oncology</i> , 2019, 37, 2201-2205.	1.6	39
202	The 2018 Nobel Prize in Medicine for breakthroughs in targeting immune checkpoint inhibitors: a brief perspective. <i>Antibody Therapeutics</i> , 2019, 2, 40-43.	1.9	2
203	Treating Penile Cancer in the Immunotherapy and Targeted Therapy Era. <i>Case Reports in Oncological Medicine</i> , 2019, 2019, 1-4.	0.3	10
204	Updates in Local-Regionally Advanced Non-Small Cell Lung Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 553-562.	3.8	13
205	Severe pulmonary toxicity from immune checkpoint inhibitor treated successfully with intravenous immunoglobulin: Case report and review of the literature. <i>Respiratory Medicine Case Reports</i> , 2019, 27, 100834.	0.4	25
206	Concerns Regarding Phase 1b Clinical Trial of Atezolizumab Plus Nab-Paclitaxel for Metastatic Breast Cancer-In Reply. <i>JAMA Oncology</i> , 2019, 5, 908.	7.1	1
207	Beyond PD-L1 Markers for Lung Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1915.	4.1	61

#	ARTICLE	IF	CITATIONS
208	AKI in Patients Receiving Immune Checkpoint Inhibitors. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 1077-1079.	4.5	34
209	Exacerbation of Previously Undiagnosed Bird Fancier's Lung by Pembrolizumab Therapy. <i>Chest</i> , 2019, 155, e79-e82.	0.8	4
210	Immune-checkpoint inhibition for metastatic triple-negative breast cancer: safety first?. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 399-400.	27.6	44
211	Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials. <i>JAMA Oncology</i> , 2019, 5, 1008.	7.1	526
212	Systematic review and case series: flexible sigmoidoscopy identifies most cases of checkpoint inhibitor-induced colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1474-1483.	3.7	38
213	Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities. <i>Trends in Immunology</i> , 2019, 40, 511-523.	6.8	180
214	Expanding Therapeutic Options for Older Adults: Case-Based Updates in Breast and Lung Cancer. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 1012-1019.	2.6	2
215	New causes of hypophysitis. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2019, 33, 101276.	4.7	24
216	Implications of Immunotherapy in Hepatobiliary Tumors. <i>Visceral Medicine</i> , 2019, 35, 18-26.	1.3	6
217	New treatment-induced adverse effects we need to learn as modern hepatologists. <i>Hepatology International</i> , 2019, 13, 391-394.	4.2	0
218	Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement. <i>Journal of Clinical Oncology</i> , 2019, 37, 72-80.	1.6	17
219	From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy. <i>Advances in Cancer Research</i> , 2019, 143, 63-144.	5.0	52
220	Sequential Blockade of PD-1 and PD-L1 Causes Fulminant Cardiotoxicity—From Case Report to Mouse Model Validation. <i>Cancers</i> , 2019, 11, 580.	3.7	28
221	Immunotherapy causing pneumonitis in a patient with non-small cell lung cancer (NSCLC). <i>BMJ Case Reports</i> , 2019, 12, e226044.	0.5	3
223	Lymphocytic colitis-like pattern of mucosal injury and the challenges in diagnosing cancer immunotherapy-related toxicity. <i>Cancer</i> , 2019, 125, 1768-1770.	4.1	5
224	PD-1 Inhibitors-Related Neurological Toxicities in Patients with Non-Small-Cell Lung Cancer: A Literature Review. <i>Cancers</i> , 2019, 11, 296.	3.7	33
225	Eruptive porokeratosis under nivolumab adjuvant treatment for melanoma. <i>International Journal of Dermatology</i> , 2019, 58, e138-e140.	1.0	6
226	Acute Respiratory Failure in the Oncologic Patient: New Era, New Issues. <i>Annual Update in Intensive Care and Emergency Medicine</i> , 2019, , 31-45.	0.2	1

#	ARTICLE	IF	CITATIONS
227	Patient-Reported Outcomes for Cancer Patients Receiving Checkpoint Inhibitors: Opportunities for Palliative Care—A Systematic Review. <i>Journal of Pain and Symptom Management</i> , 2019, 58, 137-156.e1.	1.2	39
228	How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer. <i>Annals of Oncology</i> , 2019, 30, 884-896.	1.2	78
229	Immunotherapy-related hepatitis: real-world experience from a tertiary centre. <i>Frontline Gastroenterology</i> , 2019, 10, 364-371.	1.8	65
230	Cytometric cell-based assays for anti-striational antibodies in myasthenia gravis with myositis and/or myocarditis. <i>Scientific Reports</i> , 2019, 9, 5284.	3.3	28
231	A Case of Anti-“PD-L1-associated Remitting Seronegative Symmetric Synovitis With Pitting Edema. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e549-e552.	1.9	5
232	Nivolumab-induced interstitial lung disease in a patient with gastric cancer. <i>Oxford Medical Case Reports</i> , 2019, 2019, omz007.	0.4	3
233	Inflammatory myopathy associated with PD-1 inhibitors. <i>Journal of Autoimmunity</i> , 2019, 100, 105-113.	6.5	73
234	Secondary sclerosing cholangitis with hemobilia induced by pembrolizumab: Case report and review of published work. <i>Hepatology Research</i> , 2019, 49, 950-956.	3.4	31
235	New and Novel Therapies for Gynecologic Cancers. <i>Seminars in Oncology Nursing</i> , 2019, 35, 217-219.	1.5	10
236	Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 535-548.	27.6	186
237	Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 917-926.	4.2	59
238	Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program. , 2019, 7, 99.		110
239	Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the Literature. <i>Case Reports in Oncology</i> , 2019, 12, 260-276.	0.7	63
240	Systemic treatment of advanced esophageal squamous cell carcinoma: chemotherapy, molecular-targeting therapy and immunotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 412-420.	1.3	110
241	Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System. <i>Targeted Oncology</i> , 2019, 14, 205-221.	3.6	72
242	Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities. <i>Gastroenterology</i> , 2019, 156, 2056-2072.	1.3	300
243	Management of Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitor Therapy: A Minireview of Current Clinical Guidelines. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2019, 6, 154-160.	1.6	79
244	First Case of Cytokine Release Syndrome after Nivolumab for Gastric Cancer. <i>Case Reports in Oncology</i> , 2019, 12, 147-156.	0.7	28

#	ARTICLE	IF	CITATIONS
245	Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor–induced colitis. , 2019, 7, 93.		131
246	<p><p>A case of small-cell lung cancer with adrenocorticotrophic hormone deficiency induced by nivolumab</p>. OncoTargets and Therapy, 2019, Volume 12, 2181-2186.	2.0	4
247	Can an amino acid-based oral rehydration solution be effective in managing immune therapy-induced diarrhea?. Medical Hypotheses, 2019, 127, 66-70.	1.5	5
248	Thyroid dysfunction induced by nivolumab: searching for disease patterns and outcomes. Endocrine, 2019, 64, 605-613.	2.3	46
249	Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial. , 2019, 7, 30.		68
251	Balancing the Checkpoint: Managing Colitis Associated with Dual Checkpoint Inhibitors and High-Dose Aspirin. Digestive Diseases and Sciences, 2019, 64, 685-688.	2.3	1
252	Prevalence and Clinical Patterns of Ocular Complications Associated With Anti-PD-1/PD-L1 Anticancer Immunotherapy. American Journal of Ophthalmology, 2019, 202, 109-117.	3.3	62
253	Can functional status predict for lack of benefit for immunotherapy in advanced malignancies?. Journal of Cancer Policy, 2019, 20, 100183.	1.4	0
254	Case of fulminant type 1 diabetes induced by the anti–programmed death–ligand 1 antibody, avelumab. Journal of Diabetes Investigation, 2019, 10, 1385-1387.	2.4	10
255	Myalgia and Arthralgia Immune-related Adverse Events (irAEs) in Patients With Genitourinary Malignancies Treated With Immune Checkpoint Inhibitors. Clinical Genitourinary Cancer, 2019, 17, 177-182.	1.9	11
256	Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury. , 2019, 7, 31.		94
257	Antitumor response to microscopic melanoma in the gastric mucosa mimicking ipilimumab-induced gastritis. , 2019, 7, 41.		10
258	Immunotherapy and radiotherapy for metastatic cancers. Annals of Palliative Medicine, 2019, 8, 312-325.	1.2	33
259	Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors. American Journal of Hematology, 2019, 94, 563-574.	4.1	51
260	The pioneers behind immune checkpoint blockers awarded the Nobel Prize in physiology or medicine 2018. Acta Oncologica, 2019, 58, 1-8.	1.8	14
261	Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis. Oncologist, 2019, 24, 955-962.	3.7	28
262	Immunotherapy for skin cancer. International Immunology, 2019, 31, 465-475.	4.0	47
263	Cold agglutinin disease as a new immune-related adverse event associated with anti-PD-L1s and its treatment with rituximab. European Journal of Cancer, 2019, 110, 21-23.	2.8	10

#	ARTICLE	IF	CITATIONS
265	Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal?. <i>Oncologist</i> , 2019, 24, e1148-e1155.	3.7	81
266	Nivolumab-induced large-duct cholangiopathy treated with ursodeoxycholic acid and tocilizumab. <i>Immunotherapy</i> , 2019, 11, 1527-1531.	2.0	12
267	Treatment of unresectable cutaneous squamous cell carcinoma with pembrolizumab. <i>BMJ Case Reports</i> , 2019, 12, e229915.	0.5	1
268	The new revolution of immunotherapy: is it time to pair it with the old one? "Yellow Leader as a candidate. <i>Longhua Chinese Medicine</i> , 2019, 2, 7-7.	0.5	0
269	A Case of Long-Term Survival after Checkpoint Inhibitor Pneumonitis in a Patient with Squamous Cell Lung Cancer. <i>Case Reports in Oncological Medicine</i> , 2019, 2019, 1-4.	0.3	2
270	Nivolumab-Induced, Late-Onset, Steroid-Sensitive, High-Grade Pneumonitis and Durable Tumor Suppression in Metastatic Renal Cell Carcinoma: A Case Report. <i>Case Reports in Oncological Medicine</i> , 2019, 2019, 1-5.	0.3	2
271	Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors. <i>Oncologist</i> , 2019, 24, 1128-1136.	3.7	156
272	Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy. <i>Oncologist</i> , 2019, 24, 1259-1269.	3.7	127
273	Traitements de première ligne dans les CBNPC avancés, en l'absence d'addiction oncogénique (incluant) Tj ETQqO 0 0 rgBT 2019, 11, 342-354.	0.0	0
274	Toxicity of tumor immune checkpoint inhibitors"more attention should be paid. <i>Translational Lung Cancer Research</i> , 2019, 8, 1125-1133.	2.8	7
275	Managing Pulmonary Toxicities Associated with Immunotherapy: A Case Discussion. <i>Oncologist</i> , 2019, 24, 730-734.	3.7	9
276	Myocarditis Surveillance in Patients with Advanced Melanoma on Combination Immune Checkpoint Inhibitor Therapy: The Memorial Sloan Kettering Cancer Center Experience. <i>Oncologist</i> , 2019, 24, e196-e197.	3.7	31
277	Isolated adrenocorticotrophic hormone (ACTH) deficiency and Guillain-Barré syndrome occurring in a patient treated with nivolumab. <i>BMJ Case Reports</i> , 2019, 12, e230848.	0.5	12
278	Caring for Patients Treated With Checkpoint Inhibitors for the Treatment of Metastatic Merkel Cell Carcinoma. <i>Seminars in Oncology Nursing</i> , 2019, 35, 150924.	1.5	1
279	PD-1 Inhibitors: Safety of Use and Management of Immune-Mediated Adverse Reactions in Patients With Head and Neck Cancer. <i>Clinical Journal of Oncology Nursing</i> , 2019, 23, 627-638.	0.6	1
280	Cutaneous and Pulmonary Sarcoid-Like Reaction Induced by Nivolumab. <i>Journal of Clinical Rheumatology</i> , 2021, 27, S460-S464.	0.9	7
281	Immunotherapy-induced endocrinopathies: assessment, management and monitoring. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2019, 10, 204201881989618.	3.2	29
282	Immune Checkpoint Inhibitor-Related Adverse Cardiovascular Events in Patients With Lung Cancer. <i>JACC: CardioOncology</i> , 2019, 1, 182-192.	4.0	47



#	ARTICLE	IF	CITATIONS
283	Immune Checkpoint Inhibitor-Related Cardiovascular Toxicity in Lung Cancer. <i>JACC: CardioOncology</i> , 2019, 1, 193-195.	4.0	1
284	Update on Ocular Myasthenia Gravis. <i>Seminars in Neurology</i> , 2019, 39, 749-760.	1.4	15
285	Cardiac tamponade in a patient with stage IV lung adenocarcinoma treated with pembrolizumab. <i>Immunotherapy</i> , 2019, 11, 1533-1540.	2.0	11
287	A Case of Severe Seronegative Inflammatory Arthritis due to Nivolumab and Review of the Literature. <i>Case Reports in Rheumatology</i> , 2019, 2019, 1-9.	0.6	2
288	Ten-year Clinical Trends among 575 Consecutive Oral Cancer Patients at Tokyo Dental College Oral Cancer Center. <i>Bulletin of Tokyo Dental College</i> , The, 2019, 60, 251-260.	0.5	1
289	Anti-programmed Death-1 Immunotherapy for Endometrial Cancer with Microsatellite Instability-High Tumors. <i>Current Treatment Options in Oncology</i> , 2019, 20, 83.	3.0	11
290	Immune-Mediated Colitis. <i>Current Treatment Options in Gastroenterology</i> , 2019, 17, 506-523.	0.8	6
291	The Gut Microbiome and Immune Modulation in The Treatment of Malignancy. , 2019, 04, .		0
292	Cancer Treatment-Associated Pericardial Disease: Epidemiology, Clinical Presentation, Diagnosis, and Management. <i>Current Cardiology Reports</i> , 2019, 21, 156.	2.9	36
293	Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. , 2019, 7, 319.		164
294	Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition. , 2019, 7, 322.		122
295	Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibition. <i>Current Oncology Reports</i> , 2019, 21, 108.	4.0	46
296	Aseptic Meningitis as an Immune-Related Adverse Event after Pembrolizumab. <i>Case Reports in Oncological Medicine</i> , 2019, 2019, 1-2.	0.3	11
297	Immune Checkpoint Inhibitor Associated Rheumatic Adverse Events: a Review of Their Presentations and Treatments. <i>Current Treatment Options in Rheumatology</i> , 2019, 5, 272-289.	1.4	2
298	Nivolumab and Ipilimumab-induced Acute Inflammatory Demyelinating Polyradiculoneuropathy: A Case Report. <i>Journal of Immunotherapy</i> , 2019, 42, 348-349.	2.4	4
299	Immune-related pancreatitis associated with checkpoint blockade in melanoma. <i>Melanoma Research</i> , 2019, 29, 549-552.	1.2	19
300	Checkpoint Inhibitor-Associated Autoimmunity. <i>Journal of Clinical Rheumatology</i> , 2019, Publish Ahead of Print, .	0.9	0
301	Immunotherapy in metastatic melanoma: a novel scenario of new toxicities and their management. <i>Melanoma Management</i> , 2019, 6, MMT30.	0.5	19

#	ARTICLE	IF	CITATIONS
302	New Frontiers for Molecular Pathology. <i>Frontiers in Medicine</i> , 2019, 6, 284.	2.6	21
303	Severe Immune-Related Pneumonitis With PD-1 Inhibitor After Progression on Previous PD-L1 Inhibitor in Small Cell Lung Cancer: A Case Report and Review of the Literature. <i>Frontiers in Oncology</i> , 2019, 9, 1437.	2.8	13
304	Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management. <i>Frontiers in Pharmacology</i> , 2019, 10, 1350.	3.5	75
305	Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports. <i>BMC Endocrine Disorders</i> , 2019, 19, 144.	2.2	24
306	Enteritis with immune checkpoint inhibitor use. <i>Cmaj</i> , 2019, 191, E1106-E1106.	2.0	5
307	Management of pulmonary toxicity associated with immune checkpoint inhibitors. <i>European Respiratory Review</i> , 2019, 28, 190012.	7.1	54
308	Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment. <i>Expert Review of Endocrinology and Metabolism</i> , 2019, 14, 381-398.	2.4	54
309	Cardiac toxicities of anticancer treatments. <i>Current Opinion in Cardiology</i> , 2019, 34, 441-450.	1.8	16
310	Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer. <i>European Respiratory Review</i> , 2019, 28, 190058.	7.1	73
313	Three case reports. <i>Medicine (United States)</i> , 2019, 98, e18098.	1.0	7
314	Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study. , 2019, 7, 337.		75
315	A Celiac Disease Phenotype After Checkpoint Inhibitor Exposure: An Example of Immune Dysregulation After Immunotherapy. <i>ACG Case Reports Journal</i> , 2019, 6, e00158.	0.4	12
316	Immune checkpoint inhibitor myocarditis. <i>Current Opinion in Cardiology</i> , 2019, 34, 303-306.	1.8	13
317	Management of rheumatic complications of immune checkpoint inhibitor therapy “ an oncological perspective. <i>Rheumatology</i> , 2019, 58, vii29-vii39.	1.9	22
319	Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature. <i>Oncologist</i> , 2019, 24, 435-443.	3.7	80
320	Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer. <i>Oncologist</i> , 2019, 24, 1453-1461.	3.7	75
321	Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review. <i>Oncologist</i> , 2019, 24, 735-742.	3.7	43
322	Characteristics and clinical course of type 1 diabetes mellitus related to anti-programmed cell death-1 therapy. <i>Diabetology International</i> , 2019, 10, 58-66.	1.4	65

#	ARTICLE	IF	CITATIONS
323	Managing immune dysregulation resulting from immune checkpoint inhibitors: impact of the ASCO guidelines and key take-homes for immunologists. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 211-213.	3.0	5
324	Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors. <i>European Journal of Cancer</i> , 2019, 107, 8-14.	2.8	127
325	Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy. <i>Journal of Thoracic Oncology</i> , 2019, 14, 494-502.	1.1	114
326	Peripheral nervous system involvement in lymphomas. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 5-18.	3.1	44
327	Dramatic response of nivolumab-associated psoriasiform dermatitis to etoposide. <i>European Journal of Cancer</i> , 2019, 107, 97-99.	2.8	12
328	Rheumatologic symptoms and checkpoint inhibitor “Stop pain or stop cancer?”. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, e8.	3.4	1
329	Differential effects of corticosteroids and anti-CTNF on tumor-specific immune responses: implications for the management of irAEs. <i>International Journal of Cancer</i> , 2019, 145, 1408-1413.	5.1	36
330	Cancer Immunotherapy: Beyond Checkpoint Blockade. <i>Annual Review of Cancer Biology</i> , 2019, 3, 55-75.	4.5	102
331	Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice. <i>Clinical Colorectal Cancer</i> , 2019, 18, e117-e129.	2.3	53
332	Current status of immunotherapy in metastatic colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2019, 34, 13-25.	2.2	106
333	Evolution and recurrence of gastrointestinal immune-related adverse events induced by immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2019, 106, 106-114.	2.8	41
334	Emerging Role of Combination Immunotherapy in the First-line Treatment of Advanced Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2019, 5, 411.	7.1	63
335	Causes of acute respiratory failure in the immunocompromised host. <i>Current Opinion in Critical Care</i> , 2019, 25, 21-28.	3.2	9
336	Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer. <i>Drug Safety</i> , 2019, 42, 281-294.	3.2	69
337	Management of immune-related adverse events resulting from immune checkpoint blockade. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 209-222.	2.4	20
338	Guillain-Barré Syndrome Related to Nivolumab: Case Report of a Patient With Urothelial Cancer and Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e360-e364.	1.9	9
339	Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience. , 2019, 7, 2.		213
340	Evaluation of arthralgias in adult oncology patients receiving immune checkpoint inhibitors. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1867-1872.	0.9	5

#	ARTICLE	IF	CITATIONS
341	Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 429-443.	2.5	13
342	A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma. <i>Current Urology Reports</i> , 2019, 20, 1.	2.2	63
343	Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease. <i>International Journal of Cardiology</i> , 2019, 280, 163-175.	1.7	138
344	Adverse events associated with immune checkpoint inhibitor treatment for cancer. <i>Cmaj</i> , 2019, 191, E40-E46.	2.0	36
345	Medical oncologists must get more involved in systemic treatment. <i>Annals of Oncology</i> , 2019, 30, 6-8.	1.2	2
346	Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints. <i>Endocrine Reviews</i> , 2019, 40, 17-65.	20.1	349
347	Cases from the irAE Tumor Board: A Multidisciplinary Approach to a Patient Treated with Immune Checkpoint Blockade Who Presented with a New Rash. <i>Oncologist</i> , 2019, 24, 4-8.	3.7	7
348	Fulminant Myocarditis Caused by an Immune Checkpoint Inhibitor: A Case Report With Pathologic Findings. <i>Journal of Thoracic Oncology</i> , 2019, 14, e36-e38.	1.1	22
349	Italian expert panel consensus statement on the optimal use of PD-1 blockade therapy in classical Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 1204-1213.	1.3	4
350	Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 511-521.	2.5	153
351	Characterisation of rare haematological immune-related toxicities. <i>Lancet Haematology</i> , 2019, 6, e10-e11.	4.6	0
352	Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. <i>Lancet Haematology</i> , 2019, 6, e48-e57.	4.6	195
353	Rheumatic Syndromes Associated With Immune Checkpoint Inhibitors: A Single-Center Cohort of Sixty-One Patients. <i>Arthritis and Rheumatology</i> , 2019, 71, 468-475.	5.6	104
354	Addressing New Diagnostic and Treatment Challenges Associated With a New Age of Cancer Treatment. <i>Annals of Emergency Medicine</i> , 2019, 73, 88-90.	0.6	8
355	Rheumatic diseases associated with immune checkpoint inhibitors in cancer immunotherapy. <i>Modern Rheumatology</i> , 2019, 29, 721-732.	1.8	10
356	Checkpoint inhibitor-associated immune arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e68-e68.	0.9	27
358	Pembrolizumab-induced mucositis in a patient with recurrent hypopharynx squamous cell cancer. <i>Laryngoscope</i> , 2020, 130, E140-E143.	2.0	8
359	Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis. <i>Seminars in Cancer Biology</i> , 2020, 64, 29-35.	9.6	76

#	ARTICLE	IF	CITATIONS
360	Nivolumab-induced type 1 diabetes mellitus as an immune-related adverse event. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 236-239.	0.9	14
361	Ocular Adverse Events following Use of Immune Checkpoint Inhibitors for Metastatic Malignancies. <i>Ocular Immunology and Inflammation</i> , 2020, 28, 854-859.	1.8	52
362	Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 337-345.	3.3	33
363	Dermatology consultation reduces interruption of oncologic management among hospitalized patients with immune-related adverse events: A retrospective cohort study. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 994-996.	1.2	16
364	Adverse Events of Novel Therapies for Hematologic Malignancies: What Emergency Physicians Should Know. <i>Annals of Emergency Medicine</i> , 2020, 75, 264-286.	0.6	3
365	Immune-related dermatologic toxicities: to make a long story short. <i>Cutaneous and Ocular Toxicology</i> , 2020, 39, 10-12.	1.3	1
367	Perspectives on Treatment of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitor Therapy. <i>Oncologist</i> , 2020, 25, 33-45.	3.7	87
368	Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist. <i>Journal of Rheumatology</i> , 2020, 47, 166-175.	2.0	47
369	Retinal Vasculitis Associated with Ipilimumab. <i>Ocular Immunology and Inflammation</i> , 2020, 28, 868-870.	1.8	20
370	Immune-related adverse events in the gastrointestinal tract: diagnostic utility of upper gastrointestinal biopsies. <i>Histopathology</i> , 2020, 76, 233-243.	2.9	66
371	Thyroid Dysfunction, Recovery, and Prognosis in Melanoma Patients Treated with Immune Checkpoint Inhibitors: A Retrospective Review. <i>Endocrine Practice</i> , 2020, 26, 36-42.	2.1	20
372	Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immuno-oncology. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1461-1475.	1.7	57
373	Local therapy for cancer therapy-associated uveitis: a case series and review of the literature. <i>British Journal of Ophthalmology</i> , 2020, 104, 703-711.	3.9	20
374	Immune-mediated adverse events following influenza vaccine in cancer patients receiving immune checkpoint inhibitors. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 647-654.	0.9	21
375	Fatal Simultaneous Multi-organ Failure Following Pembrolizumab Treatment for Refractory Thymoma. <i>Clinical Lung Cancer</i> , 2020, 21, e74-e77.	2.6	16
376	Clinical and Morphological Characteristics of Anti-Programmed Death Ligand 1-Associated Retinopathy. <i>Ophthalmology Retina</i> , 2020, 4, 446-450.	2.4	15
377	Principles of Immunotherapy in Melanoma. <i>Surgical Clinics of North America</i> , 2020, 100, 161-173.	1.5	28
378	Successful Retreatment Using Pembrolizumab for Non-small-cell Lung Cancer After Severe Immune-related Hepatitis: A Case Report. <i>Clinical Lung Cancer</i> , 2020, 21, e30-e32.	2.6	5

#	ARTICLE	IF	CITATIONS
379	Interaction and assembly processes of abundant and rare microbial communities during a diatom bloom process. <i>Environmental Microbiology</i> , 2020, 22, 1707-1719.	3.8	60
380	The Role of Pharmacists in Managing Adverse Events Related to Immune Checkpoint Inhibitor Therapy. <i>Journal of Pharmacy Practice</i> , 2020, 33, 338-349.	1.0	9
381	Diagnosis and Management of Rare Immune-Related Adverse Events. <i>Oncologist</i> , 2020, 25, 6-14.	3.7	31
382	Pembrolizumab-induced thrombotic thrombocytopenic purpura. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1237-1240.	0.9	27
383	The prognostic impact of immune-related adverse events during anti-PD1 treatment in melanoma and non-small-cell lung cancer: a real-life retrospective study. <i>Oncolimmunology</i> , 2020, 9, 1682383.	4.6	34
384	Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient?. <i>American Journal of Transplantation</i> , 2020, 20, 879-883.	4.7	80
385	Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms. <i>Immunology</i> , 2020, 159, 167-177.	4.4	75
386	Immunotherapy: The end of the "dark age" for metastatic triple-negative breast cancer?. <i>Breast Journal</i> , 2020, 26, 739-742.	1.0	10
387	Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy. <i>Lung Cancer</i> , 2020, 139, 1-8.	2.0	92
388	Workup and Management of Immune-Mediated Hepatobiliary Pancreatic Toxicities That Develop During Immune Checkpoint Inhibitor Treatment. <i>Oncologist</i> , 2020, 25, 105-111.	3.7	28
389	Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer. <i>Future Oncology</i> , 2020, 16, 4439-4453.	2.4	29
390	Biologic and Checkpoint Inhibitor-Induced Liver Injury: A Systematic Literature Review. <i>Hepatology Communications</i> , 2020, 4, 172-184.	4.3	40
391	Immunotherapy for the Treatment of Breast Cancer: Emerging New Data. <i>Breast Cancer: Targets and Therapy</i> , 2019, Volume 11, 321-328.	1.8	25
392	Immune Checkpoint Inhibitor-Induced Colitis Successfully Followed up by Ultrasonography. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 215-221.	0.6	3
393	Immune checkpoint inhibitors and tuberculosis: an old disease in a new context. <i>Lancet Oncology</i> , The, 2020, 21, e55-e65.	10.7	59
394	Recognition and Initial Management of Fulminant Myocarditis. <i>Circulation</i> , 2020, 141, e69-e92.	1.6	368
395	Optic Neuritis Related to Atezolizumab Treatment in a Patient With Metastatic Non-small-Cell Lung Cancer. <i>JCO Oncology Practice</i> , 2020, 16, 96-98.	2.9	17
396	Critical Care Management of Toxicities Associated With Targeted Agents and Immunotherapies for Cancer. <i>Critical Care Medicine</i> , 2020, 48, 10-21.	0.9	42

#	ARTICLE	IF	CITATIONS
397	A closer look at immune-mediated myocarditis in the era of combined checkpoint blockade and targeted therapies. <i>European Journal of Cancer</i> , 2020, 124, 15-24.	2.8	31
398	Immune-checkpoint inhibitors induced diarrhea and colitis. <i>Current Opinion in Gastroenterology</i> , 2020, 36, 25-32.	2.3	21
399	Checkpoint inhibitors in AML: are we there yet?. <i>British Journal of Haematology</i> , 2020, 188, 159-167.	2.5	31
400	Toxic epidermal necrolysis associated with pembrolizumab. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1259-1265.	0.9	23
401	Clinical Characteristics and Adverse Impact of Hepatotoxicity due to Immune Checkpoint Inhibitors. <i>American Journal of Gastroenterology</i> , 2020, 115, 251-261.	0.4	58
402	Rapid evolution of acute kidney injury after initial infusion of pembrolizumab in a melanoma patient concurrently treated with RAF/MEK inhibitors. <i>Melanoma Research</i> , 2020, 30, 219-222.	1.2	3
403	Nivolumab-Induced Delayed Autoimmune Hepatitis—A Diagnostic and Therapeutic Challenge. <i>American Journal of Therapeutics</i> , 2020, 27, e317-e319.	0.9	1
404	New insight in endocrine-related adverse events associated to immune checkpoint blockade. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2020, 34, 101370.	4.7	60
405	Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. <i>Oncologist</i> , 2020, 25, e398-e404.	3.7	10
406	Patient-Reported Outcomes From Patients Receiving Immunotherapy or Chemoimmunotherapy for Metastatic Non-Small-Cell Lung Cancer in Clinical Practice. <i>Clinical Lung Cancer</i> , 2020, 21, 255-263.e4.	2.6	28
407	Clinical Course of Preexisting Uveitis during Treatment of Lung Cancer with Durvalumab. <i>Ocular Immunology and Inflammation</i> , 2020, 28, 566-570.	1.8	6
408	Immune-Related Pancytopenia Induced by Anti-PD-1 Therapy — Interrupt or Continue Treatment — The Role of Immunohistochemical Examination. <i>Case Reports in Oncology</i> , 2020, 12, 820-828.	0.7	4
409	Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology. <i>Clinical Cancer Research</i> , 2020, 26, 984-989.	7.0	100
410	Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 44-59.	10.7	826
411	Immune-related Neutropenia Following Treatment With Immune Checkpoint Inhibitors. <i>Journal of Immunotherapy</i> , 2020, 43, 67-74.	2.4	14
412	Clinical outcome and toxicity for immunotherapy treatment in metastatic cancer patients. <i>Annals of Palliative Medicine</i> , 2020, 9, 4446-4457.	1.2	5
413	Bilateral Corneal Graft Rejection Associated With Pembrolizumab Treatment. <i>Cornea</i> , 2020, 39, 1436-1438.	1.7	15
414	Neurological immune-related adverse events associated with immune checkpoint inhibitors: A review of the literature. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 291-298.	1.1	21

#	ARTICLE	IF	CITATIONS
415	Vitiligo-like depigmentation after pembrolizumab treatment in patients with non-small cell lung cancer: a case report. <i>Translational Lung Cancer Research</i> , 2020, 9, 1585-1590.	2.8	12
416	Immune Checkpoint Inhibitors and Cardiac Toxicity in Patients Treated for Non-Small Lung Cancer: A Review. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7195.	4.1	55
417	Management of the Adverse Effects of Immune Checkpoint Inhibitors. <i>Vaccines</i> , 2020, 8, 575.	4.4	29
418	Severe combined cardiac and neuromuscular toxicity from immune checkpoint blockade: an institutional case series. <i>Cardio-Oncology</i> , 2020, 6, 21.	1.7	14
419	Nivolumab in Advanced Hepatocellular Carcinoma: Safety Profile and Select Treatment-Related Adverse Events From the CheckMate 040 Study. <i>Oncologist</i> , 2020, 25, e1532-e1540.	3.7	13
421	Management of Side Effects of Systemic Therapies for Hepatocellular Carcinoma. <i>Clinics in Liver Disease</i> , 2020, 24, 755-769.	2.1	9
422	Reversible primary adrenal insufficiency related to anti-programmed cell-death 1 protein active immunotherapy: Insight into an unforeseen outcome of a rare immune-related adverse event. <i>International Immunopharmacology</i> , 2020, 89, 107050.	3.8	7
423	Toxin-Induced Channelopathies, Neuromuscular Junction Disorders, and Myopathy. <i>Neurologic Clinics</i> , 2020, 38, 765-780.	1.8	1
424	A Case of Lenalidomide-Associated Papulopustular Rash: Beyond the Epidermal Growth Factor Receptor Inhibitor Spectrum. <i>American Journal of Therapeutics</i> , 2020, 27, e417-e419.	0.9	0
425	Neurological complications of chimeric antigen receptor T cells and immune-checkpoint inhibitors: ongoing challenges in daily practice. <i>Current Opinion in Oncology</i> , 2020, 32, 603-612.	2.4	5
426	Atezolizumab-Induced Bell's Palsy in a Patient With Small Cell Lung Cancer. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2020, 8, 232470962096501.	0.6	3
427	Relationship of hypothyroidism and immune response to pegylated IL-10/nivolumab. <i>Immunotherapy</i> , 2020, 12, 1041-1046.	2.0	2
428	Avelumab and axitinib combination therapy for the treatment of advanced renal cell carcinoma. <i>Future Oncology</i> , 2020, 16, 3021-3034.	2.4	3
429	Pembrolizumab- and ipilimumab-induced diabetic ketoacidosis and isolated adrenocorticotrophic hormone deficiency: a case report. <i>Journal of Medical Case Reports</i> , 2020, 14, 171.	0.8	12
430	Anti-estradiol antibodies: Expanding their clinical significance. <i>Clinical and Experimental Neuroimmunology</i> , 2020, 11, 218-224.	1.0	5
431	Reconsidering the management of patients with cancer with viral hepatitis in the era of immunotherapy. , 2020, 8, e000943.		23
432	Cardiac troponin I predicts clinical outcome of patients with cancer at emergency department. <i>Clinical Cardiology</i> , 2020, 43, 1585-1591.	1.8	4
433	Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade. <i>IScience</i> , 2020, 23, 101580.	4.1	22



#	ARTICLE	IF	CITATIONS
434	The Critical Role of the Oncology Nurse as a Partner in the Management of Patients With Advanced Kidney Cancer. <i>Cancer Journal (Sudbury, Mass )</i> , 2020, 26, 460-463.	2.0	5
435	Severe fistulizing pancreatitis in a patient with Merkel cell carcinoma treated with avelumab. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 1266-1267.	1.6	5
436	Secondary Causes of Myositis. <i>Current Treatment Options in Neurology</i> , 2020, 22, 38.	1.8	5
437	Autonomic enteric neuropathy following nivolumab monotherapy in a patient with Lung Cancer. <i>Current Problems in Cancer Case Reports</i> , 2020, 1, 100014.	0.1	2
438	Immune-Mediated Colitis due to Concurrent Ipilimumab and Nivolumab Therapy Treated With Infliximab. <i>American Journal of Therapeutics</i> , 2020, 27, e415-e417.	0.9	1
439	Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors. <i>JHEP Reports</i> , 2020, 2, 100170.	4.9	86
440	Pneumonitis Induced by Immune Checkpoint Inhibitors: From Clinical Data to Translational Investigation. <i>Frontiers in Oncology</i> , 2020, 10, 1785.	2.8	35
441	Central nervous system injury from novel cancer immunotherapies. <i>Current Opinion in Neurology</i> , 2020, 33, 723-735.	3.6	9
445	Management of metabolic adverse events of targeted therapies and immune checkpoint inhibitors in cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Societ� Italiana Farmacologia (SIF) multidisciplinary consensus position paper. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 154, 103066.	4.4	7
446	Isolated optic neuritis after pembrolizumab administration for non-small-cell lung carcinoma. <i>International Journal of Neuroscience</i> , 2022, 132, 643-648.	1.6	13
447	Immune escape: A critical hallmark in solid tumors. <i>Life Sciences</i> , 2020, 258, 118110.	4.3	91
448	Emergency management of immune-related toxicity. <i>Current Opinion in Oncology</i> , 2020, 32, 274-281.	2.4	5
449	Durvalumab Immunotherapy: Nursing Management of Immune-Related Adverse Events During the Journey of Patients With Stage III Non-Small Cell Lung Cancer. <i>Clinical Journal of Oncology Nursing</i> , 2020, 24, 277-283.	0.6	2
450	So slow, so fast, a case of nivolumab-induced hypothyroidism with subsequent rhabdomyolysis. <i>Immunotherapy</i> , 2020, 12, 625-628.	2.0	3
451	Minimal change disease in a patient receiving checkpoint inhibition: Another possible manifestation of kidney autoimmunity?. <i>Cancer Reports</i> , 2020, 3, e1250.	1.4	9
452	Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody. <i>BMC Cancer</i> , 2020, 20, 656.	2.6	53
453	Clinical surveillance in immunotherapy-treated patient. <i>Medicina Cl�nica (English Edition)</i> , 2020, 154, 493-495.	0.2	0
454	Insights from Pharmacovigilance: Gastrointestinal-Related Immune Checkpoint Inhibitor Adverse Events. <i>Gastroenterology</i> , 2020, 159, 1195-1200.e1.	1.3	5

#	ARTICLE	IF	CITATIONS
455	Management of Immune Checkpoint Inhibitor-Related Rheumatological Toxicities. <i>Journal of Clinical Rheumatology and Immunology</i> , 2020, 20, 25-34.	0.4	0
456	An extremely rare case of nivolumab-associated macroscopic duodenitis with spontaneous regression. <i>Respirology Case Reports</i> , 2020, 8, e00582.	0.6	0
457	Development of autoimmune diabetes with severe diabetic ketoacidosis and immune-related thyroiditis secondary to durvalumab: a case report. <i>Translational Lung Cancer Research</i> , 2020, 9, 2149-2156.	2.8	6
458	Multidisciplinary Clinical Approach to Cancer Patients with Immune-Related Adverse Events Induced by Checkpoint Inhibitors. <i>Cancers</i> , 2020, 12, 3446.	3.7	19
459	A case of oral lichenoid reaction during nivolumab therapy. <i>Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology</i> , 2020, 32, 521-524.	0.3	1
460	Bilateral Posterior Uveitis and Retinal Detachment During Immunotherapy: A Case Report and Literature Review. <i>Frontiers in Oncology</i> , 2020, 10, 549168.	2.8	9
461	The quality of reporting general safety parameters and immune-related adverse events in clinical trials of FDA-approved immune checkpoint inhibitors. <i>BMC Cancer</i> , 2020, 20, 1128.	2.6	7
462	Optimizing current standard of care therapy for stage III non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 2033-2039.	2.8	2
463	<p></p>Adverse Effects of Immune-Checkpoint Inhibitors in Hepatocellular Carcinoma</p><p></p>OncoTargets and Therapy, 2020, Volume 13, 11725-11740.	2.0	25
464	Sarcoidosis and Cancer: A Complex Relationship. <i>Frontiers in Medicine</i> , 2020, 7, 594118.	2.6	31
465	Eventos adversos gastrointestinales y hepáticos. , 2020, , .		0
466	Eventos adversos dermatológicos. , 2020, , .		0
467	Evidence for interleukin 17 involvement in severe immune-related neuroendocrine toxicity. <i>European Journal of Cancer</i> , 2020, 141, 218-224.	2.8	8
468	Eventos adversos pulmonares. , 2020, , .		0
469	Eventos adversos menos frecuentes. , 2020, , .		0
470	Optimización de la atención al paciente y reconocimiento temprano de eventos adversos relacionados con el sistema inmunitario. , 2020, , .		1
471	Eventos adversos relacionados con el sistema endocrino. , 2020, , .		0
472	Current Immunotherapy Approaches in Non-Hodgkin Lymphomas. <i>Vaccines</i> , 2020, 8, 708.	4.4	13

#	ARTICLE	IF	CITATIONS
474	Immune Checkpoint Blockade in Gynecologic Cancers: State of Affairs. <i>Cancers</i> , 2020, 12, 3301.	3.7	22
475	Long-Term MALT1 Inhibition in Adult Mice Without Severe Systemic Autoimmunity. <i>IScience</i> , 2020, 23, 101557.	4.1	14
476	Use of Cystatin C to Assess Immunotherapy Toxicity in a Patient With Melanoma. <i>Journal of Pharmacy Practice</i> , 2020, 35, 089719002096620.	1.0	0
477	Immune Checkpoint Inhibitor-Related Pneumonitis. <i>Respiration</i> , 2020, 99, 932-942.	2.6	30
478	Case Report: Ipilimumab-Induced Panhypophysitis: An Infrequent Occurrence and Literature Review. <i>Frontiers in Oncology</i> , 2020, 10, 582394.	2.8	17
479	Case report of polymyalgia rheumatica in a male patient with three different neoplasms treated with pembrolizumab. <i>Reumatismo</i> , 2020, 72, 178-181.	0.9	4
480	Première ligne des CBNPC avancés sans addiction oncogénique : quel traitement pour quel patient ?. <i>Revue Des Maladies Respiratoires Actualites</i> , 2020, 12, 2S329-2S338.	0.0	0
481	Tolérance de l'immunothérapie en combinaison dans le cancer bronchique non à petites cellules. <i>Revue Des Maladies Respiratoires Actualites</i> , 2020, 12, 2S344-2S351.	0.0	0
482	Immune Thrombocytopenia Induced by Immune Checkpoint Inhibitors in Solid Cancer: Case Report and Literature Review. <i>Frontiers in Oncology</i> , 2020, 10, 530478.	2.8	16
483	&lt;p&gt;Neuro-ophthalmic Complications of Immune Checkpoint Inhibitors: A Systematic Review&lt;/p&gt;. <i>Eye and Brain</i> , 2020, Volume 12, 139-167.	2.5	28
484	ATS Core Curriculum 2020. <i>Adult Critical Care Medicine</i> . <i>ATS Scholar</i> , 2020, 1, 436-455.	1.3	1
485	Hyperthyroidism. <i>Annals of Internal Medicine</i> , 2020, 172, ITC49.	3.9	15
486	HLA-B*27 association of autoimmune encephalitis induced by PD-L1 inhibitor. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 2243-2250.	3.7	25
487	Cardiotoxicity of Contemporary Anticancer Immunotherapy. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2020, 22, 62.	0.9	34
488	Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma. <i>Journal of Immunology Research</i> , 2020, 2020, 1-18.	2.2	12
489	Implementation of a pharmacy consult service for evaluation of immune checkpoint inhibitor related adverse events at a large community hospital. <i>Journal of Oncology Pharmacy Practice</i> , 2020, , 10781522097026.	0.9	1
490	Decreased Absolute Lymphocyte Count and Increased Neutrophil/Lymphocyte Ratio With Immune Checkpoint Inhibitor-Associated Myocarditis. <i>Journal of the American Heart Association</i> , 2020, 9, e018306.	3.7	38
491	&lt;p&gt;Thyroid Dysfunctions Due to Immune Checkpoint Inhibitors: A Review&lt;/p&gt;. <i>International Journal of General Medicine</i> , 2020, Volume 13, 1003-1009.	1.8	21

#	ARTICLE	IF	CITATIONS
492	How to manage patients with corticosteroids in oncology in the era of immunotherapy?. <i>European Journal of Cancer</i> , 2020, 141, 239-251.	2.8	52
493	Late-Onset Giant Cell Myocarditis Due to Enterovirus During Treatment With Immune Checkpoint Inhibitors. <i>JACC: CardioOncology</i> , 2020, 2, 511-514.	4.0	8
494	Metastatic Merkel Cell Carcinoma Masquerading as Multiple Immune-Related Adverse Events. <i>Case Reports in Dermatological Medicine</i> , 2020, 2020, 1-7.	0.3	2
495	Role of Immune Checkpoint Inhibitors in Gastrointestinal Malignancies. <i>Journal of Clinical Medicine</i> , 2020, 9, 2533.	2.4	15
496	Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma: a multicenter retrospective study. <i>International Journal of Hematology</i> , 2020, 112, 674-689.	1.6	19
497	Clinical Challenges of Immune Checkpoint Inhibitors. <i>Cancer Cell</i> , 2020, 38, 326-333.	16.8	286
498	Immune-Related Neuromuscular Complications of Checkpoint Inhibitors. <i>Current Treatment Options in Neurology</i> , 2020, 22, 1.	1.8	1
499	Acute Ulceronecrotic Gastritis With Cytomegalovirus Reactivation: Uncommon Toxicity of Immune Checkpoint Inhibitors in Microsatellite Instability-High Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2020, 19, e183-e188.	2.3	11
500	Nivolumab-induced seronegative encephalitis. <i>Journal of Neuroimmunology</i> , 2020, 347, 577350.	2.3	5
501	Pembrolizumab-induced pancytopenia in a patient with squamous cell lung cancer. <i>Thoracic Cancer</i> , 2020, 11, 2731-2735.	1.9	5
502	Pattern and impact of hepatic adverse events encountered during immune checkpoint inhibitors – A territory-wide cohort study. <i>Cancer Medicine</i> , 2020, 9, 7052-7061.	2.8	14
503	Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development. <i>Journal of Autoimmunity</i> , 2020, 114, 102514.	6.5	37
504	Clinical burden of immune checkpoint inhibitor-induced pneumonitis. <i>Respiratory Investigation</i> , 2020, 58, 305-319.	1.8	11
505	Differential risks of immune-related colitis among various immune checkpoint inhibitor regimens. <i>International Immunopharmacology</i> , 2020, 87, 106770.	3.8	7
506	Nivolumab-induced contact dermatitis in a patient with advanced lung cancer. <i>Respiratory Medicine Case Reports</i> , 2020, 30, 101134.	0.4	3
507	Nivolumab-induced immune thrombocytopenia in a patient with malignant pleural mesothelioma. <i>Respiratory Medicine Case Reports</i> , 2020, 31, 101170.	0.4	2
508	Pulmonary toxicity of systemic lung cancer therapy. <i>Respirology</i> , 2020, 25, 72-79.	2.3	42
509	Mechanisms of Immune-Related Complications in Cancer Patients Treated with Immune Checkpoint Inhibitors. <i>Pharmacology</i> , 2021, 106, 123-136.	2.2	24

#	ARTICLE	IF	CITATIONS
510	Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance. <i>Targeted Oncology</i> , 2020, 15, 449-466.	3.6	86
511	A nanoscale metal organic frameworks-based vaccine synergises with PD-1 blockade to potentiate anti-tumour immunity. <i>Nature Communications</i> , 2020, 11, 3858.	12.8	59
512	Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research. <i>Lancet Oncology</i> , The, 2020, 21, e398-e404.	10.7	74
513	Novel Targeted Therapies for Metastatic Thyroid Cancerâ€”A Comprehensive Review. <i>Cancers</i> , 2020, 12, 2104.	3.7	50
514	Reintroduction of immune-checkpoint inhibitors after immune-related meningitis: a case series of melanoma patients. , 2020, 8, e001034.		20
515	Untangling the Multidisciplinary Care Web: Streamlining Care Through an Immune-Related Adverse Events (IRAE) Tumor Board. <i>Targeted Oncology</i> , 2020, 15, 541-548.	3.6	6
516	Rheumatic immuneâ€related adverse events induced by immune checkpoint inhibitors. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 178-185.	1.1	17
517	Pembrolizumab-associated thrombotic microangiopathy in a patient with urothelial cancer: a case report and literature review. <i>Renal Replacement Therapy</i> , 2020, 6, .	0.7	11
518	Avelumab in Patients With Gestational Trophoblastic Tumors With Resistance to Single-Agent Chemotherapy: Cohort A of the TROPHIMMUN Phase II Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 3129-3137.	1.6	66
519	Lowâ€dose pembrolizumab and nivolumab were efficacious and safe in relapsed and refractory classical Hodgkin lymphoma: Experience in a resourceâ€constrained setting. <i>Hematological Oncology</i> , 2020, 38, 726-736.	1.7	20
520	The adverse events associated with combination immunotherapy in cancers: Challenges and chances. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, e154-e159.	1.1	11
521	Perioperative considerations for neoadjuvant immunotherapy in nonâ€small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 160, 1376-1382.	0.8	18
522	Difficulties in differentiating between checkpoint inhibitor pneumonitis and lung metastasis in a patient with melanoma. <i>Immunotherapy</i> , 2020, 12, 293-298.	2.0	4
523	Osteonecrosis of the jaw induced by treatment with anti-PD-1 immunotherapy: a case report. <i>Immunotherapy</i> , 2020, 12, 1213-1219.	2.0	6
524	Management of Immune-Related Cutaneous Adverse Reactions to PD-1 and PD-L1 Inhibitors for the Inpatient Dermatologist. <i>Current Dermatology Reports</i> , 2020, 9, 231-243.	2.1	4
525	Immunotherapy and Coronavirus Disease 2019: Challenges and Possibilities. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1709-1710.	1.1	1
526	Organ Dysfunction in Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2020, 25, e1753-e1762.	3.7	6
527	Case of anti-Zic4 antibody-mediated cerebellar toxicity induced by dual checkpoint inhibition in head and neck squamous cell carcinoma. <i>BMJ Case Reports</i> , 2020, 13, e235607.	0.5	9

#	ARTICLE	IF	CITATIONS
528	Multidisciplinary Approach to Immune-Mediated Diarrhea and Colitis From Immunotherapy for Cancer. <i>JCO Oncology Practice</i> , 2020, 16, 462-463.	2.9	2
529	Microbiota and Lung Cancer. Opportunities and Challenges for Improving Immunotherapy Efficacy. <i>Frontiers in Oncology</i> , 2020, 10, 568939.	2.8	15
530	Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2020, 6, 1952.	7.1	241
531	Evidences of CTLA-4 and PD-1 Blocking Agents-Induced Cardiotoxicity in Cellular and Preclinical Models. <i>Journal of Personalized Medicine</i> , 2020, 10, 179.	2.5	41
532	How I treat cancer: treatment of rheumatological side effects of immunotherapy. <i>ESMO Open</i> , 2020, 4, e000529.	4.5	9
533	Novel platform leveraging electronic medical record (EMR) to triage patients admitted with high-grade immune-related adverse events (irAEs) to the immune-toxicity (ITOX) service. , 2020, 8, e000992.		4
534	Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis. , 2020, 8, e001170.		28
535	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors. <i>Supportive Care in Cancer</i> , 2020, 28, 6119-6128.	2.2	20
536	Management of Immune-Related Colitis During the COVID-19 Pandemic. <i>Inflammatory Bowel Diseases</i> , 2020, 26, e110-e111.	1.9	4
537	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors. <i>Supportive Care in Cancer</i> , 2020, 28, 6159-6173.	2.2	11
538	Outcomes following immunotherapy re-challenge after immune-related adverse event: systematic review and meta-analysis. <i>Immunotherapy</i> , 2020, 12, 1183-1193.	2.0	12
539	Liver dysfunction is associated with poor prognosis in patients after immune checkpoint inhibitor therapy. <i>Scientific Reports</i> , 2020, 10, 14470.	3.3	11
540	Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma patients. <i>Scientific Reports</i> , 2020, 10, 14607.	3.3	8
541	Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis. <i>Cancer</i> , 2020, 126, 5088-5097.	4.1	30
542	Nivolumab-related tracheobronchial chondritis: Extremely rare manifestation of an immune-related adverse effect. <i>Head and Neck</i> , 2020, 42, E43-E48.	2.0	10
543	Analysis of immune-related adverse events caused by immune checkpoint inhibitors using the Japanese Adverse Drug Event Report database. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 1279-1294.	1.9	28
544	Eight pillars of oncorheumatology: Crossroads between malignancies and musculoskeletal diseases. <i>Autoimmunity Reviews</i> , 2020, 19, 102658.	5.8	9
546	MASCC 2020 recommendations for the management of immune-related adverse events of patients undergoing treatment with immune checkpoint inhibitors. <i>Supportive Care in Cancer</i> , 2020, 28, 6107-6110.	2.2	16

#	ARTICLE	IF	CITATIONS
547	Immune Related Adverse Events. <i>Cancer Journal (Sudbury, Mass )</i> , 2020, 26, 432-440.	2.0	4
549	Immunotherapy-mediated dermatological adverse events: the urgent need for a common, clinically meaningful, management strategy. <i>Supportive Care in Cancer</i> , 2020, 28, 5597-5599.	2.2	10
550	Timing of resumption of immune checkpoint inhibitor therapy after successful control of immune-related adverse events in seven advanced non-small cell lung cancer patients. <i>Anti-Cancer Drugs</i> , 2020, 31, 872-875.	1.4	3
551	Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors. <i>Journal of Immunology Research</i> , 2020, 2020, 1-8.	2.2	8
552	Clinical and radiological features of immune checkpoint inhibitor-related pneumonitis in lung cancer and non-lung cancers. <i>British Journal of Radiology</i> , 2020, 93, 20200409.	2.2	28
553	An update on the immune landscape in lung and head and neck cancers. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 505-517.	329.8	93
554	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors. <i>Supportive Care in Cancer</i> , 2020, 28, 6129-6143.	2.2	28
555	Immunotherapy use in kidney transplant recipients: Immune checkpoint inhibitors and CAR-T cell therapy. <i>Journal of Onco-Nephrology</i> , 2020, 4, 165-170.	0.6	0
558	Radiation recall pneumonitis induced by PD-1/PD-L1 blockades: mechanisms and therapeutic implications. <i>BMC Medicine</i> , 2020, 18, 275.	5.5	42
559	Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 554313.	2.8	32
560	Concomitant myopericarditis and takotsubo syndrome following immune checkpoint inhibitor therapy. <i>BMJ Case Reports</i> , 2020, 13, e235265.	0.5	18
561	Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio-Oncology Guidelines. <i>Journal of the American Heart Association</i> , 2020, 9, e018403.	3.7	149
562	Management of immunotherapy colitis: Special considerations in the COVID-19 era. <i>Cancer</i> , 2020, 126, 4630-4633.	4.1	4
563	Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1644.	2.8	48
564	ICPis-Induced Autoimmune Polyendocrine Syndrome Type 2: A Review of the Literature and a Protocol for Optimal Management. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e4208-e4218.	3.6	15
565	Diagnosis and management of immune-related adverse effects of immune checkpoint therapy in the emergency department. <i>Journal of the American College of Emergency Physicians Open</i> , 2020, 1, 1637-1659.	0.7	17
566	A long-term survival case of unresectable gastric cancer with multidisciplinary therapy including immunotherapy and abscopal effect. <i>International Cancer Conference Journal</i> , 2020, 9, 193-198.	0.5	12
567	Immune checkpoint inhibitor induced autoimmune encephalitis in a patient with metastatic melanoma. <i>Case Reports in Internal Medicine</i> , 2020, 7, 1.	0.0	0

#	ARTICLE	IF	CITATIONS
568	Successful treatment with avapritinib in patient with mucosal metastatic melanoma. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592094615.	3.2	8
569	Neurologic autoimmunity and immune checkpoint inhibitors. Neurology, 2020, 95, e2442-e2452.	1.1	94
570	Anti-PD-1 and Anti-PD-L1 Monoclonal Antibodies in People Living with HIV and Cancer. Current HIV/AIDS Reports, 2020, 17, 547-556.	3.1	21
571	Endocrine Adverse Events of Nivolumab in Non-Small Cell Lung Cancer Patientsâ€™ Literature Review. Cancers, 2020, 12, 2314.	3.7	13
572	Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis. , 2020, 8, e001887.		45
573	ResÃ¡menes de manejo. , 2020, , .		0
574	Immune-Related Neurological Toxicities of PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis. Frontiers in Immunology, 2020, 11, 595655.	4.8	8
575	The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors. Journal of Experimental and Clinical Cancer Research, 2020, 39, 284.	8.6	67
576	Immunoglobulins to mitigate paraneoplastic Lambert Eaton Myasthenic Syndrome under checkpoint inhibition in Merkel cell carcinoma. Neurological Research and Practice, 2020, 2, 52.	2.0	13
577	Immune checkpoint inhibitor-associated myopathy: a clinicoseropathologically distinct myopathy. Brain Communications, 2020, 2, fcaa181.	3.3	51
578	Strategies for improving the management of immune-related adverse events. , 2020, 8, e001754.		60
579	Full Issue PDF. JACC: CardioOncology, 2020, 2, I-CLXXX.	4.0	0
580	Checkpoint inhibitor induced esophagitis with documented resolution on infliximab. Current Problems in Cancer Case Reports, 2020, 2, 100029.	0.1	4
581	Predictors of response to immune checkpoint inhibition in a real world gynecologic cancer population. Gynecologic Oncology Reports, 2020, 34, 100671.	0.6	3
582	Postherpes zoster programmed death-1 inhibitorâ€™associated zosteriform granulomatous reactions. JAAD Case Reports, 2020, 6, 1201-1204.	0.8	3
583	A case of large-cell lung carcinoma successfully treated with pembrolizumab but complicated with cholangitis. Respiratory Medicine Case Reports, 2020, 31, 101197.	0.4	4
584	A case of simultaneous occurrence of hepatitis and pancreatitis during the combination immunochemotherapy for non-small cell lung carcinoma. Respiratory Medicine Case Reports, 2020, 31, 101266.	0.4	7
585	Case report: Fatal mesenteric and retroperitoneal serositis after pelvic chemoradiation followed by a single dose of chemotherapy and nivolumab. Current Problems in Cancer Case Reports, 2020, 1, 100018.	0.1	0



#	ARTICLE	IF	CITATIONS
586	Toxicities from immunotherapy: From clinical trials to real-world clinical practice. <i>Medicina Clínica (English Edition)</i> , 2020, 155, 541-547.	0.2	0
587	Genomic investigation of co-targeting tumor immune microenvironment and immune checkpoints in pan-cancer immunotherapy. <i>Npj Precision Oncology</i> , 2020, 4, 29.	5.4	11
588	Diagnostic utility of CT for suspected immune checkpoint inhibitor enterocolitis. , 2020, 8, e001329.		11
589	Retreatment with immune checkpoint inhibitors in solid tumors: a systematic review. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097535.	3.2	18
591	Increased rates of immunosuppressive treatment and hospitalization after checkpoint inhibitor therapy in cancer patients with autoimmune disease. , 2020, 8, e001627.		8
592	Perspectives From an Onconephrology Interest Group: Conference Report. <i>Canadian Journal of Kidney Health and Disease</i> , 2020, 7, 205435812096258.	1.1	1
593	History of Radiation to the Neck Increases the Risk of Denovo Thyroid Dysfunction after Receiving Immune Checkpoint Inhibitors. <i>Endocrines</i> , 2020, 1, 82-89.	1.0	0
594	Comparative Risks of High-Grade Adverse Events Among FDA-Approved Systemic Therapies in Advanced Melanoma: Systematic Review and Network Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 571135.	2.8	2
596	Immune Checkpoint Inhibitors and Perioperative Considerations. <i>Journal of Perianesthesia Nursing</i> , 2020, 35, 687-691.	0.7	1
597	When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report. , 2020, 8, e001322.		26
598	Update 2020: Management of Non-Small Cell Lung Cancer. <i>Lung</i> , 2020, 198, 897-907.	3.3	270
599	Fungal Infections Associated With the Use of Novel Immunotherapeutic Agents. <i>Current Clinical Microbiology Reports</i> , 2020, 7, 142-149.	3.4	12
600	Infectious complications in patients treated with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2020, 141, 137-142.	2.8	24
601	Recent Developments of Systemic Chemotherapy for Gastric Cancer. <i>Cancers</i> , 2020, 12, 1100.	3.7	31
602	Polymyalgia rheumatica in a melanoma patient 11 months after completion of immunotherapy with nivolumab. <i>Cancer Reports</i> , 2020, 3, e1244.	1.4	3
603	Early detection and management of immune-related myocarditis: Experience from a case with advanced squamous cell lung carcinoma. <i>European Journal of Cancer</i> , 2020, 131, 5-8.	2.8	5
604	Immune Checkpoint Inhibitor-Related Myositis: From Biology to Bedside. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3054.	4.1	41
605	Investigational Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Event Prediction and Diagnosis. <i>Clinical Chemistry</i> , 2020, 66, 779-793.	3.2	74

#	ARTICLE	IF	CITATIONS
606	Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non-small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study. <i>Clinical Lung Cancer</i> , 2020, 21, e567-e571.	2.6	15
607	Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?. <i>British Journal of Cancer</i> , 2020, 123, 207-215.	6.4	50
608	Association of immune-related pneumonitis with the efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092203.	3.2	26
609	What's the Price? Toxicities of Targeted Therapies in Breast Cancer Care. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 55-70.	3.8	13
610	Oncologic Emergencies: Immune-Based Cancer Therapies and Complications. <i>Western Journal of Emergency Medicine</i> , 2020, 21, 566-580.	1.1	13
611	Immune-related adverse events of checkpoint inhibitors. <i>Nature Reviews Disease Primers</i> , 2020, 6, 38.	30.5	684
613	Severe polymyalgia-like symptoms secondary to anti-PD1 therapy successfully managed without discontinuing checkpoint inhibitor. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e237-e237.	0.9	2
614	Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial. <i>Journal of Hematology and Oncology</i> , 2020, 13, 47.	17.0	84
615	Rheumatic Manifestations in Patients Treated with Immune Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3389.	4.1	19
616	Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors. <i>International Immunopharmacology</i> , 2020, 85, 106628.	3.8	14
617	T-cell lymphoma secondary to checkpoint inhibitor therapy. , 2020, 8, e000104.		25
618	Severe Refractory Checkpoint Inhibitor-Related Hepatitis Reversed With Anti-Thymocyte Globulin and n-Acetylcysteine. <i>Hepatology</i> , 2020, 72, 2235-2238.	7.3	12
619	CD47: the next checkpoint target for cancer immunotherapy. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 152, 103014.	4.4	52
620	Atezolizumab-Induced Aseptic Meningitis in Patients with NSCLC. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100012.	1.1	5
621	Early-onset meningitis associated with atezolizumab treatment for non-small cell lung cancer: case report and literature review. <i>Investigational New Drugs</i> , 2020, 38, 1901-1905.	2.6	4
623	Use of Checkpoint Inhibitors in a Kidney Transplant Recipient with Metastatic Cancer. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1190-1192.	4.5	2
624	Onco-Cardiology: Consensus Paper of the German Cardiac Society, the German Society for Pediatric Cardiology and Congenital Heart Defects and the German Society for Hematology and Medical Oncology. <i>Clinical Research in Cardiology</i> , 2020, 109, 1197-1222.	3.3	71
625	Therapeutic strategies for virus-negative myocarditis: a comprehensive review. <i>European Journal of Internal Medicine</i> , 2020, 77, 9-17.	2.2	30

#	ARTICLE	IF	CITATIONS
626	Checkpoint Inhibitor Pneumonitis: Mechanisms, Characteristics, Management Strategies, and Beyond. <i>Current Oncology Reports</i> , 2020, 22, 56.	4.0	23
627	Treatment of immune checkpoint inhibitor-induced inflammatory arthritis. <i>Current Opinion in Rheumatology</i> , 2020, 32, 315-320.	4.3	19
628	Diagnosis, Monitoring, and Management of Adverse Events From Immune Checkpoint Inhibitor Therapy. <i>Current Oncology</i> , 2020, 27, 43-50.	2.2	14
630	A case of recurrent thrombocytopenia involving divergent immune-related mechanisms associated with pembrolizumab. <i>European Journal of Cancer</i> , 2020, 131, 104-107.	2.8	5
631	Immune Checkpoint Inhibitor-Associated Myocarditis. <i>JACC: Case Reports</i> , 2020, 2, 630-635.	0.6	6
632	Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 12288-12294.	7.1	65
633	Diffuse pneumonitis from coronavirus HKU1 on checkpoint inhibitor therapy. , 2020, 8, e000898.		3
634	A case of dual-mechanism immune-related anaemia in a patient with metastatic melanoma treated with nivolumab and ipilimumab. , 2020, 8, e000380.		9
635	Encephalomyeloneuritis and arthritis after treatment with immune checkpoint inhibitors. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	9
636	A Review of Cancer Immunotherapy: From the Past, to the Present, to the Future. <i>Current Oncology</i> , 2020, 27, 87-97.	2.2	554
637	Cytokines that target immune killer cells against tumors. <i>Cellular and Molecular Immunology</i> , 2020, 17, 722-727.	10.5	20
638	Diagnostic and therapeutic differences between immune checkpoint inhibitor-induced and idiopathic bullous pemphigoid: a cross-sectional study. <i>British Journal of Dermatology</i> , 2020, 183, 1126-1128.	1.5	20
639	Emerging role of immune checkpoint inhibitors and their relevance for the cardiovascular system. <i>Herz</i> , 2020, 45, 645-651.	1.1	16
640	Inflammatory bowel disease-like conditions: medication-induced enteropathy. , 2020, , 451-469.		0
641	Hemophagocytic Lymphohistiocytosis Secondary to PD-1 and IDO Inhibition in a Patient with Refractory Glioblastoma. <i>Case Reports in Oncology</i> , 2020, 13, 508-514.	0.7	15
642	Regulatory and strategic considerations for addressing immunogenicity and related responses in biopharmaceutical development programs. <i>Journal of Clinical and Translational Science</i> , 2020, 4, 547-555.	0.6	9
643	Uveitis Induced by Biological Agents Used in Cancer Therapy. <i>Ocular Immunology and Inflammation</i> , 2021, 29, 1370-1374.	1.8	12
644	Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort. <i>Autoimmunity Reviews</i> , 2020, 19, 102595.	5.8	44

#	ARTICLE	IF	CITATIONS
645	Cases from the Immune-Related Adverse Event Tumor Board: Diagnosis and Management of Immune Checkpoint Blockade-Induced Diabetes. <i>Oncologist</i> , 2020, 25, 921-924.	3.7	9
646	Ipilimumab and Nivolumab as First-Line Treatment of Patients with Renal Cell Carcinoma: The Evidence to Date. <i>Cancer Management and Research</i> , 2020, Volume 12, 4871-4881.	1.9	29
647	Biosimilars in supportive care. <i>Current Opinion in Oncology</i> , 2020, 32, 282-288.	2.4	0
648	Advances in immune neoadjuvant/adjuvant therapy-related adverse events of non-small cell lung cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, , .	1.1	5
649	Establishing an oncocardiology service. <i>Herz</i> , 2020, 45, 626-631.	1.1	2
650	Vasoactive Intestinal Peptide in Checkpoint Inhibitor-Induced Pneumonitis. <i>New England Journal of Medicine</i> , 2020, 382, 2573-2574.	27.0	17
651	Development of Severe Heart Failure in a Patient with Squamous Non-small-cell Lung Cancer During Nivolumab Treatment. <i>Internal Medicine</i> , 2020, 59, 2003-2008.	0.7	10
652	Mycophenolate mofetil as a successful treatment of corticosteroid-resistant immune checkpoint inhibitor-induced hepatitis. <i>Oxford Medical Case Reports</i> , 2020, 2020, omaa027.	0.4	16
653	Paraneoplastic Encephalitis and Enteric Neuropathy Associated With Anti-Hu Antibody in a Patient Following Immune-checkpoint Inhibitor Therapy. <i>Journal of Immunotherapy</i> , 2020, 43, 165-168.	2.4	17
654	Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma – an update. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 582-609.	0.8	24
655	Advances in the Treatment of Non-Small Cell Lung Cancer. <i>Clinics in Chest Medicine</i> , 2020, 41, 237-247.	2.1	50
656	Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 477-488.	1.9	15
657	Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1778-1789.	2.4	34
658	Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor-Associated Myocarditis. <i>Circulation</i> , 2020, 141, 2031-2034.	1.6	142
659	Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events. <i>Kidney International Reports</i> , 2020, 5, 1139-1148.	0.8	71
660	Rare case of life-threatening thrombocytopenia occurring after radiotherapy in a patient treated with immune checkpoint inhibitor. <i>BMJ Case Reports</i> , 2020, 13, e235249.	0.5	4
661	Immune-related (IR)-pneumonitis during the COVID-19 pandemic: multidisciplinary recommendations for diagnosis and management. , 2020, 8, e000984.		15
662	Checkpoint Inhibition Causing Complete Remission of Metastatic Combined Hepatocellular-Cholangiocarcinoma after Hepatic Resection. <i>Case Reports in Oncology</i> , 2020, 13, 478-484.	0.7	15

#	ARTICLE	IF	CITATIONS
663	Infectious Complications of Immune Checkpoint Inhibitors. <i>Infectious Disease Clinics of North America</i> , 2020, 34, 235-243.	5.1	7
664	Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis. , 2020, 8, e000451.		39
665	Neurologic Toxicities of Cancer Immunotherapies: a Review. <i>Current Neurology and Neuroscience Reports</i> , 2020, 20, 27.	4.2	17
666	New Insights into Mechanisms of Immune Checkpoint Inhibitor-Induced Cardiovascular Toxicity. <i>Current Oncology Reports</i> , 2020, 22, 65.	4.0	44
667	Mapping endocrine toxicity spectrum of immune checkpoint inhibitors: a disproportionality analysis using the WHO adverse drug reaction database, Vigibase. <i>Endocrine</i> , 2020, 69, 670-681.	2.3	32
668	Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharmacovigilance Database. <i>Frontiers in Pharmacology</i> , 2020, 11, 830.	3.5	21
669	Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression $\geq 50\%$ and Their Relationship With Clinical Outcomes. <i>Clinical Lung Cancer</i> , 2020, 21, 498-508.e2.	2.6	50
670	Impact of Checkpoint Inhibitor Immunotherapy, Primarily Pembrolizumab, on Infection Risk in Patients With Advanced Lung Cancer: A Comparative Retrospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e2697-e2704.	5.8	12
671	Gastrointestinal and Hepatic Complications of Immunotherapy: Current Management and Future Perspectives. <i>Current Gastroenterology Reports</i> , 2020, 22, 15.	2.5	20
672	Complete response of renal cell carcinoma with an inferior vena cava tumor thrombus and lung metastases after treatment with nivolumab plus ipilimumab. <i>International Cancer Conference Journal</i> , 2020, 9, 88-91.	0.5	19
673	Clinical characteristics of adrenal insufficiency as an immune-related adverse event in non-small-cell lung cancer. <i>Medical Oncology</i> , 2020, 37, 30.	2.5	11
674	A case report of immune-mediated arthritis in a patient with cutaneous melanoma receiving checkpoint inhibition therapy. <i>Medicine (United States)</i> , 2020, 99, e19439.	1.0	1
675	Significant association between tumor mutational burden and immune-related adverse events during immune checkpoint inhibition therapies. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 683-687.	4.2	16
676	Environmental factors and anatomic pathology of the thyroid gland: review of literature. <i>Diagnostic Histopathology</i> , 2020, 26, 207-215.	0.4	1
677	Paraspinal muscle involvement in pembrolizumab-associated myositis. <i>Oxford Medical Case Reports</i> , 2020, 2020, omaa003.	0.4	2
678	Lessons learned from immunoadsorption for hyperviscosity in IgM multiple myeloma—A case report. <i>Journal of Clinical Apheresis</i> , 2020, 35, 227-230.	1.3	2
679	Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1177-1187.	4.2	66
680	Management of immune-related adverse events associated with immune checkpoint inhibitors in cancer patients: a patient-centred approach. <i>Internal and Emergency Medicine</i> , 2020, 15, 587-598.	2.0	16

#	ARTICLE	IF	CITATIONS
681	Immune-related adverse events of checkpoint inhibitors: Insights into immunological dysregulation. <i>Clinical Immunology</i> , 2020, 213, 108377.	3.2	44
682	Rapid regression of microsatellite instability-high/programmed cell death ligand 1-negative recurrent endometrial carcinoma by immune checkpoint blockade with pembrolizumab: A case report and literature review. <i>Gynecologic Oncology Reports</i> , 2020, 32, 100553.	0.6	2
683	Immune checkpoint inhibitor associated neurotoxicity: Much more than meets the eye. <i>Immunology Letters</i> , 2020, 221, 72-74.	2.5	0
684	Nivolumab-induced immune-mediated neurotoxicity in Hodgkin lymphoma. <i>Baylor University Medical Center Proceedings</i> , 2020, 33, 59-61.	0.5	0
685	Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in Japan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1782-1788.	2.8	22
686	A Fatal Case of Pembrolizumab-Induced Myocarditis in Non-Small Cell Lung Cancer. <i>JACC: Case Reports</i> , 2020, 2, 426-430.	0.6	7
687	Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls. <i>Current Oncology Reports</i> , 2020, 22, 39.	4.0	199
688	Endocrine adverse events related to immune-oncology agents: retrospective experience of a single institution. <i>Translational Lung Cancer Research</i> , 2020, 9, 103-110.	2.8	11
689	Systemic Adjuvant Therapy for Adult Patients at High Risk for Recurrent Cutaneous or Mucosal Melanoma: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline. <i>Current Oncology</i> , 2020, 27, 43-52.	2.2	12
690	Moving towards personalized treatments of immune-related adverse events. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 504-515.	27.6	189
691	Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors. <i>Immune Network</i> , 2020, 20, e9.	3.6	143
692	Current state and perspectives of checkpoint inhibitors in ovarian cancer treatment. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 202-206.	0.5	2
693	Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation. <i>Hepatology</i> , 2020, 72, 315-329.	7.3	131
694	The 2016-2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study. <i>European Journal of Cancer</i> , 2020, 130, 39-50.	2.8	37
695	Incidence and characteristics of neurotoxicity in immune checkpoint inhibitors with focus on neuromuscular events: Experience beyond the clinical trials. <i>Journal of the Peripheral Nervous System</i> , 2020, 25, 171-177.	3.1	32
696	Optimizing outcomes in relapsed/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072090291.	2.5	21
697	Association of Steroids Use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2020, 12, 546.	3.7	177
698	Personalized Approach to Cancer Treatment-Related Cardiomyopathy. <i>Current Heart Failure Reports</i> , 2020, 17, 43-55.	3.3	3

#	ARTICLE	IF	CITATIONS
699	Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations of the Quality in Pathology Study. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1177-1189.	1.1	81
700	Immune Checkpoint Inhibitors in the Treatment of Renal Cell Carcinoma. <i>Seminars in Nephrology</i> , 2020, 40, 76-85.	1.6	18
701	Cardiovascular immune-related adverse events: Evaluation, diagnosis and management. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 232-240.	1.1	16
702	Cutaneous immune-related adverse events to checkpoint inhibitors. <i>Clinics in Dermatology</i> , 2020, 38, 660-678.	1.6	27
703	Immune Checkpoint Inhibitor-Mediated Diarrhea and Colitis: A Clinical Review. <i>JCO Oncology Practice</i> , 2020, 16, 453-461.	2.9	42
704	FDG PET/CT for Assessment of Immune Therapy: Opportunities and Understanding Pitfalls. <i>Seminars in Nuclear Medicine</i> , 2020, 50, 518-531.	4.6	25
705	Evaluation of the usefulness of protocol-based pharmacist-facilitated laboratory monitoring to ensure the safety of immune checkpoint inhibitors in patients with lung cancer. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, 1288-1294.	1.5	7
706	Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 23-39.	2.5	52
707	Impending infliximab access crisis: a case of steroid-refractory, relapsing immunotherapy-induced colitis responsive to infliximab. <i>Internal Medicine Journal</i> , 2020, 50, 767-768.	0.8	4
708	Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes. , 2020, 8, e000467.		106
709	Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study. , 2020, 8, e000779.		75
710	Immune Checkpoint Inhibitor Nephrotoxicity: Update 2020. <i>Kidney360</i> , 2020, 1, 130-140.	2.1	62
711	Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society. <i>Lancet Respiratory Medicine</i> , the, 2020, 8, 726-737.	10.7	279
712	CMV coinfection in treatment refractory immune checkpoint inhibitor colitis. <i>BMJ Case Reports</i> , 2020, 13, e233519.	0.5	4
713	Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives. <i>Immune Network</i> , 2020, 20, e10.	3.6	86
714	Clinical Outcomes of Anti-programmed Death-1 Antibody-Related Pneumonitis in Patients with Non-Small Cell Lung Cancer. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 570-578.	0.6	8
715	Renal immune-related adverse events of immune checkpoint inhibitor. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 305-311.	1.1	6
716	Pembrolizumab-induced secondary sclerosing cholangitis in a non-small cell lung cancer patient. <i>Respirology Case Reports</i> , 2020, 8, e00560.	0.6	9

#	ARTICLE	IF	CITATIONS
717	Immune-Related Pneumonitis After Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, e435-e444.	2.6	46
718	Immunotherapy in Colorectal Cancer: Potential of Fecal Transplant and Microbiota-Augmented Clinical Trials. <i>Current Colorectal Cancer Reports</i> , 2020, 16, 81-88.	0.5	14
719	Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma. <i>Annals of Hepatology</i> , 2020, 19, 546-569.	1.5	11
720	Balancing Cancer Immunotherapy Efficacy and Toxicity. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2898-2906.	3.8	28
721	How to Monitor Cardiac Complications of Immune Checkpoint Inhibitor Therapy. <i>Frontiers in Pharmacology</i> , 2020, 11, 972.	3.5	26
722	Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events. <i>British Journal of Cancer</i> , 2020, 123, 898-904.	6.4	36
723	Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients. <i>Thoracic Cancer</i> , 2020, 11, 2406-2430.	1.9	40
724	Biologics and therapeutics. , 2020, , 1099-1111.		0
725	Immune checkpoint inhibitors in women with gynecologic cancers: Practical considerations. <i>Gynecologic Oncology</i> , 2020, 158, 531-537.	1.4	8
726	Atezolizumab-associated encephalitis in metastatic lung adenocarcinoma: a case report. <i>Journal of Medical Case Reports</i> , 2020, 14, 88.	0.8	16
727	Refractory Autoimmune Hemolytic Anemia and Pure Red Cell Aplasia Secondary to Immunotherapy Requiring Prolonged Immunosuppression. <i>JCO Oncology Practice</i> , 2020, 16, 699-700.	2.9	3
728	The Rate of Infectious Complications After Intrathecal Drug Delivery System Implant for Cancer-Related Pain Is Low Despite Frequent Concurrent Anticancer Treatment or Leukopenia. <i>Anesthesia and Analgesia</i> , 2020, 131, 280-287.	2.2	14
729	Pembrolizumab-induced Hemophagocytic Lymphohistiocytosis: an immunotherapeutic challenge. <i>Cancers of the Head &amp; Neck</i> , 2020, 5, 3.	6.2	24
730	Toxicities of novel therapies for hematologic malignancies. <i>Expert Review of Hematology</i> , 2020, 13, 241-257.	2.2	2
731	Immune-mediated adverse effects of immune-checkpoint inhibitors and their management in cancer. <i>Immunology Letters</i> , 2020, 221, 61-71.	2.5	12
732	Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update Summary. <i>JCO Oncology Practice</i> , 2020, 16, e844-e848.	2.9	18
733	A case of severe pharyngeal-cervical-brachial syndrome induced by nivolumab and responding to infliximab therapy. <i>European Journal of Cancer</i> , 2020, 129, 1-3.	2.8	3
734	Acute and Chronic Effects of Cancer Drugs on the Cardiovascular System. <i>Heart Failure Clinics</i> , 2020, 16, 231-241.	2.1	2



#	ARTICLE	IF	CITATIONS
735	Cardiac Adverse Events Related to Immune Checkpoint Inhibitors. <i>JACC: Case Reports</i> , 2020, 2, 200-202.	0.6	2
736	Very high-dose methylprednisolone for treatment of nivolumab-induced limbic encephalitis: A case report. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1538-1543.	0.9	4
737	Adoptive T-cell therapy for HBV-associated HCC and HBV infection. <i>Antiviral Research</i> , 2020, 176, 104748.	4.1	31
738	Checkpoint Inhibitor-Induced Colitis. <i>American Journal of Gastroenterology</i> , 2020, 115, 202-210.	0.4	68
739	Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum. <i>Annals of Neurology</i> , 2020, 87, 659-669.	5.3	137
741	Immunomodulatory treatment of immune checkpoint inhibitor-induced myocarditis: Pathway toward precision-based therapy. <i>Cardiovascular Pathology</i> , 2020, 47, 107211.	1.6	31
742	Renal Toxicity of Systemic Therapy for Renal Cell Carcinoma. <i>Seminars in Nephrology</i> , 2020, 40, 49-58.	1.6	4
743	Gastrointestinal adverse events associated with immune checkpoint inhibitor therapy. <i>Gastroenterology Report</i> , 2020, 8, 25-30.	1.3	41
744	Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 91.	2.8	112
745	Myocardial and Pericardial Toxicity Associated With Immune Checkpoint Inhibitors in Cancer Patients. <i>JACC: Case Reports</i> , 2020, 2, 191-199.	0.6	15
746	Complications neurologiques des immunothérapies anti-cancéreuses: une pathologie émergente. <i>Pratique Neurologique - FMC</i> , 2020, 11, 60-68.	0.1	0
747	Pembrolizumab-Induced Mobitz Type 2 Second-Degree Atrioventricular Block. <i>Case Reports in Cardiology</i> , 2020, 2020, 1-5.	0.2	6
748	Clinical Development of Immunotherapy for Deficient Mismatch Repair Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2020, 19, 73-81.	2.3	36
750	Non-small-cell Lung Cancer with Severe Skin Manifestations Related to Radiation Recall Dermatitis after Atezolizumab Treatment. <i>Internal Medicine</i> , 2020, 59, 1199-1202.	0.7	6
751	Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 72, 307-319.	3.7	310
752	A review of cancer immunotherapy toxicity. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 86-104.	329.8	753
753	Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. <i>Annals of Oncology</i> , 2020, 31, 171-190.	1.2	582
754	Toxicity of Immune Checkpoint Inhibitors: Considerations for the Surgeon. <i>Annals of Surgical Oncology</i> , 2020, 27, 1533-1545.	1.5	6

#	ARTICLE	IF	CITATIONS
755	Health-related quality of life in cancer patients treated with immune checkpoint inhibitors: A systematic review on reporting of methods in randomized controlled trials. <i>PLoS ONE</i> , 2020, 15, e0227344.	2.5	26
756	Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 72, 320-341.	3.7	165
757	Anti-PD-1 and Novel Combinations in the Treatment of Melanoma—An Update. <i>Journal of Clinical Medicine</i> , 2020, 9, 223.	2.4	95
758	Molecular Imaging for Cancer Immunotherapy: Seeing Is Believing. <i>Bioconjugate Chemistry</i> , 2020, 31, 404-415.	3.6	31
759	Mechanisms of checkpoint inhibition-induced adverse events. <i>Clinical and Experimental Immunology</i> , 2020, 200, 141-154.	2.6	33
760	Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update. <i>Journal of Clinical Oncology</i> , 2020, 38, 1608-1632.	1.6	301
761	Myositis as a neuromuscular complication of immune checkpoint inhibitors. <i>Acta Neurologica Belgica</i> , 2020, 120, 355-364.	1.1	17
762	Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment. <i>Journal of the American Heart Association</i> , 2020, 9, e013757.	3.7	240
763	Clinical and Advanced MRI Techniques for Detection of Checkpoint Inhibitor Associated Myocarditis. <i>Current Cardiovascular Imaging Reports</i> , 2020, 13, 1.	0.6	4
764	Multimodality Cardiac Imaging in the Era of Emerging Cancer Therapies. <i>Journal of the American Heart Association</i> , 2020, 9, e013755.	3.7	37
765	Re-administration of pembrolizumab with prednisolone after pembrolizumab-induced nephrotic syndrome. <i>European Journal of Cancer</i> , 2020, 126, 74-77.	2.8	6
766	Management of Patients With Immune Checkpoint Inhibitor-Induced Enterocolitis: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1393-1403.e1.	4.4	47
767	Immunotherapy and Targeted Drugs for Common Cancers. <i>Journal for Nurse Practitioners</i> , 2020, 16, 195-200.	0.8	0
768	Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 435-446.	6.1	247
769	Neurotoxicities associated with checkpoint inhibitors: Two case reports and a review of the literature. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 24-32.	0.5	8
770	Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study. <i>British Journal of Cancer</i> , 2020, 122, 771-777.	6.4	48
771	Sub-acute Toxicity in Non-cancerous Tissue and Immune-Related Adverse Events of a Novel Combination Therapy for Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 1504.	2.8	4
772	Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer. <i>Cancer Treatment Reviews</i> , 2020, 85, 101979.	7.7	21

#	ARTICLE	IF	CITATIONS
774	Checkpoint inhibitors (CPI) and autoimmune chronic inflammatory diseases (ACIDs): tolerance and loss of tolerance in the occurrence of immuno-rheumatologic manifestations. <i>Clinical Immunology</i> , 2020, 214, 108395.	3.2	16
775	Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma. <i>JAMA Network Open</i> , 2020, 3, e201611.	5.9	70
776	Drug-Induced Liver Injury in GI Practice. <i>Hepatology Communications</i> , 2020, 4, 631-645.	4.3	47
778	Immune checkpoint inhibitor-associated pituitary adverse events: an observational, retrospective, disproportionality study. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 1473-1483.	3.3	23
779	Successful management of refractory immune-mediated enterocolitis with cyclosporine. <i>European Journal of Cancer</i> , 2020, 131, 37-39.	2.8	4
780	Emergency presentations in patients treated with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2020, 130, 193-197.	2.8	33
781	Characterization of risk factors and efficacy of medical management of immune-related hepatotoxicity in real-world patients with metastatic melanoma treated with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2020, 130, 211-218.	2.8	23
782	Central diabetes insipidus related to anti-programmed cell-death 1 protein active immunotherapy. <i>International Immunopharmacology</i> , 2020, 83, 106427.	3.8	23
783	Thyroid Toxicity Following Immune Checkpoint Inhibitor Treatment in Advanced Cancer. <i>Thyroid</i> , 2020, 30, 1458-1469.	4.5	44
784	Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors. , 2020, 8, e000371.		14
785	Imaging of Adverse Events Related to Checkpoint Inhibitor Therapy. <i>Diagnostics</i> , 2020, 10, 216.	2.6	13
786	Kidney Biopsy Should Be Performed to Document the Cause of Immune Checkpoint Inhibitor-Associated Acute Kidney Injury: Commentary. <i>Kidney360</i> , 2020, 1, 166-168.	2.1	15
787	A Case of Isolated Adrenocorticotrophic Hormone Deficiency Caused by Pembrolizumab. <i>Case Reports in Oncology</i> , 2020, 13, 200-206.	0.7	15
788	Public Adverse Event Data Insights into the Safety of Pembrolizumab in Melanoma Patients. <i>Cancers</i> , 2020, 12, 1008.	3.7	3
789	Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2856.	4.1	31
790	Cutaneous adverse reactions to anti-PD-1 treatment: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1415-1424.	1.2	29
791	Role of immune checkpoint inhibitors in the revolutionization of advanced melanoma care. <i>International Immunopharmacology</i> , 2020, 83, 106417.	3.8	31
792	An update on the safety of nivolumab for the treatment of advanced melanoma. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 409-421.	2.4	5

#	ARTICLE	IF	CITATIONS
793	Autoimmune encephalitis associated with Ma2 antibodies and immune checkpoint inhibitor therapy. <i>Practical Neurology</i> , 2020, 20, 256-259.	1.1	15
794	Onkolimmun 10. <i>Oncology Research and Treatment</i> , 2020, 43, I-VIII.	1.2	0
795	Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer. <i>JAMA Oncology</i> , 2020, 6, 865.	7.1	295
798	Immunologic adverse events from immune checkpoint therapy. <i>Best Practice and Research in Clinical Rheumatology</i> , 2020, 34, 101511.	3.3	3
799	Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database. <i>Onc Immunology</i> , 2020, 9, 1722022.	4.6	27
800	Management Considerations for Immune Checkpoint Inhibitor-Induced Enterocolitis Based on Management of Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 662-668.	1.9	18
801	A case report of fulminant cytokine release syndrome complicated by dermatomyositis after the combination therapy with immune checkpoint inhibitors. <i>Medicine (United States)</i> , 2020, 99, e19741.	1.0	19
802	Mechanism-based treatment of cancer with immune checkpoint inhibitor therapies. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1690-1702.	2.4	26
803	Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: meta-analysis of a rare immune-related adverse side effect. <i>BMC Cancer</i> , 2020, 20, 300.	2.6	25
804	Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis. <i>BMC Medicine</i> , 2020, 18, 87.	5.5	189
805	Rituximab leads to early elimination of circulating CD20+ T and B lymphocytes in patients with iTTP despite ongoing TPEX. <i>Blood Advances</i> , 2020, 4, 477-481.	5.2	5
806	Systemic Therapy for Melanoma: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 3947-3970.	1.6	190
807	Reply to Y. Inagaki et al. <i>Journal of Clinical Oncology</i> , 2020, 38, 1749-1750.	1.6	1
808	Treatment-Related Adverse Events of Combination Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 258.	2.8	35
809	Immunotherapy in Metastatic Colorectal Cancer: Could the Latest Developments Hold the Key to Improving Patient Survival?. <i>Cancers</i> , 2020, 12, 889.	3.7	20
810	Therapeutic Landscape of Metastatic Non-Small-Cell Lung Cancer in Canada in 2020. <i>Current Oncology</i> , 2020, 27, 52-60.	2.2	13
811	Immune checkpoints inhibitors and hyperglycemia: A Meta-analysis of randomized controlled trials. <i>Diabetes Research and Clinical Practice</i> , 2020, 162, 108115.	2.8	8
812	Re-introducing immunotherapy in patients surviving immune checkpoint inhibitors-mediated myocarditis. <i>Clinical Research in Cardiology</i> , 2021, 110, 50-60.	3.3	20

#	ARTICLE	IF	CITATIONS
813	Pathologic Manifestations of Gastrointestinal and Hepatobiliary Injury in Immune Checkpoint Inhibitor Therapy. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 571-582.	2.5	27
814	EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 36-48.	0.9	153
815	Retrospective analysis of hospital admissions due to immune checkpoint inhibitor-induced immune-related adverse events (irAE). <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, e109-e116.	1.1	6
816	Impact of pharmacist-managed immune checkpoint inhibitor toxicities. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 596-600.	0.9	11
817	Immunotherapy-related acute kidney injury: Kidney biopsy or not?. <i>Nephrology</i> , 2021, 26, 89-90.	1.6	1
818	Acute interstitial nephritis associated with immune checkpoint inhibitors: a single-centre experience. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1364-1370.	2.9	30
819	Glucocorticoids and immune checkpoint inhibitors in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2021, 151, 13-20.	2.9	15
820	Low-dose ipilimumab plus nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease: exploratory findings of a case series of 131 stage IV cancers – a retrospective study of a single institution. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1393-1403.	4.2	25
821	Advances on immune-related adverse events associated with immune checkpoint inhibitors. <i>Frontiers of Medicine</i> , 2021, 15, 33-42.	3.4	24
822	Cardiotoxic mechanisms of cancer immunotherapy – A systematic review. <i>International Journal of Cardiology</i> , 2021, 323, 179-187.	1.7	31
823	New onset diabetes with ketoacidosis following nivolumab immunotherapy: A case report and review of literature. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 716-721.	0.9	12
824	Immunotherapy for older patients with melanoma: From darkness to light?. <i>Pigment Cell and Melanoma Research</i> , 2021, 34, 550-563.	3.3	11
825	Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management. <i>Journal of Cutaneous Medicine and Surgery</i> , 2021, 25, 59-76.	1.2	90
826	Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure. <i>Annual Review of Pharmacology and Toxicology</i> , 2021, 61, 113-134.	9.4	40
827	Treatment of rheumatic immune-related adverse events due to cancer immunotherapy with immune checkpoint inhibitors – is it time for a paradigm shift?. <i>Clinical Rheumatology</i> , 2021, 40, 1687-1695.	2.2	15
829	Clinical Outcomes of Patients with Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient Setting. <i>Oncologist</i> , 2021, 26, 49-55.	3.7	18
830	Coronary and aortic calcification are associated with cardiovascular events on immune checkpoint inhibitor therapy. <i>International Journal of Cardiology</i> , 2021, 322, 177-182.	1.7	18
831	AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review. <i>Gastroenterology</i> , 2021, 160, 1384-1393.	1.3	121

#	ARTICLE	IF	CITATIONS
832	Autoimmune polyendocrine syndrome induced by immune checkpoint inhibitors: a systematic review. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1527-1540.	4.2	21
833	Synthesis and Biological Evaluation of 10-Substituted Camptothecin Derivatives with Improved Water Solubility and Activity. <i>ChemMedChem</i> , 2021, 16, 1000-1010.	3.2	9
834	Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors. <i>Arthritis and Rheumatology</i> , 2021, 73, 866-874.	5.6	56
835	The State of the Heart Biopsy: A Clinical Review. <i>CJC Open</i> , 2021, 3, 524-531.	1.5	18
836	Incidence of venous thromboembolic events in cancer patients receiving immunotherapy: a single-institution experience. <i>Clinical and Translational Oncology</i> , 2021, 23, 1245-1252.	2.4	21
837	Prognostic factors and effect on survival of immune-related adverse events in patients with non-small-cell lung cancer treated with immune checkpoint blockade. <i>Journal of Chemotherapy</i> , 2021, 33, 32-39.	1.5	9
838	Expert Perspective: Immune Checkpoint Inhibitors and Rheumatologic Complications. <i>Arthritis and Rheumatology</i> , 2021, 73, 553-565.	5.6	21
839	Clinical characteristics and management of immune checkpoint inhibitor-related pneumonitis: A single-institution retrospective study. <i>Cancer Medicine</i> , 2021, 10, 188-198.	2.8	11
840	Pathology of immune checkpoint inhibitor-induced injury of the gastrointestinal tract and hepatobiliary system. <i>Diagnostic Histopathology</i> , 2021, 27, 62-68.	0.4	3
841	Insights into non-classic and emerging causes of hypopituitarism. <i>Nature Reviews Endocrinology</i> , 2021, 17, 114-129.	9.6	24
842	Pembrolizumab-Induced Delayed-Onset Hepatitis. <i>Case Reports in Gastroenterology</i> , 2021, 14, 586-592.	0.6	13
843	Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors. <i>Thoracic Cancer</i> , 2021, 12, 153-164.	1.9	28
844	Current status and perspectives of immune checkpoint inhibitors for colorectal cancer. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 10-19.	1.3	33
845	Neurologic Complications of Immune Checkpoint Inhibitors in Thoracic Malignancies. <i>Journal of Thoracic Oncology</i> , 2021, 16, 381-394.	1.1	12
846	Cardiotoxicity Related to Immune Checkpoint Inhibitors. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2021, 23, 1.	0.9	1
847	Efficacy of Rezafungin in Prophylactic Mouse Models of Invasive Candidiasis, Aspergillosis, and <i>Pneumocystis</i> Pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	29
848	Cost-effectiveness of nivolumab in advanced melanoma: a drug review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 13-28.	1.4	1
849	A Systematic Review of Immune Checkpoint Inhibitor-Associated Glomerular Disease. <i>Kidney International Reports</i> , 2021, 6, 66-77.	0.8	84

#	ARTICLE	IF	CITATIONS
850	Successful mycophenolate mofetil treatment of a patient with severe steroidâ€refractory hepatitis evoked by nivolumab plus ipilimumab treatment for relapsed bladder cancer. Clinical Case Reports (discontinued), 2021, 9, 654-659.	0.5	10
851	Safe administration of ipilimumab plus nivolumab to a dialysis patient with renal cell carcinoma. IJU Case Reports, 2021, 4, 32-35.	0.3	7
852	Renal cell carcinoma with central nervous system demyelination caused by nivolumab. IJU Case Reports, 2021, 4, 44-48.	0.3	0
853	Collagenous colitis and atezolizumab therapy: an atypical case. Clinical Journal of Gastroenterology, 2021, 14, 165-169.	0.8	9
854	Abdominal immune-related adverse events: detection on ultrasonography, CT, MRI and 18F-Fluorodeoxyglucose positron emission tomography. British Journal of Radiology, 2021, 94, 20200663.	2.2	13
855	Oncologic Emergencies. Critical Care Clinics, 2021, 37, 85-103.	2.6	13
856	Immune Checkpoint Inhibitor-associated Uveitis: Review of Treatments and Outcomes. Ocular Immunology and Inflammation, 2021, 29, 203-211.	1.8	42
857	Clinical Pharmacology and Interplay of Immune Checkpoint Agents: A Yin-Yang Balance. Annual Review of Pharmacology and Toxicology, 2021, 61, 85-112.	9.4	50
858	Magnifying endoscopy with crystal violet staining for immune checkpoint inhibitorâ€associated colitis. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 1180-1186.	2.8	1
859	Autoimmune Endocrinopathies: An Emerging Complication of Immune Checkpoint Inhibitors. Annual Review of Medicine, 2021, 72, 313-330.	12.2	24
860	Brain Stem Encephalitis in a Patient With Recurrent Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor: Case Presentation and Review of the Literature. Cureus, 2021, 13, e13034.	0.5	8
861	Neurologic Complications of Chemotherapy and Radiation Therapy. , 2021, , 521-537.		0
864	Management of Rheumatic Immune-Related Adverse Events (irAEs): General Principles. , 2021, , 309-321.		0
865	Clinical types of checkpoint inhibitor-related pneumonitis in lung cancer patients: a multicenter experience. Translational Lung Cancer Research, 2021, 10, 415-429.	2.8	13
866	Checkpoint inhibitors: Interface of cancer and autoimmunity: Opportunity for second level precision medicine. , 2021, , 109-134.		0
867	Immunotherapy-related toxicity in lung cancer: clinical characteristics and managing strategy. Chinese Medical Journal, 2021, 134, 780-782.	2.3	1
868	Lip Ulcer Induced by Nivolumab: A Case Report. Internal Medicine, 2021, 60, 3847-3848.	0.7	0
869	Fatal Immune Checkpoint Inhibitor-related Pancreatitis. Internal Medicine, 2021, 60, 3905-3911.	0.7	15

#	ARTICLE	IF	CITATIONS
870	Targeting cancer-promoting inflammation " have anti-inflammatory therapies come of age?. Nature Reviews Clinical Oncology, 2021, 18, 261-279.	27.6	171
872	Toxicities of Novel Antineoplastic Therapies. , 2021, , 711-738.		1
873	Neurotoxicities associated with immune checkpoint inhibitor therapy. Journal of Neuro-Oncology, 2021, 152, 265-277.	2.9	33
874	Ophthalmic complications of immune checkpoint inhibitors. Orbit, 2021, , 1-6.	0.8	6
875	Drug-Induced Liver Injury in Older Adults. , 2021, , 1391-1406.		0
876	GI Toxicities from Cancer Therapy. , 2021, , 341-379.		0
877	Durvalumab-associated Late-onset Myocarditis Successfully Treated with Corticosteroid Therapy. Internal Medicine, 2022, 61, 527-531.	0.7	6
878	Ipilimumab in Melanoma: An Evergreen Drug. , 2021, , 217-235.		0
879	Organ-specific Adverse Events of Immune Checkpoint Inhibitor Therapy, with Special Reference to Endocrinopathies. European Endocrinology, 2021, 1, 21.	1.5	0
880	Incidence and risk factors of acute kidney injury, and its effect on mortality among Japanese patients receiving immune check point inhibitors: a single-center observational study. Clinical and Experimental Nephrology, 2021, 25, 479-487.	1.6	25
881	Cardiovascular Oncologic Emergencies. , 2021, , 269-290.		0
883	Cardiac Toxicities Associated with Immune Checkpoints Inhibitors: Mechanisms, Manifestations and Management. Korean Circulation Journal, 2021, 51, 579.	1.9	3
884	Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes. , 2021, 9, e001731.		45
885	Paraneoplastic neurological syndromes: clinical presentations and management. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642098532.	3.5	41
886	Immunotherapy-Associated Cardiotoxicity of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T Cell Therapy: Diagnostic and Management Challenges and Strategies. Current Cardiology Reports, 2021, 23, 11.	2.9	35
887	Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110311.	3.2	19
888	Colitis inducida por inmunoterapia: ¿puede ser una colitis ulcerosa?. Gastroenterología Y Hepatología, 2021, 44, 28-29.	0.5	1
889	Pembrolizumab in Melanoma: From Care to Cure. , 2021, , 249-264.		1



#	ARTICLE	IF	CITATIONS
890	Neurologic Complications of Transplantation and Immunosuppressive Agents. , 2021, , 785-801.		0
891	Effect of Systemic Corticosteroid Therapy on the Efficacy and Safety of Nivolumab in the Treatment of Non-Small-Cell Lung Cancer. <i>Cancer Control</i> , 2021, 28, 107327482098579.	1.8	4
892	Organ-specific Adverse Events of Immune Checkpoint Inhibitor Therapy, with Special Reference to Endocrinopathies. <i>European Endocrinology</i> , 2021, 17, 21.	1.5	7
893	Risk Factors for Emergency Room and Hospital Care Among Patients With Solid Tumors on Immune Checkpoint Inhibitor Therapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 114-120.	1.3	1
894	Immune checkpoint inhibitor-induced myocarditis in lung cancer patients: a case report of sintilimab-induced myocarditis and a review of the literature. <i>Annals of Palliative Medicine</i> , 2021, 10, 793-802.	1.2	12
895	A Case of Guillain-Barré Syndrome and Stevens-Johnson Syndrome/Toxic Epidermal Necrosis Overlap After Pembrolizumab Treatment. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2021, 9, 232470962110374.	0.6	5
897	Skin Adverse Reactions from New Cancer Immunotherapy. , 2021, , 355-367.		0
898	Immunotherapy for Metastatic Urothelial Carcinoma. , 2021, , 305-313.		0
899	Myocarditis and Pericarditis. , 2021, , .		1
900	Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110069.	2.7	13
901	Cardio-Oncología Toxicidad cardiovascular y antineoplásicos. , 2021, 32, 42-55.		0
903	Immune-Related Adverse Events in the Older Adult with Cancer Receiving Immune Checkpoint Inhibitor Therapy. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2021, 8, 18.	1.6	3
904	A case of hyperprogressive disease following atezolizumab therapy for pulmonary pleomorphic carcinoma with epidermal growth factor receptor mutation. <i>Respiratory Medicine Case Reports</i> , 2021, 33, 101405.	0.4	6
905	Refractory constrictive pericarditis caused by an immune checkpoint inhibitor properly managed with infliximab: a case report. <i>European Heart Journal - Case Reports</i> , 2021, 5, ytab002.	0.6	16
907	Case Report: Fatal Multiorgan Failure and Heterochronous Pneumonitis Following Pembrolizumab Treatment in a Patient With Large-Cell Neuroendocrine Carcinoma of Lung. <i>Frontiers in Pharmacology</i> , 2020, 11, 569466.	3.5	9
908	Cardiovascular Disease Amongst Women Treated for Breast Cancer: Traditional Cytotoxic Chemotherapy, Targeted Therapy, and Radiation Therapy. <i>Current Cardiology Reports</i> , 2021, 23, 16.	2.9	12
909	Nephrotoxicity in patients with solid tumors treated with anti-PD-1/PD-L1 monoclonal antibodies: a systematic review and meta-analysis. <i>Investigational New Drugs</i> , 2021, 39, 860-870.	2.6	12
910	Mechanisms and Management of Immune Checkpoint Inhibitor-Related Cardiac Adverse Events. <i>JMA Journal</i> , 2021, 4, 91-98.	0.8	13

#	ARTICLE	IF	CITATIONS
911	Abdominal aortitis with immune checkpoint inhibition. <i>Journal of Case Reports and Images in Oncology</i> , 2021, 7, 1-6.	0.0	0
912	Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors. <i>Current Oncology Reports</i> , 2021, 23, 13.	4.0	38
913	Immunotherapy-induced colitis: Could it be ulcerative colitis?. <i>Gastroenterologÿa Y Hepatologÿa (English Edition)</i> , 2021, 44, 28-29.	0.1	1
915	A case of gastric cancer that developed thrombocytopenia during treatment with nivolumab. <i>Clinical Journal of Gastroenterology</i> , 2021, 14, 725-729.	0.8	2
916	Reconsidering Dexamethasone for Antiemesis when Combining Chemotherapy and Immunotherapy. <i>Oncologist</i> , 2021, 26, 269-273.	3.7	22
917	Targeted Cancer Therapy and Its Ophthalmic Side Effects: A Review. <i>Journal of Immunotherapy and Precision Oncology</i> , 2021, 4, 6-15.	1.4	12
918	Case Report: Pseudoprogression With Nivolumab and Bevacizumab Followed by Recurrent Immune-Related Pneumonitis in Urothelial Carcinoma With Lung Metastasis. <i>Frontiers in Oncology</i> , 2020, 10, 611810.	2.8	1
919	Pembrolizumab-induced myocarditis in a patient with malignant mesothelioma: plasma exchange as a successful emerging therapyâ€”case report. <i>Translational Lung Cancer Research</i> , 2021, 10, 1039-1046.	2.8	18
920	Paraneoplastic neurological syndrome: an evolving story. <i>Neuro-Oncology Practice</i> , 2021, 8, 362-374.	1.6	5
921	Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. <i>European Journal of Cancer</i> , 2021, 144, 182-191.	2.8	57
922	Efficacy and safety of Infliximab for steroidâ€”resistant immuneâ€”related adverse events: A retrospective study. <i>Molecular and Clinical Oncology</i> , 2021, 14, 65.	1.0	14
923	Addressing an Unmet Need in Relapsed or Refractory Hodgkin Lymphoma. <i>JCO Oncology Practice</i> , 2021, 17, 74-76.	2.9	2
925	CAR-T and checkpoint inhibitors: toxicities and antidotes in the emergency department. <i>Clinical Toxicology</i> , 2021, 59, 376-385.	1.9	4
926	Nivolumab-caused hyperprogression of diffuse large B-cell lymphoma of the testis and spontaneous remission of type 2 diabetes mellitus in an elderly patient: a case report. <i>Anti-Cancer Drugs</i> , 2021, 32, 575-579.	1.4	1
927	Thermal Ablation, Embolization, and Selective Internal Radiation Therapy Combined with Checkpoint Inhibitor Cancer Immunotherapy: Safety Analysis. <i>Journal of Vascular and Interventional Radiology</i> , 2021, 32, 187-195.	0.5	17
928	CT imaging findings of anti-PD-1 inhibitor-related enterocolitis.. <i>Abdominal Radiology</i> , 2021, 46, 3033-3043.	2.1	4
929	Shifting From a â€œOne Size Fits Allâ€”to a Tailored Approach for Immune-Related Adverse Events. <i>Journal of Thoracic Oncology</i> , 2021, 16, 183-186.	1.1	4
930	How we treat endocrine complications of immune checkpoint inhibitors. <i>ESMO Open</i> , 2021, 6, 100011.	4.5	32

#	ARTICLE	IF	CITATIONS
932	The Clinical and Histopathological Features of Cutaneous Immune-Related Adverse Events and Their Outcomes. <i>Journal of Clinical Medicine</i> , 2021, 10, 728.	2.4	8
933	Reações Adversas Imunomediadas em pacientes tratados com Inibidores de Checkpoints Imunológicos em um Hospital filantrópico de Salvador. <i>Research, Society and Development</i> , 2021, 10, e58510212928.	0.1	0
934	Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin's lymphoma. , 2021, 9, e002097.		28
935	Immune checkpoint inhibitors: Significant advancements in non-small cell lung cancer treatment. <i>American Journal of Health-System Pharmacy</i> , 2021, 78, 769-780.	1.0	11
936	Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 435-453.	27.6	31
937	A case of immune checkpoint inhibitor-associated gastroenteritis detected by ultrasonography. <i>Journal of Clinical Ultrasound</i> , 2021, 49, 605-609.	0.8	6
938	Phospholipase A2 receptor antibody mediated membranous nephropathy associated with cemiplimab. <i>Journal of Onco-Nephrology</i> , 2021, 5, 27-30.	0.6	4
940	Causes of Pruritus in Patients Treated With Immune Checkpoint Inhibitors for Melanomas or Skin Carcinomas. <i>Frontiers in Medicine</i> , 2021, 8, 632683.	2.6	1
941	Treatment and relapse of interstitial lung disease in nivolumab-treated patients with non-small cell lung cancer. <i>Cancer Science</i> , 2021, 112, 1506-1513.	3.9	14
942	Tackling cancer cell dormancy: Insights from immune models, and transplantation. <i>Seminars in Cancer Biology</i> , 2022, 78, 5-16.	9.6	9
943	Impact of Baseline Corticosteroids on Immunotherapy Efficacy in Patients With Advanced Melanoma. <i>Journal of Immunotherapy</i> , 2021, 44, 167-174.	2.4	12
944	Neuro-ophthalmic Complications of Immune-Checkpoint Inhibitors. <i>Seminars in Ophthalmology</i> , 2021, 36, 241-249.	1.6	6
945	The Cytokine Expression in Patients with Cardiac Complication after Immune Checkpoint Inhibitor Therapy. <i>Internal Medicine</i> , 2021, 60, 423-429.	0.7	18
946	COVID-19 lung injury as a primer for immune checkpoint inhibitors (ICIs)-related pneumonia in a patient affected by squamous head and neck carcinoma treated with PD-L1 blockade: a case report. , 2021, 9, e001870.		10
947	Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study. <i>Clinical Cancer Research</i> , 2021, 27, 3360-3369.	7.0	47
948	Neurological Complications of Targeted Therapies and Immunotherapies for Cancer. <i>Current Treatment Options in Neurology</i> , 2021, 23, 1.	1.8	3
949	Mending Broken Hearts. <i>Circulation</i> , 2021, 143, 767-769.	1.6	5
950	Recurrent Uveitis Related to Ibrutinib for Treatment of Chronic Lymphocytic Leukemia. <i>Ocular Immunology and Inflammation</i> , 2022, 30, 1005-1008.	1.8	7

#	ARTICLE	IF	CITATIONS
951	Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 72.	17.1	191
952	Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not?. <i>Cancers</i> , 2021, 13, 989.	3.7	38
953	Managing Immune checkpoint inhibitor induced hepatitis in a patient with concurrent hepatitis C. <i>Current Problems in Cancer Case Reports</i> , 2021, 3, 100066.	0.1	0
954	The Entire Intestinal Tract Surveillance Using Capsule Endoscopy after Immune Checkpoint Inhibitor Administration: A Prospective Observational Study. <i>Diagnostics</i> , 2021, 11, 543.	2.6	3
955	Therapeutic Targeting of Checkpoint Receptors within the DNAM1 Axis. <i>Cancer Discovery</i> , 2021, 11, 1040-1051.	9.4	24
956	Newly diagnosed cardiovascular disease in patients treated with immune checkpoint inhibitors: a retrospective analysis of patients at an academic tertiary care center. <i>Cardio-Oncology</i> , 2021, 7, 10.	1.7	12
957	Endocrine complications of immunotherapies: a review. <i>Clinical Medicine</i> , 2021, 21, e212-e222.	1.9	29
958	Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA. , 2021, 9, e001935.		38
959	Immune thrombocytopenia after immune checkpoint inhibitor therapy. <i>British Journal of Haematology</i> , 2021, 193, 677-681.	2.5	3
960	Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 2789-2800.	2.5	11
961	Immune Checkpoint Inhibitor-related Guillain-Barré Syndrome: A Case Series and Review of the Literature. <i>Journal of Immunotherapy</i> , 2021, 44, 276-282.	2.4	17
962	Management of Immune Checkpoint Inhibitor-induced Myocarditis. <i>JACC: CardioOncology</i> , 2021, 3, 157-161.	4.0	22
963	Checkpoint blockade toxicities: Insights into autoimmunity and treatment. <i>Seminars in Immunology</i> , 2021, 52, 101473.	5.6	11
964	An Underdiagnosed Hypothyroidism and Its Clinical Significance in Patients with Advanced Hepatocellular Carcinoma. <i>Oncologist</i> , 2021, 26, 422-426.	3.7	8
965	Pharmacological Interventions for the Prevention and Treatment of Immune Checkpoint Inhibitor-Associated Enterocolitis: A Systematic Review. <i>Digestive Diseases and Sciences</i> , 2022, 67, 1128-1155.	2.3	4
966	Associations of Cutaneous Immune-Related Adverse Effects of Immunotherapy With Treatment Response in Patients With Metastatic Melanoma. <i>SKIN the Journal of Cutaneous Medicine</i> , 2021, 5, 108-117.	0.3	1
967	Therapy for Stage IV Non-small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update. <i>Journal of Clinical Oncology</i> , 2021, 39, 1040-1091.	1.6	192
968	Hypophysitis due to Immune Checkpoint Inhibitors. <i>Endocrinology and Disorders</i> , 2021, 5, 01-07.	0.1	0

#	ARTICLE	IF	CITATIONS
969	Immune checkpoint inhibitor toxicity: A new indication for therapeutic plasma exchange?. <i>Journal of Clinical Apheresis</i> , 2021, 36, 645-648.	1.3	10
970	Overview of checkpoint inhibitor pneumonitis: incidence and associated risk factors. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 537-547.	2.4	9
971	Supportive oncodermatologyâ€”a narrative review of its utility and the way forward. <i>Supportive Care in Cancer</i> , 2021, 29, 4931-4937.	2.2	2
972	Steroid-refractory dermatologic and pulmonary toxicity in a patient on rituximab treated with pembrolizumab for progressive urothelial carcinoma: a case report. <i>Journal of Medical Case Reports</i> , 2021, 15, 124.	0.8	6
973	Extending the conversation over the immune-related hepatotoxicity: author response to Dr. Gauci <i>et al</i> . , 2021, 9, e002391.		3
974	Clinical Outcomes, Costs, and Healthcare Resource Utilization in Patients with Metastatic Merkel Cell Carcinoma Treated with Immune Checkpoint Inhibitors vs Chemotherapy. <i>ClinicoEconomics and Outcomes Research</i> , 2021, Volume 13, 213-226.	1.9	1
975	Survival outcomes associated with corticosteroid use before chemoimmunotherapy in patients with advanced lung cancer. <i>European Journal of Cancer</i> , 2021, 145, 234-244.	2.8	9
976	Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society. <i>Radiology</i> , 2021, 298, 550-566.	7.3	53
977	The Evolving Immunotherapy LandscapeÂand the Epidemiology, Diagnosis, and Management ofÂCardiotoxicity. <i>JACC: CardioOncology</i> , 2021, 3, 35-47.	4.0	80
978	Recent Progress in Systemic Therapy for Hepatocellular Cancer (HCC). <i>Current Treatment Options in Gastroenterology</i> , 2021, 19, 351-368.	0.8	6
979	Supportive care for new cancer therapies. <i>Current Opinion in Oncology</i> , 2021, 33, 287-294.	2.4	6
980	A case with hepatic immune-related adverse events caused by nivolumab exhibiting impaired accumulation of regulatory T cells. <i>Clinical Journal of Gastroenterology</i> , 2021, 14, 1191-1196.	0.8	7
981	Immune checkpoint inhibitorâ€”associated myocarditis: manifestations and mechanisms. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	84
982	Drug-Related Pneumonitis in Cancer Treatment during the COVID-19 Era. <i>Cancers</i> , 2021, 13, 1052.	3.7	5
983	Checkpoint inhibitor therapy-associated acute kidney injury: time to move on to evidence-based recommendations. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1301-1306.	2.9	12
984	Renal toxicity of targeted therapies for renal cell carcinoma in patients with normal and impaired kidney function. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 723-742.	2.3	13
985	Lymphangiogenesis-inducing vaccines elicit potent and long-lasting T cell immunity against melanomas. <i>Science Advances</i> , 2021, 7, .	10.3	36
986	An Evaluation of the Use of Corticosteroids for the Management of Immune-Mediated Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors. <i>Journal of the Advanced Practitioner in Oncology</i> , 2021, 12, 137-145.	0.4	1

#	ARTICLE	IF	CITATIONS
987	Usefulness of Cardiac Computed Tomography in the Diagnosis of Anti-Cancer Therapy-Related Cardiac Dysfunction—Consistency With Magnetic Resonance Imaging. <i>Circulation Journal</i> , 2021, 85, 393-396.	1.6	9
988	Supportive Care: Low Cost, High Value. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, 240-250.	3.8	6
989	Immune-Related Adverse Events Predict the Efficacy of Immune Checkpoint Inhibitors in Lung Cancer Patients: A Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 631949.	2.8	26
990	Chest CT Diagnosis and Clinical Management of Drug-Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors. <i>Chest</i> , 2021, 159, 1107-1125.	0.8	53
991	Systemic Therapy of Metastatic Melanoma: On the Road to Cure. <i>Cancers</i> , 2021, 13, 1430.	3.7	50
992	Treatment of corticosteroid refractory immune checkpoint inhibitor myocarditis with Infliximab: a case series. <i>Cardio-Oncology</i> , 2021, 7, 13.	1.7	16
993	Combination of echocardiography and emergency endomyocardial biopsy for suspected myocarditis in the cardiovascular emergency medical care. <i>Journal of Echocardiography</i> , 2021, 19, 86-94.	0.8	4
994	Strategies to overcome relapse of immunotherapy-related hepatitis: dose reduction is not the key. <i>Acta Clinica Belgica</i> , 2021, , 1-6.	1.2	1
995	Cardiotoxicities of novel cancer immunotherapies. <i>Heart</i> , 2021, 107, 1694-1703.	2.9	42
996	Supportive care practice: do we need guidelines?. <i>Current Opinion in Oncology</i> , 2021, 33, 273-278.	2.4	0
997	Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors. <i>Clinical Science</i> , 2021, 135, 703-724.	4.3	18
998	Safety of current immune checkpoint inhibitors in non-small cell lung cancer. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 651-667.	2.4	4
999	Dual immune check point blockade or immune check point-tyrosine kinase inhibitor combination: as a first-line treatment in metastatic renal cell carcinoma?. <i>Current Opinion in Urology</i> , 2021, 31, 270-275.	1.8	5
1000	Diagnosis and Management of Neuroendocrine Disorders of Survivors of Brain Tumors. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, 47-55.	3.8	4
1001	Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors. <i>BMC Cancer</i> , 2021, 21, 314.	2.6	9
1002	Clinical Characteristics, Management, and Potential Biomarkers of Endocrine Dysfunction Induced by Immune Checkpoint Inhibitors. <i>Endocrinology and Metabolism</i> , 2021, 36, 312-321.	3.0	15
1003	Role of Key Guidelines in an Era of Precision Oncology: A Primer for the Radiologist. <i>American Journal of Roentgenology</i> , 2021, 216, 1112-1125.	2.2	0
1004	Cytomegalovirus pneumonia complicating immune checkpoint inhibitors-induced pneumonitis: A case report. <i>Molecular and Clinical Oncology</i> , 2021, 14, 120.	1.0	3

#	ARTICLE	IF	CITATIONS
1005	Ocular surface disease associated with immune checkpoint inhibitor therapy. <i>Ocular Surface</i> , 2021, 20, 115-129.	4.4	12
1006	Immune checkpoint inhibitors-associated pericardial disease: a systematic review of case reports. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3041-3053.	4.2	19
1007	Gastrointestinal and liver immune-related adverse effects induced by immune checkpoint inhibitors: A descriptive observational study. <i>Gastroenterology &amp; Hepatology (English Edition)</i> , 2021, 44, 261-268.	0.1	3
1008	Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 563-572.	1.2	51
1009	Incidence and Risk Factors of Pneumonitis in Patients with Non-Small Cell Lung Cancer: An Observational Analysis of Real-World Data. <i>Oncology and Therapy</i> , 2021, 9, 471-488.	2.6	6
1010	Imaging spectrum of adverse events of immune checkpoint inhibitors. <i>Clinical Radiology</i> , 2021, 76, 262-272.	1.1	9
1011	A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors. <i>Journal of Medical Toxicology</i> , 2021, 17, 411-424.	1.5	54
1012	Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines. <i>Trends in Immunology</i> , 2021, 42, 293-311.	6.8	62
1013	How can we manage the cardiac toxicity of immune checkpoint inhibitors?. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1-10.	2.4	8
1014	Immune Checkpoint Inhibitor-Related Adrenal Insufficiency. <i>Seminars in Oncology Nursing</i> , 2021, 37, 151131.	1.5	2
1015	Immune-checkpoint inhibitors for lung cancer patients amid the COVID-19 pandemic: a case report of severe meningoencephalitis after switching to an extended-interval higher flat-dose nivolumab regimen. <i>Translational Lung Cancer Research</i> , 2021, 10, 1917-1923.	2.8	2
1016	Development of Vogt-Koyanagi-Harada Disease-like Uveitis during Treatment by Anti-programmed Death Ligand-1 Antibody for Non-small Cell Lung Cancer: A Case Report. <i>Ocular Immunology and Inflammation</i> , 2022, 30, 1522-1526.	1.8	10
1017	Dermatomyositis Flare With Immune Checkpoint Inhibitor Therapy for Melanoma. <i>Cureus</i> , 2021, 13, e14387.	0.5	5
1018	Do we need skin toxicity? Association of immune checkpoint inhibitor and tyrosine kinase inhibitor-related cutaneous adverse events with outcomes in metastatic renal cell carcinoma. <i>International Journal of Dermatology</i> , 2021, 60, 1242-1247.	1.0	2
1019	Hypophysitis related to immune checkpoint inhibitors: An intriguing adverse event with many faces. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1097-1120.	3.1	5
1021	Paraneoplastic Neurological Syndromes and Beyond Emerging With the Introduction of Immune Checkpoint Inhibitor Cancer Immunotherapy. <i>Frontiers in Neurology</i> , 2021, 12, 642800.	2.4	26
1022	Overlap of immunotherapy-related pneumonitis and COVID-19 pneumonia: diagnostic and vaccine considerations. , 2021, 9, e002307.		7
1023	Graves™ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review). <i>Cancers</i> , 2021, 13, 1944.	3.7	21

#	ARTICLE	IF	CITATIONS
1024	Cancer Therapy-Related Cardiovascular Complications in Clinical Practice: Current Perspectives. <i>Journal of Clinical Medicine</i> , 2021, 10, 1647.	2.4	13
1025	Gastrointestinal disorders as immune-related adverse events. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , .	0.8	2
1026	Case Report: Longitudinal Extensive Transverse Myelitis With Novel Autoantibodies Following Two Rounds of Pembrolizumab. <i>Frontiers in Neurology</i> , 2021, 12, 655283.	2.4	11
1027	Adrenal insufficiency development during chemotherapy plus anti-programmed death receptor-1 monoclonal antibody (tislelizumab) therapy in patients with advanced gastric cancer: two case reports. <i>Yeungnam University Journal of Medicine</i> , 2022, 39, 62-66.	1.4	3
1029	Pericardial Involvement in Cancer. <i>American Journal of Cardiology</i> , 2021, 145, 151-159.	1.6	22
1030	A Durable Response after the Discontinuation of Nivolumab in an Advanced Gastric Cancer Patient. <i>Internal Medicine</i> , 2021, 60, 1011-1017.	0.7	7
1031	Acute pancreatitis without abdominal pain induced by administration of nivolumab and ipilimumab. <i>Modern Rheumatology Case Reports</i> , 2021, 5, 425-430.	0.7	6
1032	Controversies on the possible role of immune checkpoint inhibitors in pediatric cancers: balancing irAEs and efficacy. <i>Tumori</i> , 2021, 107, 276-281.	1.1	6
1033	Radiological assessment of response and adverse events associated with novel systemic oncological therapies. <i>Clinical Radiology</i> , 2021, 76, 247-261.	1.1	0
1034	Hematological immune related adverse events after treatment with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2021, 147, 170-181.	2.8	40
1035	Regulatory T-cell Transcriptomic Reprogramming Characterizes Adverse Events by Checkpoint Inhibitors in Solid Tumors. <i>Cancer Immunology Research</i> , 2021, 9, 726-734.	3.4	19
1036	Rapid corticosteroid taper versus standard of care for immune checkpoint inhibitor induced nephritis: a single-center retrospective cohort study. , 2021, 9, e002292.		25
1037	The Next Decade of Immune Checkpoint Therapy. <i>Cancer Discovery</i> , 2021, 11, 838-857.	9.4	363
1038	Endocrine toxicities of immune checkpoint inhibitors. <i>Nature Reviews Endocrinology</i> , 2021, 17, 389-399.	9.6	162
1039	Immune Checkpoint Inhibitors: Common Questions About Uncommon Adverse Events. <i>Journal of the Advanced Practitioner in Oncology</i> , 2021, 12, 289-292.	0.4	0
1041	Refractory dermatitis contributed by pityriasis versicolor: a case report. <i>Journal of Medical Case Reports</i> , 2021, 15, 212.	0.8	2
1042	A case of successful pembrolizumab rechallenge in a patient with non-small-cell lung cancer and grade 3 dermatomyositis. <i>Immunotherapy</i> , 2021, 13, 477-481.	2.0	5
1043	Adverse events induced by immune checkpoint inhibitors. <i>Current Opinion in Immunology</i> , 2021, 69, 29-38.	5.5	25



#	ARTICLE	IF	CITATIONS
1044	Immune-checkpoint inhibitor toxicity during a pandemic: Overcoming patient fears to provide care. A case report. <i>Journal of Oncology Pharmacy Practice</i> , 2021, , 107815522110127.	0.9	4
1045	Immune Checkpoint Inhibitor-Induced Gastroduodenitis: Recurrence after Rechallenge with Pembrolizumab. <i>GE Portuguese Journal of Gastroenterology</i> , 2022, 29, 1-2.	0.8	0
1046	Evaluation of practical experiences of German speaking radiation oncologists in combining radiation therapy with checkpoint blockade. <i>Scientific Reports</i> , 2021, 11, 7624.	3.3	5
1047	Pembrolizumab-induced myasthenia gravis-like disorder, ocular myositis, and hepatitis: a case report. <i>Journal of Medical Case Reports</i> , 2021, 15, 244.	0.8	8
1048	Efectos adversos inmunomediados gastrointestinales y hepáticos inducidos por los inhibidores del punto de control inmunitario: estudio descriptivo observacional. <i>Gastroenterología Y Hepatología</i> , 2021, 44, 261-268.	0.5	8
1049	Expected and non-expected immune-related adverse events detectable by CT. <i>European Journal of Radiology</i> , 2021, 138, 109617.	2.6	3
1050	Adverse events of systemic immune-based combination therapies in the first-line treatment of patients with metastatic renal cell carcinoma: systematic review and network meta-analysis. <i>Current Opinion in Urology</i> , 2021, 31, 332-339.	1.8	9
1051	Investigating the Impact of Immune-Related Adverse Events, Glucocorticoid Use and Immunotherapy Interruption on Long-Term Survival Outcomes. <i>Cancers</i> , 2021, 13, 2365.	3.7	11
1052	Progressive Pulmonary Infiltrates in a Man with Mediastinal Lymphoma. <i>Annals of the American Thoracic Society</i> , 2021, 18, 884-888.	3.2	1
1053	Anti-pituitary antibodies and susceptible human leukocyte antigen alleles as predictive biomarkers for pituitary dysfunction induced by immune checkpoint inhibitors. , 2021, 9, e002493.		44
1054	Cardiotoxicity of Immune Checkpoint Inhibitors. <i>Current Oncology Reports</i> , 2021, 23, 79.	4.0	85
1056	Treatment-resistant bullous pemphigoid developing during therapy with immune checkpoint inhibitors. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e591-e593.	2.4	7
1057	Influenza vaccination in cancer patients receiving immune checkpoint inhibitors: A systematic review. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13604.	3.4	18
1058	Immune checkpoint inhibitor-related pneumonitis induced by camrelizumab: a case report and review of literature. <i>Annals of Palliative Medicine</i> , 2021, 10, 35-35.	1.2	4
1059	Uveitis in Tumor Patients Treated with Immunological Checkpoint- and Signal Transduction Pathway-Inhibitors. <i>Ocular Immunology and Inflammation</i> , 2022, 30, 1588-1594.	1.8	8
1060	Treatment-Related Serious Adverse Events of Immune Checkpoint Inhibitors in Clinical Trials: A Systematic Review. <i>Frontiers in Oncology</i> , 2021, 11, 621639.	2.8	12
1061	Vaginal mucositis related to immunotherapy in endometrial cancer. <i>Gynecologic Oncology Reports</i> , 2021, 36, 100742.	0.6	1
1062	Pembrolizumab-caused polyradiculoneuropathy as an immune-related adverse event. <i>Neuropathology</i> , 2021, 41, 266-272.	1.2	3

#	ARTICLE	IF	CITATIONS
1063	Cancer Therapeuticsâ€‘related Cardiac Dysfunction in Patients Treated With Immune Checkpoint Inhibitors: An Understudied Manifestation. <i>Journal of Immunotherapy</i> , 2021, 44, 179-184.	2.4	5
1064	Neuro-Oncologic Emergencies. <i>Neurologic Clinics</i> , 2021, 39, 545-563.	1.8	3
1065	Immune checkpoint inhibitor use in patients with end-stage kidney disease: an analysis of reported cases and literature review. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 2012-2022.	2.9	29
1066	An Emergent Form of Cardiotoxicity: Acute Myocarditis Induced by Immune Checkpoint Inhibitors. <i>Biomolecules</i> , 2021, 11, 785.	4.0	9
1068	Infectious Challenges with Novel Antibodyâ€‘Based Therapies. <i>Current Infectious Disease Reports</i> , 2021, 23, 1.	3.0	0
1069	What the Cardiologist Needs to Know About Cancer Immunotherapies and Complications. <i>Current Treatment Options in Oncology</i> , 2021, 22, 53.	3.0	2
1070	A Severe Case of Diabetic Ketoacidosis and New-Onset Type 1 Diabetes Mellitus Associated with Anti-Glutamic Acid Decarboxylase Antibodies Following Immunotherapy with Pembrolizumab. <i>American Journal of Case Reports</i> , 2021, 22, e931702.	0.8	10
1071	Non-inferior clinical outcomes of immune checkpoint inhibitors in non-small cell lung cancer patients with interstitial lung disease. <i>Lung Cancer</i> , 2021, 155, 120-126.	2.0	23
1072	The efficacy and safety of Nivolumab combined with Ipilimumab in the immunotherapy of cancer: a meta-analysis. <i>Immunopharmacology and Immunotoxicology</i> , 2021, 43, 386-394.	2.4	6
1073	Secondary pneumothorax during immunotherapy in two patients with metastatic solid tumors; a new entity. <i>Immunotherapy</i> , 2021, 13, 565-570.	2.0	7
1074	Single-cell Analysis Technologies for Immuno-oncology Research: from Mechanistic Delineation to Biomarker Discovery. <i>Genomics, Proteomics and Bioinformatics</i> , 2021, 19, 191-207.	6.9	5
1075	Informing the new developments and future of cancer immunotherapy. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 549-562.	5.9	17
1076	ACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury. <i>American Journal of Gastroenterology</i> , 2021, 116, 878-898.	0.4	144
1077	Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy. <i>Cancer Discovery</i> , 2021, 11, 2602-2619.	9.4	90
1078	Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy â€‘ A multicentre study of 90 patients from the German Dermat oncology Group. <i>European Journal of Cancer</i> , 2021, 149, 1-10.	2.8	10
1079	Clinical implications of bronchoscopy for immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer. <i>BMC Pulmonary Medicine</i> , 2021, 21, 155.	2.0	8
1080	Cutaneous Toxicities in Lung Cancer Patients on Immune Checkpoint Inhibitor Therapy. <i>Clinical Lung Cancer</i> , 2021, 22, 195-200.e1.	2.6	11
1081	Impact of concomitant medication on clinical outcomes in patients with advanced nonâ€‘small cell lung cancer treated with immune checkpoint inhibitors: A retrospective study. <i>Thoracic Cancer</i> , 2021, 12, 1983-1994.	1.9	26

#	ARTICLE	IF	CITATIONS
1082	Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management. <i>Frontiers in Immunology</i> , 2021, 12, 663986.	4.8	50
1083	Molecular and Clinical Features of Hospital Admissions in Patients with Thoracic Malignancies on Immune Checkpoint Inhibitors. <i>Cancers</i> , 2021, 13, 2653.	3.7	2
1084	Immunotherapy Management in Special Cancer Patient Populations. <i>JCO Oncology Practice</i> , 2021, 17, 240-245.	2.9	8
1085	The Impact of Adverse Events on Health Care Resource Utilization, Costs, and Mortality Among Patients Treated with Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2021, 26, e1205-e1215.	3.7	10
1086	Comparison of clinical features between immune-related sclerosing cholangitis and hepatitis. <i>Investigational New Drugs</i> , 2021, 39, 1716-1723.	2.6	17
1087	Assessment of the Clinical Trials Safety Profile of PD-1/PD-L1 Inhibitors Among Patients With Cancer: An Updated Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 662392.	2.8	3
1088	C-reactive protein as a biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting. <i>Melanoma Research</i> , 2021, 31, 371-377.	1.2	12
1089	Management of adverse events in cancer treatment with immune checkpoint inhibitors. <i>Journal of the Korean Medical Association</i> , 2021, 64, 358-365.	0.3	0
1090	Organ-Specific Immune-Related Adverse Events for PD-1 Antibodies in Lung Cancer Treatment. <i>Frontiers in Oncology</i> , 2021, 11, 628243.	2.8	1
1091	Durvalumab-induced myocarditis, myositis, and myasthenia gravis: a case report. <i>Journal of Medical Case Reports</i> , 2021, 15, 278.	0.8	11
1092	Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials. <i>European Journal of Cancer</i> , 2021, 148, 76-91.	2.8	33
1093	Histopathology of Gastrointestinal Immune-related Adverse Events. <i>American Journal of Surgical Pathology</i> , 2021, Publish Ahead of Print, e15-e26.	3.7	7
1094	Anti-Ma paraneoplastic opsoclonusâ€“myoclonus syndrome. <i>BMJ Case Reports</i> , 2021, 14, e243136.	0.5	0
1095	Combining anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and -programmed cell death protein 1 (PD-1) agents for cancer immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1623-1634.	3.1	10
1096	Clinical and Hematological Predictors of High-Grade Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors. <i>Journal of Clinical Medicine Research</i> , 2021, 13, 268-275.	1.2	7
1097	Role of Cardiac Imaging in the Diagnosis of Immune Checkpoints Inhibitors Related Myocarditis. <i>Frontiers in Oncology</i> , 2021, 11, 640985.	2.8	9
1098	Management of Hematologic Adverse Events Associated With Immune Checkpoint Inhibitors. <i>Journal of the Advanced Practitioner in Oncology</i> , 2021, 12, 392-404.	0.4	2
1099	Automated Identification of Patients With Immune-Related Adverse Events From Clinical Notes Using Word Embedding and Machine Learning. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 541-549.	2.1	8

#	ARTICLE	IF	CITATIONS
1100	Real-World Evidence of the Incidence of and Risk Factors for Type 1 Diabetes Mellitus and Hypothyroidism as Immune-Related Adverse Events Associated With Programmed Cell Death-1 Inhibitors. <i>Endocrine Practice</i> , 2021, 27, 586-593.	2.1	10
1101	A Late Dermatologic Presentation of Bullous Pemphigoid Induced by Anti-PD-1 Therapy and Associated with Unexplained Neurological Disorder. <i>Case Reports in Oncology</i> , 2021, 14, 861-867.	0.7	7
1102	Neurological Immunotoxicity from Cancer Treatment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6716.	4.1	9
1103	Multi-detector computed tomography (MDCT)-based severity score as a prognostic tool in patients with suspected immune checkpoint inhibitor therapy associated colitis. <i>European Radiology</i> , 2021, 31, 8868-8878.	4.5	2
1104	Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice. <i>Cancer Treatment Reviews</i> , 2021, 97, 102187.	7.7	31
1105	Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?. , 2021, 9, e002248.		35
1106	Post-immunotherapy imaging in lung cancer. <i>Clinical Radiology</i> , 2022, 77, 44-57.	1.1	3
1108	Endocrine Toxicity and Outcomes in Patients With Metastatic Malignancies Treated With Immune Checkpoint Inhibitors. <i>Journal of the Endocrine Society</i> , 2021, 5, bvab100.	0.2	9
1109	Safe anti-programmed cell death-1 rechallenge with antibody switching after immune-related adverse events: brief communication. <i>Immunotherapy</i> , 2021, 13, 745-752.	2.0	2
1110	Plasma Proteomic Analysis in Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Blockade. <i>Cancers</i> , 2021, 13, 3116.	3.7	17
1111	Immune Checkpoint Inhibitors-Related Thyroid Dysfunction: Epidemiology, Clinical Presentation, Possible Pathogenesis, and Management. <i>Frontiers in Endocrinology</i> , 2021, 12, 649863.	3.5	24
1112	Outcomes of Immune Checkpoint Inhibitor-related Diarrhea or Colitis in Cancer Patients With Superimposed Gastrointestinal Infections. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 402-408.	1.3	7
1113	Recent Advances in the Treatment of Melanoma. <i>New England Journal of Medicine</i> , 2021, 384, 2229-2240.	27.0	201
1114	The Comprehensive "Omics" Approach from Metabolomics to Advanced Omics for Development of Immune Checkpoint Inhibitors: Potential Strategies for Next Generation of Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6932.	4.1	9
1115	Managing side effects of immune checkpoint inhibitors in breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 162, 103354.	4.4	15
1116	Meta-analysis of immune-related adverse events in phase 3 clinical trials assessing immune checkpoint inhibitors for lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 162, 103351.	4.4	24
1117	Association of immune-related pneumonitis with clinical benefit of anti-programmed cell death-1 monotherapy in advanced non-small cell lung cancer. <i>Cancer Medicine</i> , 2021, 10, 4796-4804.	2.8	13
1118	A case of immune-related adverse effect diffuse gastritis induced by nivolumab. <i>Progress of Digestive Endoscopy</i> , 2021, 98, 91-92.	0.0	1

#	ARTICLE	IF	CITATIONS
1119	Risk factors for adverse events induced by immune checkpoint inhibitors in patients with non-small-cell lung cancer: a systematic review and meta-analysis. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3069-3080.	4.2	31
1120	Trial eligibility in advanced hepatocellular carcinoma: Does it support clinical practice in underrepresented subgroups?. <i>World Journal of Gastroenterology</i> , 2021, 27, 3429-3439.	3.3	4
1121	Preexisting autoimmune disease is a risk factor for immune-related adverse events: a meta-analysis. <i>Supportive Care in Cancer</i> , 2021, 29, 7747-7753.	2.2	14
1122	New-Onset Refractory Status Epilepticus (NORSE) as a Recurrence of Anti-Neuronal Nuclear Antibody 2 (ANNA-2) Encephalitis After Immune Checkpoint Inhibition Therapy. <i>Cureus</i> , 2021, 13, e16074.	0.5	1
1123	Atezolizumab, a PD-L1 Inhibitor: An Association of Bleeding Gastric Ulcer With Its Use. <i>Cureus</i> , 2021, 13, e15637.	0.5	2
1124	Cardiovascular Complications Associated with Contemporary Lung Cancer Treatments. <i>Current Treatment Options in Oncology</i> , 2021, 22, 71.	3.0	3
1125	Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1030-1041.	1.1	79
1127	PD-L1 detection on circulating tumor-derived extracellular vesicles (T-EVs) from patients with lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 2441-2451.	2.8	19
1128	Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis. , 2021, 9, e002553.		24
1129	The Diagnosis and Management of Endocrine Side Effects of Immune Checkpoint Inhibitors. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 2021, 118, .	0.9	7
1130	Symphony of nanomaterials and immunotherapy based on the cancerâ€™immunity cycle. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 107-134.	12.0	70
1131	Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency. <i>Scientific Reports</i> , 2021, 11, 11617.	3.3	9
1132	Combined immunotherapy of colorectal cancer in young patient with microsatellite instability (clinical case). <i>Medical Alphabet</i> , 2021, , 16-21.	0.2	0
1133	Cardiooncologyâ€™ dealing with modern drug treatment, long-term complications, and cancer survivorship. <i>Clinical and Experimental Metastasis</i> , 2021, 38, 361-371.	3.3	7
1134	Managing toxicities associated with immune checkpoint inhibitors. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2021, 34, 32-39.	0.3	5
1135	Guidelines for clinical evaluation of antiâ€™cancer drugs. <i>Cancer Science</i> , 2021, 112, 2563-2577.	3.9	17
1136	Real World Outcomes and Hepatotoxicity of Infliximab in the Treatment of Steroid-Refractory Immune-Related Adverse Events. <i>Current Oncology</i> , 2021, 28, 2173-2179.	2.2	14
1137	The knowns & unknowns of pulmonary toxicity following immune checkpoint inhibitor therapies: a narrative review. <i>Translational Lung Cancer Research</i> , 2021, 10, 2752-2765.	2.8	5

#	ARTICLE	IF	CITATIONS
1138	Unified exact design with early stopping rules for single arm clinical trials with multiple endpoints. <i>Statistical Methods in Medical Research</i> , 2021, 30, 1575-1588.	1.5	1
1139	Triple Combination Therapy With PD-1/PD-L1, BRAF, and MEK Inhibitor for Stage III-IV Melanoma: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 693655.	2.8	16
1141	Drug-induced immune-mediated thrombocytopenia secondary to durvalumab use. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e04227.	0.5	5
1142	Renal Complications Related to Checkpoint Inhibitors: Diagnostic and Therapeutic Strategies. <i>Diagnostics</i> , 2021, 11, 1187.	2.6	10
1143	Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance. <i>Drug Safety</i> , 2021, 44, 957-971.	3.2	38
1144	Adverse Events Induced by PD-1/PD-L1 Inhibitors: A Real-World Single-Centre Experience with a Management-Based Approach. <i>Therapeutics and Clinical Risk Management</i> , 2021, Volume 17, 669-677.	2.0	10
1145	Atezolizumab and bevacizumab-induced encephalitis in advanced hepatocellular carcinoma. <i>Medicine (United States)</i> , 2021, 100, e26377.	1.0	10
1146	Kidney injury associated with antitumor therapy: focus on the adverse events of modern immuno-oncological drugs. <i>Terapevticheskii Arkhiv</i> , 2021, 93, 649-660.	0.8	0
1147	Metabolic disease and adverse events from immune checkpoint inhibitors. <i>European Journal of Endocrinology</i> , 2021, 184, 857-865.	3.7	12
1149	Long-term immune-related adverse events after discontinuation of immunotherapy. <i>Immunotherapy</i> , 2021, 13, 735-740.	2.0	5
1150	Immune Checkpoint Inhibitors in the Management of Urothelial Carcinoma. , 2021, 3, 115-136.		2
1151	Current controversies and advances in the management of pancreatic adenocarcinoma. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 472-494.	2.0	9
1152	Late-onset adverse events of anti-PD1 therapy in melanoma patients: An observational study from MELBASE, a nationwide prospective cohort. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 345-352.	1.2	5
1153	Hypersensitivity reactions and anaphylaxis to checkpoint inhibitor monoclonal antibodies and desensitization. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 126, 623-629.	1.0	10
1154	Impact of the development of immune related adverse events in metastatic melanoma treated with PD -1 inhibitors. <i>Melanoma Research</i> , 2021, 31, 258-263.	1.2	9
1155	Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy. <i>European Journal of Heart Failure</i> , 2021, 23, 1725-1735.	7.1	51
1156	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. , 2021, 9, e002435.		298
1157	Immune checkpoint inhibitors: current status. <i>BMJ Supportive and Palliative Care</i> , 2021, , bmjspcare-2021-002954.	1.6	1

#	ARTICLE	IF	CITATIONS
1158	Genetic variation associated with thyroid autoimmunity shapes the systemic immune response to PD-1 checkpoint blockade. <i>Nature Communications</i> , 2021, 12, 3355.	12.8	40
1159	Case Report: Durvalumab-Associated Encephalitis in Extensive-Stage Small Cell Lung Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 693279.	2.8	3
1160	High-dose corticosteroid use and risk of hospitalization for infection in patients treated with immune checkpoint inhibitors—A nationwide register-based cohort study. <i>Cancer Medicine</i> , 2021, 10, 4957-4963.	2.8	8
1161	Pericardial disease in patients treated with immune checkpoint inhibitors. , 2021, 9, e002771.		33
1162	Immune checkpoint inhibitors-related encephalitis in melanoma and non-melanoma cancer patients: a single center experience. <i>Supportive Care in Cancer</i> , 2021, 29, 7563-7568.	2.2	8
1163	A Review of Treatment-Induced Pulmonary Toxicity in Breast Cancer. <i>Clinical Breast Cancer</i> , 2022, 22, 1-9.	2.4	6
1164	Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system. <i>International Immunopharmacology</i> , 2021, 95, 107498.	3.8	45
1165	Sarcoidosis and malignancy: the chicken and the egg?. <i>Current Opinion in Pulmonary Medicine</i> , 2021, 27, 455-462.	2.6	6
1166	Intrahepatic Bile Duct Injury as a Hepatic Immune-Related Adverse Event after Immune-Checkpoint Inhibitor Treatment. <i>Case Reports in Gastroenterology</i> , 2021, 15, 645-651.	0.6	2
1167	Prognostic impact of immune-related adverse events on patients with and without cardiovascular disease: a retrospective review. <i>Cardio-Oncology</i> , 2021, 7, 26.	1.7	3
1168	The incidence of gastrointestinal adverse events in patients with advanced non-small cell lung cancer (NSCLC) treated with PD-1 inhibitors: a meta-analysis. <i>Translational Cancer Research</i> , 2021, 10, 3389-3403.	1.0	1
1169	Peripheral Blood Biomarkers for Early Diagnosis, Severity, and Prognosis of Checkpoint Inhibitor-Related Pneumonitis in Patients With Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 698832.	2.8	27
1170	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer. , 2021, 9, e002552.		16
1171	Cardiovascular toxicity of angiogenesis inhibitors and immune checkpoint inhibitors: synergistic anti-tumour effects at the cost of increased cardiovascular risk?. <i>Clinical Science</i> , 2021, 135, 1649-1668.	4.3	10
1172	Takotsubo Cardiomyopathy as Epiphenomenon of Cardiotoxicity in Patients With Cancer: A Meta-summary of Case Reports. <i>Journal of Cardiovascular Pharmacology</i> , 2021, 78, e20-e29.	1.9	17
1173	Refractory Nivolumab-Induced Myasthenia Gravis Treated With Abatacept. <i>American Journal of Therapeutics</i> , 2021, Publish Ahead of Print, .	0.9	3
1174	Management of Gastrointestinal Side Effects of Immune Checkpoint Inhibitors. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2262-2265.	4.4	2
1175	Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. , 2021, 9, e002890.		87

#	ARTICLE	IF	CITATIONS
1176	Mogamulizumab-Associated Acute Myocarditis in a Patient With T-Cell Lymphoma. <i>JACC: Case Reports</i> , 2021, 3, 1018-1023.	0.6	5
1177	Immunotherapy for esophageal carcinoma: a narrative review. <i>Shanghai Chest</i> , 0, 5, 26-26.	0.3	0
1178	Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria. <i>Hepatology Research</i> , 2021, 51, 979-989.	3.4	20
1179	Improvement in Labeling Efficiency of Hydrophilic and Hydrophobic Fluorescent Molecules in Thick Tissue Sections. <i>Microscopy Today</i> , 2021, 29, 22-29.	0.3	0
1180	Cemiplimab for Locally Advanced and Metastatic Cutaneous Squamous-Cell Carcinomas: Real-Life Experience from the French CAREPI Study Group. <i>Cancers</i> , 2021, 13, 3547.	3.7	31
1181	Neoadjuvant Programmed Cell Death 1 (PD-1) Inhibitor Treatment in Patients With Hepatocellular Carcinoma Before Liver Transplant: A Cohort Study and Literature Review. <i>Frontiers in Immunology</i> , 2021, 12, 653437.	4.8	41
1182	Cutaneous adverse events associated with immune checkpoint blockade: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103376.	4.4	9
1183	Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor-Associated Myocarditis. <i>JAMA Cardiology</i> , 2021, 6, 1329.	6.1	64
1184	Targeting the Gut Microbiome to Mitigate Immunotherapy-Induced Colitis in Cancer. <i>Trends in Cancer</i> , 2021, 7, 583-593.	7.4	26
1185	Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2021, 26, e1742-e1750.	3.7	17
1186	Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events. , 2021, 9, e002850.		15
1187	Clinical complete response after nivolumab administered as a third-line treatment for unresectable advanced gastric cancer with peritoneal dissemination: A case report. <i>International Journal of Surgery Case Reports</i> , 2021, 84, 106161.	0.6	6
1188	Immunotherapy in Older Adults With Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2115-2127.	1.6	33
1189	Real-World Experience of Talimogene Laherparepvec (T-VEC) in Old and Oldest-Old Patients with Melanoma: A Retrospective Single Center Study. <i>Cancer Management and Research</i> , 2021, Volume 13, 5699-5709.	1.9	6
1190	Clinical Course and Treatment Implications of Combination Immune Checkpoint Inhibitor-Mediated Hepatitis: A Multicentre Cohort. <i>Journal of the Canadian Association of Gastroenterology</i> , 2022, 5, 39-47.	0.3	3
1191	Myocarditis Induced by Immune Checkpoint Inhibitors: Mechanisms and Therapeutic Prospects. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 3077-3088.	3.5	5
1192	Hypersensitivity and Immune-related Adverse Events in Biologic Therapy. <i>Clinical Reviews in Allergy and Immunology</i> , 2022, 62, 413-431.	6.5	6
1193	Ocular adverse events in PD-1 and PD-L1 inhibitors. , 2021, 9, e002119.		13



#	ARTICLE	IF	CITATIONS
1194	Management of PD-1/PD-L1 blockade immune-related skin toxicities: perspectives and issues. <i>Immunotherapy</i> , 2021, 13, 795-798.	2.0	0
1195	Immune-Related Meningoencephalitis following Nivolumab in Metastatic Renal Cell Carcinoma. <i>Case Reports in Oncology</i> , 2021, 14, 1051-1058.	0.7	5
1196	Palliative Chemotherapy and the Surgical Oncologist. <i>Surgical Oncology Clinics of North America</i> , 2021, 30, 545-561.	1.5	0
1197	Mechanisms Driving Immune-Related Adverse Events in Cancer Patients Treated with Immune Checkpoint Inhibitors. <i>Current Cardiology Reports</i> , 2021, 23, 98.	2.9	34
1198	Rituximab for Immune Checkpoint Inhibitor Myasthenia Gravis. <i>Cureus</i> , 2021, 13, e16337.	0.5	10
1199	Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data. , 2021, 9, e002896.		20
1200	Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial. <i>European Urology Oncology</i> , 2022, 5, 225-234.	5.4	17
1202	Current cancer therapies and their influence on glucose control. <i>World Journal of Diabetes</i> , 2021, 12, 1010-1025.	3.5	10
1203	A case of cancer-associated hyponatraemia: primary adrenal insufficiency secondary to nivolumab. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2021, 21, .	1.2	5
1204	Serum Troponin T Concentrations Are Frequently Elevated in Advanced Skin Cancer Patients Prior to Immune Checkpoint Inhibitor Therapy: Experience From a Single Tertiary Referral Center. <i>Frontiers in Medicine</i> , 2021, 8, 691618.	2.6	4
1205	Rare side effect caused by atezolizumab, an immune checkpoint inhibitor: Cold agglutinin disease. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 2066-2068.	0.9	3
1206	New systemic therapies for cutaneous melanoma: why, who and what. <i>Italian Journal of Dermatology and Venereology</i> , 2021, 156, 344-355.	0.2	2
1207	Intravenous immunoglobulin efficacy on pembrolizumab induced severe toxic epidermal necrolysis. <i>Anti-Cancer Drugs</i> , 2022, 33, e738-e740.	1.4	6
1208	Endocrine adverse effects of immune checkpoint inhibitors. <i>Internal Medicine Journal</i> , 2021, 51, 1016-1020.	0.8	2
1209	Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12. <i>Cancer Research and Treatment</i> , 2021, 53, 671-677.	3.0	14
1210	Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis. <i>Journal of Hepatology</i> , 2021, 75, 177-189.	3.7	29
1211	Immune-related myocarditis in two patients receiving camrelizumab therapy and document analysis. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 1350-1356.	0.9	8
1212	Toxicity of Immunotherapeutic Agents. <i>Critical Care Clinics</i> , 2021, 37, 605-624.	2.6	2

#	ARTICLE	IF	CITATIONS
1213	Early presentation of pembrolizumab-associated pneumonitis. <i>BMJ Case Reports</i> , 2021, 14, e242493.	0.5	3
1214	Chinese expert recommendations on management of hepatocellular carcinoma during COVID-19 pandemic: a nationwide multicenter survey. <i>Hpb</i> , 2022, 24, 342-352.	0.3	5
1216	Inhibitors of immune checkpointsâ€”PD-1, PD-L1, CTLA-4â€”new opportunities for cancer patients and a new challenge for internists and general practitioners. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 949-982.	5.9	72
1217	Characterization and management of neurological adverse events during immune-checkpoint inhibitors treatment: an Italian multicentric experience. <i>Neurological Sciences</i> , 2022, 43, 2031-2041.	1.9	16
1218	Checkpoint inhibitor-induced fulminant myocarditis, complete atrioventricular block and myasthenia gravisâ€”a case report. <i>Cardiovascular Diagnosis and Therapy</i> , 2021, 11, 1013-1019.	1.7	18
1219	Clinical implications of isolated troponinemia following immune checkpoint inhibitor therapy. <i>ESMO Open</i> , 2021, 6, 100216.	4.5	17
1220	Cancer treatment-related cardiovascular disease: Current status and future research priorities. <i>Biochemical Pharmacology</i> , 2021, 190, 114599.	4.4	14
1221	Use and Toxicity of Checkpoint Inhibitors for Solid Tumor Treatment in a Veteran Population. , 2021, 38, S46-S51.		0
1222	Trends in the Research Into Immune Checkpoint Blockade by Anti-PD1/PDL1 Antibodies in Cancer Immunotherapy: A Bibliometric Study. <i>Frontiers in Pharmacology</i> , 2021, 12, 670900.	3.5	9
1223	Lung cancer. <i>Lancet, The</i> , 2021, 398, 535-554.	13.7	896
1224	Systemic Treatment of Cutaneous Adverse Events After Immune Checkpoint Inhibitor Therapy: A Review. <i>Dermatitis</i> , 2023, 34, 201-208.	1.6	4
1225	Anti-PD-1 treatment-induced immediate central diabetes insipidus: a case report. <i>Immunotherapy</i> , 2021, 13, 1255-1260.	2.0	13
1226	Anti-PD-1 and regorafenib induce severe multisystem adverse events in microsatellite stability metastatic colorectal cancer: a case report. <i>Immunotherapy</i> , 2021, 13, 1317-1323.	2.0	4
1227	A case report of immune checkpoint inhibitor-related steroid-refractory myocarditis and myasthenia gravis-like myositis treated with abatacept and mycophenolate mofetil. <i>European Heart Journal - Case Reports</i> , 2021, 5, ytab342.	0.6	23
1228	Advances in immune therapies for the treatment of microsatellite instabilityâ€”high/deficient mismatch repair metastatic colorectal cancer (Review). <i>International Journal of Oncology</i> , 2021, 59, .	3.3	4
1229	Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity. <i>Nature Communications</i> , 2021, 12, 5137.	12.8	63
1230	Presynaptic Paraneoplastic Disorders of the Neuromuscular Junction: An Update. <i>Brain Sciences</i> , 2021, 11, 1035.	2.3	6
1231	Biological Therapies for Rheumatoid Arthritis: An Overview for the Clinician. <i>Biologics: Targets and Therapy</i> , 2021, Volume 15, 343-352.	3.2	10

#	ARTICLE	IF	CITATIONS
1232	ECCO Topical Review on Clinicopathological Spectrum and Differential Diagnosis of Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 343-368.	1.3	17
1233	Immunotherapy Treatment for Triple Negative Breast Cancer. <i>Pharmaceuticals</i> , 2021, 14, 763.	3.8	30
1234	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. , 2021, 9, e002597.		45
1235	Knowledge About Risks, Benefits, and Curative Potential of Immunotherapy Among Patients with Advanced Cancer. <i>Oncologist</i> , 2021, 26, e2090-e2093.	3.7	5
1236	Consecutive severe immune-related adverse events after PD-1 inhibitor induction and surgery in locally advanced non-small cell lung cancer: a case report. <i>Translational Lung Cancer Research</i> , 2021, 10, 3682-3688.	2.8	9
1237	Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice. <i>Cancers</i> , 2021, 13, 3958.	3.7	29
1238	Liver Injury and Use of Contrast-Enhanced Ultrasound for Evaluating Intrahepatic Recurrence in a Case of TACE-Refractory Hepatocellular Carcinoma Receiving Atezolizumab-Bevacizumab Combination Therapy: A Case Report. <i>Diagnostics</i> , 2021, 11, 1394.	2.6	1
1239	Keeping immune checkpoint inhibitor myocarditis in check: advanced circulatory mechanical support as a bridge to recovery. <i>ESC Heart Failure</i> , 2021, 8, 4301-4306.	3.1	10
1240	<sc>Real-World</sc> Clinical and Economic Outcomes in Selected <sc>Immune-Related</sc> Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2021, 26, e2002-e2012.	3.7	11
1241	Immune checkpoint inhibitor-associated myasthenia gravis, myositis, and myocarditis overlap syndrome. <i>American Journal of Emergency Medicine</i> , 2021, 46, 51-55.	1.6	26
1242	Human immunocompetent Organ-on-Chip platforms allow safety profiling of tumor-targeted T-cell bispecific antibodies. <i>ELife</i> , 2021, 10, .	6.0	33
1243	Metastatic acral melanoma treatment outcomes: a systematic review and meta-analysis. <i>Melanoma Research</i> , 2021, 31, 482-486.	1.2	9
1244	Acute cardiac manifestations under immune checkpoint inhibitorsâ€”beware of the obvious: a case report. <i>European Heart Journal - Case Reports</i> , 2021, 5, ytab262.	0.6	6
1245	Immune checkpoint inhibitor-mediated colitis in gastrointestinal malignancies and inflammatory bowel disease. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 772-798.	2.0	11
1246	Clinical course of liver injury induced by immune checkpoint inhibitors in patients with advanced malignancies. <i>Hepatology International</i> , 2021, 15, 1278-1287.	4.2	16
1247	Guillain-BarrÃ© Syndrome-Like Polyneuropathy Associated with Immune Checkpoint Inhibitors: A Systematic Review of 33 Cases. <i>BioMed Research International</i> , 2021, 2021, 1-17.	1.9	10
1248	Understanding adverse events related to perioperative immunotherapy: A primer for thoracic surgeons. <i>Thoracic Cancer</i> , 2021, 12, 2291-2292.	1.9	0
1249	Predictors of Rheumatic <sc>Immune-Related</sc> Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer. <i>Arthritis and Rheumatology</i> , 2022, 74, 527-540.	5.6	21

#	ARTICLE	IF	CITATIONS
1250	Immune checkpoint inhibitor-induced myocarditis in cancer patients: a case report and review of reported cases. <i>Cardio-Oncology</i> , 2021, 7, 27.	1.7	17
1251	Improvement in recurring nivolumab-induced pneumonitis with repetitive administration of infliximab in a patient with head and neck cancer: A case report. <i>Molecular and Clinical Oncology</i> , 2021, 15, 221.	1.0	2
1252	Telomere Shortening in Peripheral Leukocytes Is Associated With Poor Survival in Cancer Patients Treated With Immune Checkpoint Inhibitor Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 729207.	2.8	5
1254	Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer. <i>Chest</i> , 2021, 160, 731-742.	0.8	64
1255	Emergency Presentations of Immune Checkpoint Inhibitor-Related Endocrinopathies. <i>Journal of Emergency Medicine</i> , 2021, 61, 140-146.	0.7	2
1256	Pneumonitis, appendicitis, and biliary obstruction during toripalimab treatment in a patient with extensive-stage small-cell lung cancer: a case report. <i>Annals of Palliative Medicine</i> , 2021, 10, 9267-9275.	1.2	2
1257	Cemiplimab- and nivolumab-induced myasthenia gravis: two clinical cases. <i>Tumori</i> , 2021, 107, NP123-NP126.	1.1	3
1258	How Could Antibiotics, Probiotics, and Corticoids Modify Microbiota and Its Influence in Cancer Immune Checkpoint Inhibitors: A Review. <i>Infection and Immunity</i> , 2021, 89, e0066520.	2.2	7
1260	Immune checkpoint inhibitor-related hepatotoxicity: A review. <i>World Journal of Gastroenterology</i> , 2021, 27, 5376-5391.	3.3	52
1261	Challenges of Immunotherapy in Stage IV Non-Small-Cell Lung Cancer. <i>JCO Oncology Practice</i> , 2021, 17, 465-471.	2.9	6
1262	Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series. <i>European Journal of Internal Medicine</i> , 2021, 93, 87-94.	2.2	41
1263	Case Report: The Neuromuscular Triad of Immune Checkpoint Inhibitors: A Case Report of Myositis, Myocarditis, and Myasthenia Gravis Overlap Following Toripalimab Treatment. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 714460.	2.4	12
1264	Current Status of Immune Checkpoint Inhibitor Immunotherapy for Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 704336.	2.8	29
1266	Pembrolizumab-induced autoimmune side effects of colon and pancreas in a patient with lung cancer. <i>Clinical Journal of Gastroenterology</i> , 2021, 14, 1692-1699.	0.8	12
1267	Phase Ib study of patients with metastatic castrate-resistant prostate cancer treated with different sequencing regimens of atezolizumab and sipuleucel-T. , 2021, 9, e002931.		18
1268	Imaging Features of Pulmonary Immune-related Adverse Events. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1449-1460.	1.1	8
1269	Downregulation of DNMT3a expression by RNAi and its effect on NF- $\kappa$ Bs expression of thymic epithelial cells. <i>Immunology Letters</i> , 2021, 237, 17-26.	2.5	3
1270	Immune checkpoint inhibitors and cardiotoxicity: possible mechanisms, manifestations, diagnosis and management. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1211-1228.	2.4	1

#	ARTICLE	IF	CITATIONS
1271	Utility of Liver Biopsy in Diagnosis and Management of High-grade Immune Checkpoint Inhibitor Hepatitis in Patients With Cancer. <i>JAMA Oncology</i> , 2021, 7, 1711.	7.1	18
1272	Immune-Related Adverse Events Associated With Outcomes in Patients With NSCLC Treated With Anti-PD-1 Inhibitors: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 708195.	2.8	16
1273	Activated osteoarthritis following immune checkpoint inhibitor treatment: an observational study. , 2021, 9, e003260.		7
1274	Hypothyroidism is a predictive factor of superior antitumour efficacy of programmed death 1 inhibitors in hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2022, 150, 472-481.	5.1	8
1275	Immunopathological basis of immune-related adverse events induced by immune checkpoint blockade therapy. <i>Immunological Medicine</i> , 2022, 45, 108-118.	2.6	10
1276	Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer. , 2021, 9, e002886.		9
1277	Development of Nivolumab/Ipilimumab-Associated Autoimmune Nephritis during Steroid Therapy. Case Reports in Nephrology and Dialysis, 2021, 11, 270-274.	0.6	6
1278	Hypophysitis, the Growing Spectrum of a Rare Pituitary Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 10-28.	3.6	48
1279	Clinical Review on the Management of Metastatic Renal Cell Carcinoma. <i>JCO Oncology Practice</i> , 2022, 18, 187-196.	2.9	62
1280	Drug-induced liver injury: A management position paper from the Latin American Association for Study of the liver. <i>Annals of Hepatology</i> , 2021, 24, 100321.	1.5	19
1282	Management and Outcomes of Hematological Immune-related Adverse Events: Systematic Review and Meta-analysis. <i>Journal of Immunotherapy</i> , 2022, 45, 13-24.	2.4	10
1283	Impact of Pharmacists on Identification of Immune Checkpoint Inhibitor Toxicities. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 0, , .	1.0	0
1284	Interventional Strategies in Cancer-induced Cardiovascular Disease. <i>Current Oncology Reports</i> , 2021, 23, 133.	4.0	2
1285	Usage Patterns and Incidence of Thyroid-related Adverse Events in Patients Treated with PD-1 Inhibitors. <i>Korean Journal of Clinical Pharmacy</i> , 2021, 31, 188-197.	0.3	0
1286	Healthcare costs related to adverse events in hepatocellular carcinoma treatment: A retrospective observational claims study. <i>Cancer Reports</i> , 2022, 5, e1504.	1.4	3
1287	In Vivo Measurement of Granzyme Proteolysis from Activated Immune Cells with PET. <i>ACS Central Science</i> , 2021, 7, 1638-1649.	11.3	30
1288	Gastrointestinal Adverse Events Induced by Immune-Checkpoint Inhibitors. <i>Digestion</i> , 2021, 102, 965-973.	2.3	2
1289	Minimal Change Disease Associated With Durvalumab. <i>Kidney International Reports</i> , 2021, 6, 2733-2734.	0.8	5

#	ARTICLE	IF	CITATIONS
1290	Nephrotoxicity of cancer therapeutic drugs: Focusing on novel agents. <i>Kidney Research and Clinical Practice</i> , 2021, 40, 344-354.	2.2	5
1291	Real-World Incidence and Management of Immune-Related Adverse Events from Immune Checkpoint Inhibitors: Retrospective Claims-Based Analysis. <i>Cancer Investigation</i> , 2021, 39, 789-796.	1.3	5
1292	Cardiotoxicity in cancer immune-checkpoint therapy: Mechanisms, clinical evidence, and management strategies. <i>International Journal of Cardiology</i> , 2021, 344, 170-178.	1.7	13
1293	Management of Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 720759.	2.8	3
1294	Inflammatory Myositis in a Patient With Melanoma. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 865.	7.4	1
1295	Cardiac Toxicity Associated with Cancer Immunotherapy and Biological Drugs. <i>Cancers</i> , 2021, 13, 4797.	3.7	12
1296	The Prognostic Significance of the Continuous Administration of Anti-PD-1 Antibody via Continuation or Rechallenge After the Occurrence of Immune-Related Adverse Events. <i>Frontiers in Oncology</i> , 2021, 11, 704475.	2.8	7
1297	Atezolizumab-associated Dermatomyositis in Advanced Small-cell Lung Carcinoma. <i>Internal Medicine</i> , 2021, 60, 3025-3029.	0.7	10
1298	Research Progresses in Immunological Checkpoint Inhibitors for Breast Cancer Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 582664.	2.8	11
1299	Tumors, tumor therapies, autoimmunity and the eye. <i>Autoimmunity Reviews</i> , 2021, 20, 102892.	5.8	7
1300	Is rechallenge appropriate in patients that develop immune checkpoint inhibitor-associated AKI? CON. <i>Kidney360</i> , 0, , 10.34067/KID.0003902021.	2.1	0
1301	Embracing cancer immunotherapy with vital micronutrients. <i>World Journal of Clinical Oncology</i> , 2021, 12, 712-724.	2.3	10
1302	Neurological disorders associated with immune checkpoint inhibitors: an association with autoantibodies. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 769-775.	4.2	22
1303	Immunomodulating Therapies in Breast Cancer—From Prognosis to Clinical Practice. <i>Cancers</i> , 2021, 13, 4883.	3.7	15
1304	Spontaneous recovery of immune checkpoint inhibitor-induced thyroiditis with high free T4 level: A case report. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e04781.	0.5	1
1305	Hypophysitis induced by ipilimumab and nivolumab combination therapy for advanced renal cell carcinoma: A case report. <i>Urology Case Reports</i> , 2021, 38, 101661.	0.3	3
1306	Immune checkpoint inhibitors in melanoma. <i>Lancet, The</i> , 2021, 398, 1002-1014.	13.7	462
1308	Immune-related adverse events in cancer patients being treated with immune checkpoint inhibitors. <i>European Journal of Haematology</i> , 2021, 107, 650-657.	2.2	4

#	ARTICLE	IF	CITATIONS
1309	Efficacy and safety of PD-1/PD-L1 plus CTLA-4 antibodies ± other therapies in lung cancer: a systematic review and meta-analysis. <i>European Journal of Hospital Pharmacy</i> , 2023, 30, 3-8.	1.1	9
1310	Xerostomia: an immunotherapy-related adverse effect in cancer patients. <i>Supportive Care in Cancer</i> , 2022, 30, 1681-1687.	2.2	12
1311	Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet</i> , The, 2021, 398, 1344-1357.	13.7	689
1312	Critically ill patients with severe immune checkpoint inhibitor related neurotoxicity: A multi-center case series. <i>Journal of Critical Care</i> , 2021, 65, 126-132.	2.2	6
1313	Cutaneous adverse events caused by immune checkpoint inhibitors. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 956-966.	1.2	59
1314	Interstitial Lung Abnormalities: State of the Art. <i>Radiology</i> , 2021, 301, 19-34.	7.3	63
1315	Antiphospholipid syndrome-induced ischemic stroke following pembrolizumab: Case report and systematic review. <i>Lung Cancer</i> , 2021, 160, 59-65.	2.0	6
1316	Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1759-1764.	1.1	49
1317	Clinical Characteristics and Outcomes in Immune Checkpoint Inhibitor Therapy-Associated Myocarditis. <i>Cardiology Research</i> , 2021, 12, 270-278.	1.1	6
1318	Interferon-Gamma-Producing CD8+ Tissue Resident Memory T Cells Are a Targetable Hallmark of Immune Checkpoint Inhibitor-Associated Colitis. <i>Gastroenterology</i> , 2021, 161, 1229-1244.e9.	1.3	87
1319	Nivolumab-associated DRESS in a genetic susceptible individual. , 2021, 9, e002879.		16
1320	Neurological complications induced by immune checkpoint inhibitors: a comprehensive descriptive case-series unravelling high risk of long-term sequelae. <i>Brain Communications</i> , 2021, 3, fcab220.	3.3	16
1321	Important Surgical and Clinical End Points in Neoadjuvant Immunotherapy Trials in Resectable NSCLC. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100221.	1.1	13
1322	Successful Treatment of Steroid-Refractory Checkpoint Inhibitor Myocarditis with Globulin Derived-Therapy: A Case Report and Literature Review. <i>American Journal of the Medical Sciences</i> , 2021, 362, 424-432.	1.1	5
1323	Current treatment of brain tumours. <i>Neurologie Pro Praxi</i> , 2021, 22, 206-211.	0.1	3
1324	Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC. <i>Lung Cancer</i> , 2021, 161, 34-41.	2.0	7
1325	Treatment strategy for myocarditis in patients using immune checkpoint inhibitors or combined anti-vascular endothelial growth factor therapy by clinical severity. <i>European Journal of Cancer</i> , 2021, 157, 10-20.	2.8	4
1326	Sex differences in the behavioral and immune responses of mice to tumor growth and cancer therapy. <i>Brain, Behavior, and Immunity</i> , 2021, 98, 161-172.	4.1	6

#	ARTICLE	IF	CITATIONS
1327	Immune checkpoint inhibitor cardiotoxicity: Breaking barriers in the cardiovascular immune landscape. <i>Journal of Molecular and Cellular Cardiology</i> , 2021, 160, 121-127.	1.9	6
1328	Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 100, 102280.	7.7	10
1329	Current status and future perspective of immune checkpoint inhibitors in colorectal cancer. <i>Cancer Letters</i> , 2021, 521, 119-129.	7.2	16
1330	Ocular side effects of checkpoint inhibitors. <i>Survey of Ophthalmology</i> , 2021, 66, 951-959.	4.0	16
1331	Autopsy of a patient with fatal Epstein-Barr virus-associated encephalitis after treatment with immune checkpoint inhibitors for advanced lung adenocarcinoma: A case report. <i>Current Problems in Cancer Case Reports</i> , 2021, 4, 100108.	0.1	0
1332	Cardiotoxicity associated with immune checkpoint inhibitors and CAR T-cell therapy. <i>American Journal of Emergency Medicine</i> , 2021, 50, 51-58.	1.6	6
1333	Immune checkpoint inhibitors: An emergency medicine focused review. <i>American Journal of Emergency Medicine</i> , 2021, 50, 335-344.	1.6	5
1334	Multitarget therapy for pembrolizumab-induced refractory hemophagocytic lympho histiocytosis. <i>Current Problems in Cancer Case Reports</i> , 2021, 4, 100120.	0.1	0
1335	Atezolizumab-induced bilateral anterior uveitis: A case report. <i>American Journal of Ophthalmology Case Reports</i> , 2021, 24, 101205.	0.7	2
1336	Treatment and Management of Infectious, Granulomatous, and Toxic Neuromuscular Disorders. , 2022, , 345-379.		0
1337	Results of Mechanical Ventilation in Cancer Patients. , 2022, , 555-561.		0
1338	Follow-up Care for Patients Receiving Immune Checkpoint Inhibitors. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2021, 8, 596-603.	1.6	6
1339	Development of Skin Rash Predicts Outcome of Anti-PD-1- and Anti-CTLA4-Based Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer or Squamous Cell Carcinoma of the Head and Neck: A Single-Center Analysis. <i>Oncology Research and Treatment</i> , 2021, 44, 538-546.	1.2	5
1340	Oral Immune-Related Adverse Events – Current Concepts and their Management. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2021, 8, 604-609.	1.6	2
1341	Neurologic complications of immune checkpoint inhibitors. , 2021, , 371-380.		1
1342	Febrile neutropenia in a patient with non-small-cell lung cancer treated with atezolizumab: A case report. <i>Respiratory Medicine Case Reports</i> , 2021, 33, 101439.	0.4	4
1343	Continuous monitoring of neutrophils to lymphocytes ratio for estimating the onset, severity, and subsequent prognosis of immune related adverse events. <i>Scientific Reports</i> , 2021, 11, 1324.	3.3	38
1344	New Onset Ocular Myasthenia Gravis After Pembrolizumab Therapy: a Case Report. <i>SN Comprehensive Clinical Medicine</i> , 2021, 3, 309-311.	0.6	3



#	ARTICLE	IF	CITATIONS
1345	Exploiting the CRISPR-Cas9 gene editing system for human cancers and immunotherapy. <i>Clinical and Translational Immunology</i> , 2021, 10, e1286.	3.8	11
1346	Immune Checkpoint Inhibitor (ICI)-Associated Myocarditis. , 2021, , 27-37.		0
1347	Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Literature Review. <i>Dermatology Practical and Conceptual</i> , 2021, 11, e2021155.	0.9	25
1348	Spectrum and Management of Immune Related Adverse Events Due to Immune Checkpoint Inhibitors. <i>Current Cancer Research</i> , 2021, , 139-173.	0.2	0
1349	Miscellaneous Rheumatic Syndromes. , 2021, , 169-189.		0
1350	Autoanticuerpos: una manifestaci3n de los eventos adversos inmunol3gicos de la inmunoterapia en c3ncer. <i>Revista Colombiana De Reumatolog3a</i> , 2021, 29, 3-3.	0.1	0
1352	Ocular adverse events associated with immune checkpoint inhibitors: a novel multidisciplinary management algorithm. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592199298.	3.2	16
1353	Management of Hospital Admissions for Checkpoint Inhibitor Immune-Related Adverse Events at a Regional Cancer Center. <i>Oncology Issues</i> , 2021, 36, 34-41.	0.1	1
1354	A hypoxia-linked gene signature for prognosis prediction and evaluating the immune microenvironment in patients with hepatocellular carcinoma. <i>Translational Cancer Research</i> , 2021, 10, 3979-3992.	1.0	3
1355	Checkpoint Inhibitors and Hepatotoxicity. <i>Biomedicines</i> , 2021, 9, 101.	3.2	17
1356	Immune checkpoint inhibitor-induced aseptic meningitis and encephalitis: a case-series and narrative review. <i>Therapeutic Advances in Drug Safety</i> , 2021, 12, 204209862110047.	2.4	20
1357	Delayed immune thrombocytopenia after discontinuation of nivolumab therapy: A case report and literature review. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 1548-1552.	0.9	6
1358	Assessment of Trends in Second Primary Cancers in Patients With Metastatic Melanoma From 2005 to 2016. <i>JAMA Network Open</i> , 2020, 3, e2028627.	5.9	22
1359	Managing Checkpoint Inhibitor Symptoms and Toxicity for Metastatic Melanoma. , 2020, , 1187-1214.		2
1360	Neurological Complications of Immune-Based Therapies. , 2020, , 365-372.		2
1362	Skin Reactions to Immune Checkpoint Inhibitors. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 235-246.	1.6	7
1363	Gastrointestinal Tract Adverse Events. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 247-253.	1.6	5
1364	Immune-Related Adverse Events: Pneumonitis. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 255-269.	1.6	38

#	ARTICLE	IF	CITATIONS
1365	Immune Checkpoint Inhibitors (ICIs)-Related Cardiotoxicity. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 277-285.	1.6	9
1366	Immune-Related Oral, Otologic, and Ocular Adverse Events. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 295-307.	1.6	10
1367	Gastrointestinal Bleeding in Critically Ill Cancer Patients. , 2020, , 857-867.		1
1368	Drug-Induced Liver Injury in Older Adults. , 2020, , 1-16.		1
1369	Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort. , 2020, 69, 1177.		1
1370	Anti-glycin-receptor antibody related stiff-person syndrome under treatment with an immune checkpoint inhibitor. <i>Journal of Neurology</i> , 2021, 268, 709-711.	3.6	4
1371	Supportive care in cancerâ€™a MASCC perspective. <i>Supportive Care in Cancer</i> , 2020, 28, 3467-3475.	2.2	47
1372	SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019). <i>Clinical and Translational Oncology</i> , 2020, 22, 213-222.	2.4	14
1373	Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 1719-1726.	3.3	21
1374	Immune-related Encephalitis in Two Patients Treated With Immune Checkpoint Inhibitor. <i>Clinical Lung Cancer</i> , 2020, 21, e474-e477.	2.6	12
1375	Metabolic consequences of immune checkpoint inhibitors: A new challenge in clinical practice. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 151, 102979.	4.4	5
1376	Double immune checkpoint blockade in advanced NSCLC. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 152, 102980.	4.4	12
1377	Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study. <i>European Journal of Cancer</i> , 2020, 134, 19-28.	2.8	45
1378	Sinus Arrest and Cardiogenic Shock Precipitated by Immune Checkpoint Inhibitors. <i>JACC: CardioOncology</i> , 2020, 2, 810-814.	4.0	1
1379	Immune Checkpoint Inhibitor-Associated Myocarditis With Persistent Troponin Elevation Despite Abatacept and Prolonged Immunosuppression. <i>JACC: CardioOncology</i> , 2020, 2, 800-804.	4.0	17
1380	Toxicities from immunotherapy: From clinical trials to real-world clinical practice. <i>Medicina ClÃnica</i> , 2020, 155, 541-547.	0.6	8
1381	Checkpoint inhibitor immunotherapy in kidney cancer. <i>Nature Reviews Urology</i> , 2020, 17, 137-150.	3.8	162
1382	Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1047-1059.	3.1	9

#	ARTICLE	IF	CITATIONS
1383	Endoscopic and pathological dissociation in severe colitis induced by immune-checkpoint inhibitors. <i>Oncolmmunology</i> , 2020, 9, 1760676.	4.6	4
1384	Understanding adverse events of immunotherapy: A mechanistic perspective. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	22
1385	Safety of Immunotherapy Rechallenge After Immune-related Adverse Events in Patients With Advanced Cancer. <i>Journal of Immunotherapy</i> , 2021, 44, 41-48.	2.4	13
1386	Incidence and Prediction of Immune Checkpoint Inhibitor-related Nephrotoxicity. <i>Journal of Immunotherapy</i> , 2021, 44, 127-131.	2.4	19
1387	Anti-PD-1 induced collagenous colitis in metastatic melanoma: a rare severe adverse event. <i>Melanoma Research</i> , 2020, 30, 603-605.	1.2	6
1388	Inflammatory Cardiomyopathy: Case-based Review on Clinical Presentation, Diagnosis, and Management. <i>Cardiology in Review</i> , 2021, 29, 230-237.	1.4	2
1389	Advanced Merkel cell carcinoma—A focus on medical drug therapy. <i>Dermatologic Therapy</i> , 2020, 33, e13675.	1.7	3
1390	Atezolizumab-induced myositis and myocarditis in a patient with metastatic urothelial carcinoma. <i>BMJ Case Reports</i> , 2020, 13, e236357.	0.5	9
1391	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma. , 2020, 8, e001235.		11
1392	Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade 2 immune-related adverse events in patients with cancer. , 2020, 8, e001622.		68
1393	Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma. , 2020, 8, e001675.		9
1394	Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). <i>Liver Cancer</i> , 2020, 9, 682-720.	7.7	427
1395	Acute Bilateral Uveitis, Hypotony, and Cataracts Associated with Ipilimumab and Nivolumab Therapy: Optical Coherence Tomography Angiography Findings. <i>Case Reports in Ophthalmology</i> , 2021, 11, 606-611.	0.7	10
1396	MicroRNA-146a regulates immune-related adverse events caused by immune checkpoint inhibitors. <i>JCI Insight</i> , 2020, 5, .	5.0	49
1397	Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity. <i>Journal of Clinical Investigation</i> , 2018, 129, 349-363.	8.2	99
1398	An adapted anti-CTLA4 therapeutic aimed at mitigating the toxicities of checkpoint inhibition. <i>Journal of Clinical Investigation</i> , 2018, 129, 75-77.	8.2	1
1399	Time to dissect the autoimmune etiology of cancer antibody immunotherapy. <i>Journal of Clinical Investigation</i> , 2020, 130, 51-61.	8.2	66
1400	Immunotherapy Induced Myasthenic-Like Syndrome in a Metastatic Melanoma Patient With Amyotrophic Lateral Sclerosis. <i>Clinical Medicine Insights: Oncology</i> , 2020, 14, 117955492097802.	1.3	3

#	ARTICLE	IF	CITATIONS
1401	Immune-related adverse events: a retrospective look into the future of oncology in the intensive care unit. <i>Annals of Intensive Care</i> , 2020, 10, 143.	4.6	24
1402	Perforation of small intestinal metastasis of lung adenocarcinoma treated with pembrolizumab: a case report. <i>Surgical Case Reports</i> , 2019, 5, 166.	0.6	6
1403	Guideline-Recommended Symptom Management Strategies That Cross Over Two or More Cancer Symptoms. <i>Oncology Nursing Forum</i> , 2020, 47, 498-511.	1.2	16
1404	The real-world incidence of immunotherapy-related thyroid dysfunction: A retrospective analysis of a single center's experience over five years.. <i>Journal of Clinical Oncology</i> , 2020, 38, 98-98.	1.6	5
1405	Toxicity Management of Front-Line Pembrolizumab Combined With Axitinib in Clear Cell Metastatic Renal Cell Carcinoma: A Case Study Approach. <i>JCO Oncology Practice</i> , 2020, 16, 15s-19s.	2.9	8
1406	Optic Neuritis Related to Atezolizumab Treatment in a Patient With Metastatic Non-Small-Cell Lung Cancer. <i>JCO Oncology Practice</i> , 2020, 16, 96-98.	2.9	1
1407	Toxic Myopathies. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2019, 25, 1712-1731.	0.8	22
1408	Lambert-Eaton Myasthenic Syndrome, Botulism, and Immune Checkpoint Inhibitor-Related Myasthenia Gravis. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2019, 25, 1785-1806.	0.8	12
1409	Hepatocellular carcinoma: recent advances and emerging medical therapies. <i>F1000Research</i> , 2020, 9, 620.	1.6	41
1410	Cardio-oncology for the general physician: old and new cardiovascular toxicities and how to manage them. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2020, 81, 1-11.	0.5	2
1411	Immune checkpoint inhibitor-induced colitis: A comprehensive review. <i>World Journal of Clinical Cases</i> , 2019, 7, 405-418.	0.8	171
1412	Myocarditis associated with immune check-point inhibitors: Practical considerations in diagnosis and management. <i>Anatolian Journal of Cardiology</i> , 2020, 24, 68-75.	0.9	12
1413	Anti-pituitary antibodies as a marker of autoimmunity in pituitary glands. <i>Endocrine Journal</i> , 2020, 67, 1077-1083.	1.6	16
1414	DIAGNOSIS OF ENDOCRINE DISEASE: Drug-induced endocrinopathies and diabetes: a combo-endocrinology overview. <i>European Journal of Endocrinology</i> , 2019, 181, R73-R105.	3.7	7
1415	Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review. <i>European Journal of Endocrinology</i> , 2019, 181, 363-374.	3.7	154
1416	Anticancer Drug-induced Thyroid Dysfunction. <i>European Endocrinology</i> , 2020, 16, 32.	1.5	22
1417	Rapid onset type 1 diabetes with anti-PD-1 directed therapy. <i>Oncotarget</i> , 2020, 11, 2740-2746.	1.8	17
1418	The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients. <i>Cancer Biology and Medicine</i> , 2020, 17, 599-611.	3.0	45

#	ARTICLE	IF	CITATIONS
1419	Implications of pneumonitis after chemoradiation and durvalumab for locally advanced non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2020, 12, 6690-6700.	1.4	25
1420	Infliximab Was Found to Be Effective for Treating Immunosuppressive Drug-resistant Hepatitis due to Durvalumab. <i>Internal Medicine</i> , 2020, 59, 3055-3059.	0.7	11
1421	Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution. <i>Anticancer Research</i> , 2019, 39, 781-790.	1.1	25
1422	Endocrine adverse events related with immune checkpoint inhibitors: an update for clinicians. <i>Immunotherapy</i> , 2020, 12, 481-510.	2.0	7
1423	Endocrine dysfunctions during treatment of immune-checkpoint inhibitors. <i>Trends in Immunotherapy</i> , 2018, 2, .	0.2	6
1424	Retrospective analysis of treatment-naïve Slovenian patients with metastatic melanoma treated with pembrolizumab – real-world experience. <i>Radiology and Oncology</i> , 2020, 54, 119-127.	1.7	8
1425	Acute Demyelinating Polyneuropathy Occurring Four Days After Nivolumab Administration in a Patient with Lung Adenocarcinoma. <i>Japanese Journal of Lung Cancer</i> , 2020, 60, 991-994.	0.1	1
1426	Immune Response Checkpoint Inhibitors: New Risks of a New Class of Antitumor Agents. <i>Safety and Risk of Pharmacotherapy</i> , 2020, 8, 9-22.	0.2	10
1427	Arthritis and Myositis in a Patient Treated with Programmed Cell Death-1 (PD-1) Inhibitor Pembrolizumab for Lung Cancer. <i>Mediterranean Journal of Rheumatology</i> , 2020, 31, 355.	0.8	6
1428	Safety and efficacy of nivolumab as a second line therapy in metastatic renal cell carcinoma: a retrospective chart review. <i>Croatian Medical Journal</i> , 2020, 61, 326-332.	0.7	4
1429	Biomarkers for precision immunotherapy in the metastatic setting: hope or reality?. <i>Ecancermedalscience</i> , 2020, 14, 1150.	1.1	27
1430	Novel Nuclear Medicine Imaging Applications in Immuno-Oncology. <i>Cancers</i> , 2020, 12, 1303.	3.7	6
1431	Pembrolizumab Induces an Unexpected Conformational Change in the C-terminal-loop of PD-1. <i>Cancers</i> , 2021, 13, 5.	3.7	8
1432	Monoclonal Antibody-Based Immunotherapy and Its Role in the Development of Cardiac Toxicity. <i>Cancers</i> , 2021, 13, 86.	3.7	14
1433	Emergency Department Utilization for Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Analysis of Identification and Outcomes for Those Presenting for Immune-Related Adverse Events. <i>Current Oncology</i> , 2021, 28, 52-59.	2.2	8
1434	PD-L1 Targeting Immune-Microbubble Complex Enhances Therapeutic Index in Murine Colon Cancer Models. <i>Pharmaceuticals</i> , 2021, 14, 6.	3.8	15
1435	Kidney Biopsy Should Be Performed to Document the Cause of Immune Checkpoint Inhibitor-Associated Acute Kidney Injury: CON. <i>Kidney360</i> , 2020, 1, 162-165.	2.1	10
1436	Acute Interstitial Nephritis and Checkpoint Inhibitor Therapy. <i>Kidney360</i> , 2020, 1, 16-24.	2.1	42

#	ARTICLE	IF	CITATIONS
1437	Kidney Biopsy Should Be Performed to Document the Cause of Immune Checkpoint Inhibitor-Associated Acute Kidney Injury: PRO. <i>Kidney</i> 360, 2020, 1, 158-161.	2.1	12
1438	Reactivation of Hepatitis B Virus Among Patients With Cancer Receiving Immunotherapy. <i>Journal of Immunotherapy and Precision Oncology</i> , 2021, 4, 53-55.	1.4	5
1439	Inclusion of Anesthesiologists and Surgeons While Developing Guidelines for Management of Immune-Related Adverse Events. <i>Journal of Immunotherapy and Precision Oncology</i> , 2020, 3, 56-57.	1.4	1
1440	Severe steroid refractory gastritis induced by Nivolumab: A case report. <i>World Journal of Gastroenterology</i> , 2020, 26, 1971-1978.	3.3	15
1441	Relapse of aseptic meningitis induced by ipilimumab and nivolumab therapy for metastatic renal cell carcinoma: A case report. <i>Molecular and Clinical Oncology</i> , 2019, 11, 590-594.	1.0	8
1442	Guillain-Barré syndrome induced by pembrolizumab and sunitinib: A case report. <i>Molecular and Clinical Oncology</i> , 2020, 13, 38-42.	1.0	8
1443	Elevated levels of IL-17A and IL-35 in plasma and bronchoalveolar lavage fluid are associated with checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer. <i>Oncology Letters</i> , 2020, 20, 611-622.	1.8	34
1444	Rheumatic complications in cancer patients treated with immune checkpoint inhibitors. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 1197-1209.	1.7	11
1445	Systemic treatment for advanced urothelial cancer: an update on recent clinical trials and current treatment options. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 834-853.	1.7	10
1446	Current Status of Immunotherapy for Lung Cancer and Future Perspectives. <i>Tuberculosis and Respiratory Diseases</i> , 2020, 83, 14.	1.8	19
1447	Cardiovascular Complications of Novel Anti-Cancer Immunotherapy: Old Problems from New Agents?. <i>Korean Circulation Journal</i> , 2020, 50, 743.	1.9	6
1448	Adverse effects of immuno-oncology drugs—Awareness, diagnosis, and management: A literature review of immune-mediated adverse events. <i>Indian Journal of Cancer</i> , 2019, 56, 10.	0.2	3
1449	Immune checkpoint inhibitors in the driver's seat: Evaluating the evolving evidence in the treatment of extensive-stage small-cell lung cancer. <i>Journal of Current Oncology</i> , 2019, 2, 43.	0.2	1
1450	Cardiotoxicity of FDA-approved immune checkpoint inhibitors: A rare but serious adverse event. <i>Journal of Immunotherapy and Precision Oncology</i> , 2018, 1, 68-77.	1.4	8
1451	Neuromuscular Weakness Syndromes from Immune Checkpoint Inhibitors: A Case Series and Literature Review. <i>Journal of Immunotherapy and Precision Oncology</i> , 2019, 2, 93-100.	1.4	3
1452	Cardiac adverse events of immune checkpoint inhibitors in oncology patients: A systematic review and meta-analysis. <i>World Journal of Cardiology</i> , 2020, 12, 584-598.	1.5	24
1453	Surviving Cancer without a Broken Heart. <i>Rambam Maimonides Medical Journal</i> , 2019, 10, e0012.	1.0	5
1455	Clinical Management of Pneumonitis in Patients Receiving Anti-PD-1/PD-L1 Therapy. <i>Journal of the Advanced Practitioner in Oncology</i> , 2018, 9, .	0.4	5

#	ARTICLE	IF	CITATIONS
1456	Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 255-289.	4.9	393
1457	Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 750-757.	4.9	86
1458	NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 230-241.	4.9	284
1459	Immune-Related Adverse Events (irAEs): Implications for Immune Checkpoint Inhibitor Therapy. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1287-1290.	4.9	5
1460	Nephrotoxicity of Immune Checkpoint Inhibitors: Acute Kidney Injury and Beyond. Cureus, 2020, 12, e12204.	0.5	8
1461	Incidence and Risk of Thyroid Dysfunction in Advanced or Metastatic Non-small Cell Lung Cancer Patients Treated with Pembrolizumab: A Meta-analysis. Cureus, 2019, 11, e5997.	0.5	5
1462	Toxicities of Immune Checkpoint Inhibitors: Itis-Ending Adverse Reactions and More. Cureus, 2020, 12, e6935.	0.5	11
1463	Glucocorticoid use and complications following immune checkpoint inhibitor use in melanoma. Clinical Medicine, 2020, 20, 163-168.	1.9	21
1464	Is immune checkpoint inhibitor-associated diabetes the same as fulminant type 1 diabetes mellitus?. Clinical Medicine, 2020, 20, 417-423.	1.9	31
1465	The Advancement in Diagnosis and Therapy of Liver Injury Induced by Immune Checkpoint Inhibitors. Advances in Clinical Medicine, 2021, 11, 4628-4634.	0.0	0
1467	Severe Cardiac Toxicity Induced by Cancer Therapies Requiring Intensive Care Unit Admission. Frontiers in Cardiovascular Medicine, 2021, 8, 713694.	2.4	10
1468	Algorithme thérapeutique des CBNPC sans anomalie moléculaire actionnable. Revue Des Maladies Respiratoires Actualites, 2021, 13, 2S121-2S134.	0.0	0
1469	Gestion des toxicités de l'immunothérapie. Revue Des Maladies Respiratoires Actualites, 2021, 13, 2S258-2S265.	0.0	0
1470	Immune checkpoint inhibitor-induced pneumonitis: Incidence, clinical characteristics, and outcomes. Hematology/ Oncology and Stem Cell Therapy, 2021, , .	0.9	3
1471	Rheumatological Adverse Events of Cancer Therapy with Immune Checkpoint Inhibitors. Archives of Medical Research, 2022, 53, 113-121.	3.3	2
1472	Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival. Cancer Immunology, Immunotherapy, 2022, 71, 1157-1165.	4.2	12
1473	Cure the Incurable? Recent Breakthroughs in Immune Checkpoint Blockade for Hepatocellular Carcinoma. Cancers, 2021, 13, 5295.	3.7	9
1474	Consensus statement of Russian experts on the prevention, diagnosis and treatment of cardiotoxicity of anticancer therapy. Russian Journal of Cardiology, 2021, 26, 4703.	1.4	36

#	ARTICLE	IF	CITATIONS
1475	Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates. <i>JAMA Oncology</i> , 2021, 7, 1873.	7.1	66
1476	Hepatic immune-mediated adverse effects of immune checkpoint inhibitors: analysis of real-life experience. <i>Annals of Hepatology</i> , 2021, 26, 100561.	1.5	5
1477	Case Report: Severe Immune-Related Cholestatic Hepatitis and Subsequent Pneumonia After Pembrolizumab Therapy in a Geriatric Patient With Metastatic Gastric Cancer. <i>Frontiers in Medicine</i> , 2021, 8, 719236.	2.6	3
1478	Quality of Life and Symptom Management in Advanced Biliary Tract Cancers. <i>Cancers</i> , 2021, 13, 5074.	3.7	14
1479	Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review. <i>Cancers</i> , 2021, 13, 5218.	3.7	53
1480	Bradyarrhythmias in Cardio-Oncology. <i>South Asian Journal of Cancer</i> , 2021, 10, 195-210.	0.6	0
1481	Immune Checkpoint Inhibitors and Kidney Toxicity: Advances in Diagnosis and Management. <i>Kidney Medicine</i> , 2021, 3, 1074-1081.	2.0	26
1482	Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2022, 11, 9-21.	7.7	29
1483	A case of repetitive seizures following immune checkpoint inhibitor therapy as a feature of autoimmune encephalitis. <i>Epileptic Disorders</i> , 2021, 23, 733-738.	1.3	1
1484	Risk of corticosteroid treatment and hospitalization after checkpoint inhibitor and radiation therapy in patients with cancer. <i>Cancer</i> , 2022, 128, 819-827.	4.1	3
1485	Primary esophageal malignant melanoma with severe liver injury of immune-related adverse events caused by nivolumab. <i>Acta Hepatologica Japonica</i> , 2021, 62, 630-638.	0.1	1
1486	Drug-induced pulmonary toxicity in breast cancer patients treated with systemic therapy: a systematic literature review. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1399-1410.	2.4	0
1487	Sintilimab plus sorafenib: a novel regimen for hepatocellular carcinoma. <i>Immunotherapy</i> , 2021, 13, 1387-1393.	2.0	2
1488	Immune-related Liver Injury is a Poor Prognostic Factor in Patients with Nonsmall Cell Lung Cancer Treated with Immune Checkpoint Inhibitors. <i>Cancer Investigation</i> , 2022, 40, 189-198.	1.3	9
1489	Immune related adverse events and treatment discontinuation in patients older and younger than 75 years with advanced melanoma receiving nivolumab or pembrolizumab. <i>Journal of Geriatric Oncology</i> , 2021, , .	1.0	4
1490	Conjugation of glucosylated polymer chains to checkpoint blockade antibodies augments their efficacy and specificity for glioblastoma. <i>Nature Biomedical Engineering</i> , 2021, 5, 1274-1287.	22.5	33
1491	Treatment of advanced cutaneous squamous cell carcinoma: a Mohs surgery and dermatologic oncology perspective. <i>Future Oncology</i> , 2021, 17, 4971-4982.	2.4	5
1492	Hematologic complications of immune checkpoint inhibitors. <i>Blood</i> , 2022, 139, 3594-3604.	1.4	30



#	ARTICLE	IF	CITATIONS
1493	Onconeurology. , 2022, , 185-209.		0
1494	The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry. <i>European Journal of Cancer</i> , 2021, 158, 217-224.	2.8	35
1495	Insights into Potential Pathogenesis and Treatment Options for Immune-Checkpoint Inhibitor-Related Pneumonitis. <i>Biomedicines</i> , 2021, 9, 1484.	3.2	10
1496	First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 161-170.	1.6	283
1497	Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition – A Descriptive Observational Retrospective Multicenter Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 765608.	2.8	10
1498	Non- $\epsilon$ sclerosing large duct cholangitis secondary to checkpoint inhibition. <i>Internal Medicine Journal</i> , 2021, 51, 1758-1759.	0.8	0
1499	The Continuum of Thyroid Disorders Related to Immune Checkpoint Inhibitors: Still Many Pending Queries. <i>Cancers</i> , 2021, 13, 5277.	3.7	12
1500	Rare case of chemotherapy-refractory metastatic vaginal squamous cell carcinoma with complete response to concurrent pembrolizumab and radiotherapy- case report and literature review. <i>Gynecologic Oncology Reports</i> , 2021, 38, 100878.	0.6	3
1502	Immune check point inhibitors for head and neck cancer and its proper management on utilizing head and neck cancer collaborative program. <i>Journal of Japanese Society of Oral Oncology</i> , 2018, 30, 144-150.	0.1	0
1503	Immune check point inhibitors for head and neck cancer. <i>Japanese Journal of Head and Neck Cancer</i> , 2018, 44, 336-341.	0.1	0
1504	Inflammatory Colitis after Treatment of Melanoma with Talimogene Laherparepvec (T-VEC). <i>Journal of Immunotherapy and Precision Oncology</i> , 2018, 1, 46-48.	1.4	0
1506	ã,ãf³ã,³ãfã,ãf¼ã,ãfžãf¼ã,ã,ãf³ã,ãf¼. <i>Japanese Journal of Lung Cancer</i> , 2018, 58, 914-919.	0.1	2
1507	Complications and Toxicities Associated with Cancer Therapies in the Intensive Care Unit. , 2019, , 1-27.		0
1508	Managing Checkpoint Inhibitor Symptoms and Toxicity. , 2019, , 1-28.		0
1509	Chemotherapy and molecular biological therapy. , 2019, , 463-471.		0
1510	Introduction to Melanoma Immunology. , 2019, , 1-15.		0
1511	Programmed Death-1 and Programmed Death Ligand-1 Blockade for Advanced Urothelial Carcinoma. <i>Urological Science</i> , 2019, 30, 2-7.	0.6	2
1512	Melanoma Immunology and Immunotherapy. , 2019, , 1-15.		0

#	ARTICLE	IF	CITATIONS
1513	Updates in Lung Cancer 2018â€”What the Pulmonologist Needs to Know. <i>Oncology &amp; Hematology Review</i> , 2019, 15, 20.	0.2	0
1514	Meeting the Challenge of Immune-Related Adverse Events With Optimized Telephone Triage and Dedicated Oncology Acute Care. <i>Journal of the Advanced Practitioner in Oncology</i> , 2019, 10, 9-20.	0.4	11
1515	Checkpoint Inhibitor Immunotherapy for Head and Neck Cancer: Incorporating Care Step Pathways for Effective Side-Effect Management. <i>Journal of the Advanced Practitioner in Oncology</i> , 2019, 10, 37-46.	0.4	5
1516	PD-1/PD-L1 Inhibitors for Nonâ€”Small Cell Lung Cancer: Incorporating Care Step Pathways for Effective Side-Effect Management. <i>Journal of the Advanced Practitioner in Oncology</i> , 2019, 10, 21-35.	0.4	7
1517	Immune-Related Adverse Events From Immunotherapy: Incorporating Care Step Pathways to Improve Management Across Tumor Types. <i>Journal of the Advanced Practitioner in Oncology</i> , 2019, 10, 47-62.	0.4	8
1518	The Advanced Practice Provider Perspective: Treating Patients With Immuno-Oncology Combination Therapy Across Tumor Types. <i>Journal of the Advanced Practitioner in Oncology</i> , 2019, 10, 367-386.	0.4	0
1519	2. Cancer Immunotherapy: A Novel Approach to Cancer Treatment. <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , 2019, 50, 107-111.	0.1	0
1520	Management of Adverse Events Induced by Immune Checkpoint Inhibitors in Lung Cancer Treatment. <i>Japanese Journal of Lung Cancer</i> , 2019, 59, 231-237.	0.1	0
1521	Nivolumab-induced Third Degree Atrioventricular Block in a Patient with Stage IV Squamous Cell Lung Carcinoma. <i>Cureus</i> , 2019, 11, e4869.	0.5	7
1523	<i>Journal of the Japanese Society of Internal Medicine</i> , 2019, 108, 1793-1797.	0.0	0
1524	Identifying MicroRNA Pathway Variants as Biomarkers of Patient Selection for Immune Therapy. <i>Methods in Molecular Biology</i> , 2020, 2055, 203-212.	0.9	1
1525	Inmunoterapia, cÃ¡ncer y enfermedades reumatolÃ³gicas. <i>ReumatologÃ­a ClÃ¡nica</i> , 2019, 15, 249-251.	0.5	2
1526	ToxicitÃ©s pulmonaires des immunothÃ©rapies : Ã©valuer et traiter. <i>Revue Des Maladies Respiratoires Actualites</i> , 2019, 11, S491-S501.	0.0	0
1527	Complications and Toxicities Associated with Cancer Therapies in the Intensive Care Unit. , 2020, , 201-227.		0
1528	GI Toxicities from Cancer Therapy. , 2020, , 1-39.		0
1530	How to effectively recognize adrenocorticotrophic hormone deficiency as an immune-related adverse event associated with immune checkpoint blockade. <i>Tenri Medical Bulletin</i> , 2019, 22, 94-100.	0.1	0
1531	Safety Evaluation of Retreatment with Immune Checkpoint Inhibitors. <i>Iryo Yakugaku (Japanese Journal)</i> Tj ETQq0 0 0 rgBT /Overlock 10	0.1	1
1532	Cancer immunotherapy and its potential cardiac complications. <i>British Journal of Cardiology</i> , 2020, , .	0.2	0

#	ARTICLE	IF	CITATIONS
1534	Gastrointestinal Toxicities of Immunotherapy. , 2020, , 201-222.		0
1535	Cardivasular Toxicities of Immunotherapy. , 2020, , 259-276.		0
1536	Endocrine Toxicities of Immunotherapy. , 2020, , 187-200.		0
1537	Immune-related neutropenia in cancer patients â€“ review. Oncolog-Hematolog Ro, 2020, 2, 24.	0.0	0
1538	Immune checkpoint blockade in allogeneic hematopoietic cell transplantation. Journal of Hematopoietic Cell Transplantation, 2020, 9, 13-22.	0.1	0
1539	Management of Acute Pancreatitis Associated With Checkpoint Inhibitors. Journal of the Advanced Practitioner in Oncology, 2020, 11, 49-62.	0.4	8
1540	Next Generation of Advanced Non-Small Cell Lung Cancer Therapy: Targeted and Immuno-Therapies. International Journal of Medical Students, 2020, 8, 26-32.	0.5	0
1541	A Case of Acute Heart Failure Following Immunotherapy for Metastatic Lung Cancer. Cureus, 2020, 12, e8093.	0.5	7
1542	Cardiovascular effects of innovative therapies in lung cancer. , 2020, , 154-166.		0
1544	Vigilancia clÃnica de los pacientes que reciben inmunoterapia. Medicina ClÃnica, 2020, 154, 493-495.	0.6	0
1545	Side effects and management in immunotherapy based on immune checkpoint inhibitors. World Chinese Journal of Digestology, 2020, 28, 755-764.	0.1	1
1546	Combination Immunotherapy Associated With Severe Hepatotoxicity and Fatal Aplastic Anemia. American Journal of Therapeutics, 2020, Publish Ahead of Print, .	0.9	1
1547	Medicine, 2020, 109, 1796-1800.	0.0	0
1548	Role of Cardiac Biomarkers in Cancer Patients. Cancers, 2021, 13, 5426.	3.7	22
1549	Uveitis associated with cancer immunotherapy: long-term outcomes. Immunotherapy, 2021, 13, 1465-1481.	2.0	3
1550	Mechanisms of Immune Checkpoint Inhibitor-Mediated Colitis. Frontiers in Immunology, 2021, 12, 768957.	4.8	22
1551	Pembrolizumab-induced focal segmental glomerulosclerosis. Medicine (United States), 2021, 100, e27546.	1.0	5
1552	Effect of corticosteroid dosing on outcomes in highâ€“grade immune checkpoint inhibitor hepatitis. Hepatology, 2022, 75, 531-540.	7.3	32

#	ARTICLE	IF	CITATIONS
1553	The application of immune checkpoint blockade in breast cancer and the emerging role of nanoparticle. <i>Journal of Controlled Release</i> , 2021, 340, 168-187.	9.9	20
1554	Immune checkpoint inhibitors and intensive care medicine. <i>Journal of the Japanese Society of Intensive Care Medicine</i> , 2021, 28, 506-507.	0.0	0
1555	Biological Bases of Immune-Related Adverse Events and Potential Crosslinks With Immunogenic Effects of Radiation. <i>Frontiers in Pharmacology</i> , 2021, 12, 746853.	3.5	14
1556	ICU admission due to immune-related adverse events caused by immune checkpoint inhibitors: a retrospective study. <i>Journal of the Japanese Society of Intensive Care Medicine</i> , 2021, 28, 543-544.	0.0	0
1557	Clinical Presentations and Outcomes of Patients Receiving Immune Checkpoint Inhibitors Presenting to the Emergency Department. <i>Mayo Clinic Proceedings Innovations, Quality &amp; Outcomes</i> , 2021, 5, 1029-1035.	2.4	4
1558	Hepatobiliary Adverse Events. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 271-276.	1.6	3
1559	First report of pembrolizumab extravasation. <i>Hematology &amp; Medical Oncology</i> , 2020, 5, .	0.1	0
1560	Colonoscopic evaluation of diarrhea/colitis occurring as an immune-related adverse event. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 363-370.	1.3	4
1561	Pembrolizumab-Induced Severe Neuropathy in a Patient with Metastatic Urothelial Carcinoma after Achieving Complete Response: Guillain-Barré Syndrome-Like Onset. <i>Case Reports in Oncology</i> , 2021, 13, 1490-1494.	0.7	3
1562	The Mechanism and Management of Adverse Cardiac Reactions Induced by Immune Checkpoint Inhibitors Therapy. <i>Cardiology Research and Practice</i> , 2020, 2020, 1-5.	1.1	0
1563	Diagnosis and Management of Checkpoint Inhibitor Side Effects in Patients with Bladder Cancer: the Urologist's Perspective. <i>Bladder Cancer</i> , 2020, 6, 425-433.	0.4	0
1564	Pharmaceutical Care Contributes to the Advanced Management of Patients Receiving Immune Checkpoint Inhibitors. <i>Biological and Pharmaceutical Bulletin</i> , 2020, 43, 1969-1974.	1.4	7
1565	Molecular Pathology of Immune Checkpoint Inhibitor-Induced Myocarditis. <i>Journal of Analytical Oncology</i> , 0, 9, 25-32.	0.1	1
1567	A Case of Isolated ACTH Deficiency and Polyarthritits during Nivolumab Therapy for Gastric Cancer. <i>Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)</i> , 2020, 81, 1120-1126.	0.0	0
1568	Pulmonary Toxicities of Immunotherapy. , 2020, , 243-252.		0
1569	Rheumatological Toxicities of Immunotherapy. , 2020, , 277-286.		0
1570	Cancer of the Skin. , 2020, , 143-155.		0
1571	Dermatologic Toxicities of Immunotherapy. , 2020, , 253-258.		0

#	ARTICLE	IF	CITATIONS
1572	Axitinib plus Immuncheckpoint-Inhibitor: evidenz- und expertenbasierte Konsensusempfehlungen für die Behandlungsoptimierung und das Management von therapieassoziierten Nebenwirkungen. Karger Kompass Onkologie, 2020, 7, 180-189.	0.0	0
1573	The knowledge and management of steroid side effects for head and neck cancer oncology treatment physician. Japanese Journal of Head and Neck Cancer, 2020, 46, 26-30.	0.1	1
1574	Exercise Oncology from Diagnosis to Treatment: An Overview of Outcomes and Considerations. , 2020, , 87-110.		0
1575	Cardiovascular complications of anti-cancer immune checkpoint inhibitor therapy and their combinations: are we ready for challenges ahead?. British Journal of Cardiology, 2020, , .	0.2	0
1576	Tumor- und therapieassoziierte Notfälle. , 2020, , 281-304.		0
1577	Nephrotoxizität onkologischer Therapien. , 2020, , 205-220.		0
1578	Development of Pharmacodynamic Biomarkers for Phase I Trials. , 2020, , 139-158.		0
1579	Neurological Toxicities of Immunotherapy. , 2020, , 223-242.		0
1580	Oral Lichenoid Lesions Due to Nivolumab: A Case Report and Review of the Literature. Journal of Japanese Society of Oral Medicine, 2020, 26, 56-62.	0.1	0
1581	Protocolo diagnóstico de la hepatopatía en el paciente oncológico. Medicine, 2020, 13, 225-229.	0.0	0
1582	Development of a Functional Assessment of Chronic Illness Therapy item library and primary symptom list for the assessment of patient-reported adverse events associated with immune checkpoint modulators. Journal of Cancer Metastasis and Treatment, 2020, 2020, .	0.8	3
1584	Creating Clarity in Metastatic Melanoma: Optimizing Treatment and Improving Outcomes. Journal of the Advanced Practitioner in Oncology, 2020, 11, 280-283.	0.4	0
1585	Expert Insights on Triple-Negative Breast Cancer: Preparing for the Next Wave of Treatments. Journal of the Advanced Practitioner in Oncology, 2020, 11, 266-270.	0.4	0
1586	The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma. European Urology, 2022, 81, 95-103.	1.9	158
1587	Complete remission of combined pulmonary large cell neuroendocrine carcinoma: a case report. Journal of International Medical Research, 2021, 49, 030006052110553.	1.0	3
1588	Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival. World Journal of Gastroenterology, 2021, 27, 7190-7206.	3.3	8
1589	Two cases of steroid-resistant nivolumab-induced sclerosing cholangitis. Acta Hepatologica Japonica, 2021, 62, 712-723.	0.1	2
1590	Life-threatening immune checkpoint inhibitor-induced myocarditis and myasthenia gravis overlap syndrome treated with abatacept: a case report. BMJ Case Reports, 2021, 14, e244334.	0.5	4

#	ARTICLE	IF	CITATIONS
1591	Defining the correlation between immune-checkpoint inhibitors-related adverse events and clinical outcomes: a narrative review. <i>Ecancermedalscience</i> , 2021, 15, 1314.	1.1	1
1592	The Price of Success: Immune-Related Adverse Events from Immunotherapy in Lung Cancer. <i>Current Oncology</i> , 2021, 28, 4392-4407.	2.2	4
1593	Combination of Juzentaihoto and chemotherapy improves the prognosis of patients with postoperative recurrence of non-small cell lung cancer. <i>Molecular and Clinical Oncology</i> , 2020, 13, 13.	1.0	5
1594	Journal of Otolaryngology		
1595	Immunotherapy for Metastatic Urothelial Cancer. , 2021, , 201-213.		0
1596	Immunotherapy-induced Pneumonitis: A Review of Diagnostic Workup and Treatment Guidelines. <i>Clinical Pulmonary Medicine</i> , 2020, 27, 141-147.	0.3	0
1597	Immune-related Pulmonary Toxicity From Cancer Immunotherapy: A Systematic Approach. <i>Clinical Pulmonary Medicine</i> , 2020, 27, 183-192.	0.3	0
1598	Optimizing Care for Patients With Adverse Events From Immunotherapeutics. <i>Cancer Journal (Sudbury, Tj ETQq1</i> 1,0,784314 rgBT /Ove	2.0	0
1599	Acute liver injury associated with rechallenge with a different type of immune checkpoint inhibitor in a patient with a history of severe immune-related adverse events. <i>Acta Hepatologica Japonica</i> , 2020, 61, 572-581.	0.1	2
1600	Role of Infliximab in Immune Checkpoint Inhibitor-Induced Pneumonitis. <i>Journal of Immunotherapy and Precision Oncology</i> , 2020, 3, 172-174.	1.4	5
1601	Immunotherapy induced enterocolitis and gastritis â€“ What to do and when?. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2020, 48-49, 101703.	2.4	8
1602	A case report of a severe hyperosmolar hyperglycemic state (HHS) and metabolic acidosis caused by colitis after combination therapy with nivolumab and ipilimumab. <i>Journal of the Japanese Society of Intensive Care Medicine</i> , 2020, 27, 489-490.	0.0	0
1603	Immune Checkpoint Inhibitors for Urothelial Cancer: An Update on New Therapies. <i>Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS</i> , 2018, 35, S62-S64.	0.6	0
1604	Clinical Management of Pneumonitis in Patients Receiving Anti-PD-1/PD-L1 Therapy. <i>Journal of the Advanced Practitioner in Oncology</i> , 2018, 9, 422-428.	0.4	5
1606	Cutaneous Toxicities of Immune Checkpoint Inhibitors: The Role of the Dermatologist. <i>Yale Journal of Biology and Medicine</i> , 2020, 93, 123-132.	0.2	23
1607	From Radical to Partial Nephrectomy in the Setting of Solitary Functioning Kidney: Neoadjuvant Treatment of Renal Cell Carcinoma. <i>Reviews in Urology</i> , 2020, 22, 126-129.	0.9	0
1609	Immunotherapy. <i>Canadian Family Physician</i> , 2021, 67, 512-515.	0.4	0
1611	Diagnosis and Management of Immune Checkpoint Inhibitor Colitis. <i>Gastroenterology and Hepatology</i> , 2021, 17, 358-366.	0.1	3

#	ARTICLE	IF	CITATIONS
1612	Neurological Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Perspectives and New Development. <i>Clinical Medicine Insights: Oncology</i> , 2021, 15, 117955492110562.	1.3	5
1613	Gastrointestinal adverse events of immunotherapy. <i>BJR   Open</i> , 2021, 3, .	0.6	0
1614	Zentrales Nervensystem. , 2022, , 119-123.		0
1615	IgA Nephropathy that Developed as an Immune-related Adverse Event of Pembrolizumab Complicated with Interstitial Nephritis: A Case Study. <i>Internal Medicine</i> , 2022, , .	0.7	2
1616	Pembrolizumab-related Immune Thrombocytopenia in a Patient with Lung Adenocarcinoma Treated by Radiotherapy: Potential Immune-related Adverse Event Elicited by Radiation Therapy. <i>Internal Medicine</i> , 2022, 61, 1731-1734.	0.7	3
1617	Pembrolizumab-Induced Type 1 Diabetes in a 95-Year-Old Veteran With Metastatic Melanoma. , 2021, 38, 520-523.		1
1618	Immune Checkpoint Blockade and Skin Toxicity Pathogenesis. <i>Journal of Investigative Dermatology</i> , 2021, , .	0.7	11
1619	Venous thromboembolism events in patients with advanced cancer on immune checkpoint inhibitors. <i>Immunotherapy</i> , 2022, 14, 23-30.	2.0	5
1620	Severe pseudomembranous keratoconjunctivitis with deterioration of eyesight induced by immune checkpoint inhibitors. <i>Immunotherapy</i> , 2022, 14, 173-178.	2.0	1
1621	IgA Nephropathy Secondary to Ipilimumab Use. <i>Case Reports in Nephrology and Dialysis</i> , 2022, 11, 327-333.	0.6	3
1622	Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma. <i>Frontiers in Pharmacology</i> , 2021, 12, 710943.	3.5	6
1623	Arzneimittlexantheme unter modernen zielgerichteten Therapien â€œ Immunecheckpointâ€ und EGFRâ€ Inhibitoren. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 1621-1645.	0.8	2
1624	A review of neurotoxicities associated with immunotherapy and a framework for evaluation. <i>Neuro-Oncology Advances</i> , 2021, 3, v108-v120.	0.7	6
1625	Immune Checkpoint Inhibitor-Induced Gastrointestinal Toxicity: The Opinion of a Gastroenterologist. <i>Cureus</i> , 2021, 13, e19945.	0.5	2
1626	Systematic review: disease activity indices for immune checkpoint inhibitorâ€ associated enterocolitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 178-190.	3.7	6
1627	Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysis. <i>Hepatology Research</i> , 2022, 52, 269-280.	3.4	28
1628	Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors. <i>Cancers</i> , 2021, 13, 5665.	3.7	5
1629	Drug eruptions with novel targeted therapies â€œ immune checkpoint and EGFR inhibitors. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 1621-1643.	0.8	6

#	ARTICLE	IF	CITATIONS
1630	Increased Risk of Thyroid Dysfunction by PD-1 and CTLA-4 Blockade in Patients Without Thyroid Autoantibodies at Baseline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e1620-e1630.	3.6	15
1631	Drug-induced liver injury: Pathogenesis, epidemiology, clinical features, and practical management. <i>European Journal of Internal Medicine</i> , 2022, 97, 26-31.	2.2	34
1632	Use of abatacept in steroid refractory, immune checkpoint-induced myocarditis. <i>Internal Medicine Journal</i> , 2021, 51, 1971-1972.	0.8	3
1633	Supportive therapy and complementary medicine in renal cell carcinoma. <i>World Journal of Urology</i> , 2021, , 1.	2.2	0
1634	Correlation between immune-related adverse events and the efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: systematic review and meta-analysis. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 1-9.	2.3	10
1635	Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2021, 385, 1919-1920.	27.0	9
1636	Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis. <i>BMC Cancer</i> , 2021, 21, 1275.	2.6	6
1637	Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study. , 2021, 9, e003277.		49
1638	Update on Myositis Therapy: from Today's Standards to Tomorrow's Possibilities. <i>Current Pharmaceutical Design</i> , 2021, 27, .	1.9	2
1639	Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 749064.	2.8	17
1640	Immunotherapies for hepatocellular carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 151-172.	27.6	643
1641	Risk of HBV reactivation during therapies for HCC: A systematic review. <i>Hepatology</i> , 2022, 75, 1257-1274.	7.3	26
1642	How we identify and treat neuromuscular toxicity induced by immune checkpoint inhibitors. <i>ESMO Open</i> , 2021, 6, 100317.	4.5	10
1643	Infliximab treatment in immune-related pneumonitis with respiratory failure after high-dose steroids: A patient with metastatic gastric cancer. <i>Journal of Cancer Research and Practice</i> , 2020, 7, 170.	0.2	1
1644	Neurologic Toxicities of Immunotherapy. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 417-429.	1.6	2
1645	Immune-Related Oral, Otologic, and Ocular Adverse Events. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 399-416.	1.6	2
1646	Skin Reactions to Immune Checkpoint Inhibitors. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 319-330.	1.6	3
1647	Liver Biochemical Flare with Immune Checkpoint Therapy in Metastatic Merkel Cell Carcinoma: A Liver Biopsy is Always Necessary. <i>Hepatology Forum</i> , 2021, , .	0.5	1



#	ARTICLE	IF	CITATIONS
1648	Colitis Induced by Immune-checkpoint Inhibitors. <i>Nihon Daicho Komonbyo Gakkai Zasshi</i> , 2021, 74, 599-605.	0.0	0
1649	Hepatobiliary and Pancreatic Adverse Events. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 339-355.	1.6	6
1650	Pulmonary Toxicities of Immunotherapy. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 357-375.	1.6	4
1651	Immunotherapy-Mediated Luminal Gastrointestinal Toxicities. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 331-337.	1.6	0
1652	Cancer Imaging in Immunotherapy. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 431-447.	1.6	2
1653	Adverse events of immunotherapy in non-small cell lung cancer: A systematic review and network meta-analysis. <i>International Immunopharmacology</i> , 2022, 102, 108353.	3.8	19
1654	Immune Checkpoint Inhibitor-related New-onset Thyroid Dysfunction: A Retrospective Analysis Using the US FDA Adverse Event Reporting System. <i>Oncologist</i> , 2022, 27, e126-e132.	3.7	8
1655	Bridging the Gap: Connecting the Mechanisms of Immune-Related Adverse Events and Autoimmunity Through PD-1. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 790386.	3.7	8
1656	Camrelizumab-Related Myocarditis and Myositis With Myasthenia Gravis: A Case Report and Literature Review. <i>Frontiers in Oncology</i> , 2021, 11, 778185.	2.8	10
1657	Atezolizumab-induced autoimmune haemolytic anaemia caused by drug-independent antibodies. <i>European Journal of Cancer</i> , 2022, 162, 158-160.	2.8	3
1658	Pembrolizumab-induced uveitis in a patient with metastatic urothelial carcinoma. <i>Journal of Cancer Research and Practice</i> , 2019, 6, 92.	0.2	0
1659	Organizing Pneumonia Due to Nivolumab. <i>American Journal of Therapeutics</i> , 2020, Publish Ahead of Print, .	0.9	2
1660	Pembrolizumab Induced Acute Tubulointerstitial Nephritis. <i>American Journal of Therapeutics</i> , 2020, Publish Ahead of Print, .	0.9	2
1661	Overlapping NMDA-R and GFAP Antibody Autoimmune Encephalitis After Nivolumab Therapy. <i>Neurology: Clinical Practice</i> , 2021, 11, e913-e915.	1.6	0
1662	Immune Thrombocytopenia Induced by Immune Checkpoint Inhibitors in Lung Cancer: Case Report and Literature Review. <i>Frontiers in Immunology</i> , 2021, 12, 790051.	4.8	10
1663	Case Series of Steroid-Resistant Immune Checkpoint Inhibitor Associated Myocarditis: A Comparative Analysis of Corticosteroid and Tofacitinib Treatment. <i>Frontiers in Pharmacology</i> , 2021, 12, 770631.	3.5	23
1664	Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects. <i>Cells</i> , 2022, 11, 320.	4.1	43
1665	Autoimmune and Inflammatory Encephalopathies as Complications of Cancer. , 2022, , 430-459.		0

#	ARTICLE	IF	CITATIONS
1666	Paraneoplastic Autoimmune Neurological Syndromes and the Role of Immune Checkpoint Inhibitors. <i>Neurotherapeutics</i> , 2022, 19, 848-863.	4.4	10
1667	Relato de caso “ eventos neuromusculares relacionados com inibidores de checkpoint. <i>Revista Neurociencias</i> , 0, 30, 1-12.	0.0	0
1668	Electrolyte and Acid-Base Disorders Associated with Cancer Immunotherapy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 922-933.	4.5	15
1669	Management of the Top 10 Most Common Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy. <i>JCO Oncology Practice</i> , 2022, 18, 431-444.	2.9	11
1670	The Occurrence of Encephalitis Due to Immune Checkpoint Inhibitors: A Pharmacovigilance Study. <i>Therapeutic Innovation and Regulatory Science</i> , 2022, 56, 323-332.	1.6	4
1671	Endocrine Toxicities of Antineoplastic Therapy: The Adrenal Topic. <i>Cancers</i> , 2022, 14, 593.	3.7	6
1672	Multiple rechallenges with anti-PD-1 immunotherapy in patients with checkpoint inhibitor-related pneumonitis: A report of two cases. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 1234-1238.	0.9	1
1673	Harnessing big data to characterize immune-related adverse events. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 269-280.	27.6	41
1674	Differentiation between immune checkpoint inhibitor-related and radiation pneumonitis in lung cancer by CT radiomics and machine learning. <i>Medical Physics</i> , 2022, 49, 1547-1558.	3.0	28
1675	Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy. , 2022, 10, e003779.		34
1676	A retrospective chart review of management strategies for lichenoid eruptions associated with immune-checkpoint inhibitor therapy from a single institution. <i>Cancer Treatment and Research Communications</i> , 2022, 30, 100506.	1.7	4
1677	Methods of screening, monitoring and management of cardiac toxicity induced by chemotherapeutics°. <i>Chinese Chemical Letters</i> , 2022, , .	9.0	3
1678	Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis. <i>European Urology</i> , 2022, 81, 414-425.	1.9	40
1679	Cytokine Release Syndrome in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Case Series of 25 Patients and Review of the Literature. <i>Frontiers in Immunology</i> , 2022, 13, 807050.	4.8	30
1680	Paraneoplastic Opsoclonus-myooclonus Syndrome with Anti-Hu and Anti-SOX-1 Antibodies after Immune-checkpoint Inhibitor Treatment Combined with Chemotherapy in a Patient with Small-cell Lung Cancer. <i>Internal Medicine</i> , 2022, 61, 71-74.	0.7	8
1681	Complications following novel therapies for non-small cell lung cancer. <i>Journal of Internal Medicine</i> , 2022, 291, 732-754.	6.0	6
1682	Immune checkpoint inhibitor-induced diabetes mellitus with pembrolizumab. <i>BMJ Case Reports</i> , 2022, 15, e245846.	0.5	8
1684	Interstitial lung abnormalities: new insights between theory and clinical practice. <i>Insights Into Imaging</i> , 2022, 13, 6.	3.4	9

#	ARTICLE	IF	CITATIONS
1685	Pembrolizumab-related cholangitis with multiple fatal liver abscesses after endoscopic biliary drainage: a case report and review of the literature. <i>Clinical Journal of Gastroenterology</i> , 2022, 15, 475.	0.8	6
1686	Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies. , 2022, 10, e003024.		15
1687	Pembrolizumab-induced Focal Pancreatitis Diagnosed by Endoscopic Ultrasound-guided Fine-needle Aspiration. <i>Internal Medicine</i> , 2022, 61, 2463-2469.	0.7	4
1689	Immune-Related Pneumonitis Was Decreased by Addition of Chemotherapy with PD-1/L1 Inhibitors: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials (RCTs). <i>Current Oncology</i> , 2022, 29, 267-282.	2.2	1
1690	Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2169-2181.	4.2	16
1691	A Cost-effectiveness Analysis Comparing Pembrolizumab-Axitinib, Nivolumab-Ipilimumab, and Sunitinib for Treatment of Advanced Renal Cell Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2022, 45, 66-73.	1.3	6
1693	Hepatotoxicity Induced by Biological Agents: Clinical Features and Current Controversies. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 000, 000-000.	1.4	6
1694	A Review of Potential Role of Capsule Endoscopy in the Work-Up for Chemotherapy-Induced Diarrhea. <i>Healthcare (Switzerland)</i> , 2022, 10, 218.	2.0	1
1695	Asymptomatic Myocarditis with Mild Cardiac Marker Elevation Following Nivolumab-Induced Myositis. <i>International Heart Journal</i> , 2022, 63, 180-183.	1.0	9
1696	Immune-related adverse events in various organs caused by immune checkpoint inhibitors. <i>Allergology International</i> , 2022, 71, 169-178.	3.3	34
1697	Frequently Asked Questions on Autoimmune Encephalitis and Related Disorders. , 2022, , 630-655.		1
1698	Consider Myocarditis When Patients Treated with Immune Checkpoint Inhibitors Present with Ocular Symptoms. <i>Oncologist</i> , 2022, 27, e402-e405.	3.7	7
1699	Pembrolizumab-Related Side Effects: Acute Renal Failure and Severe Neurological Toxicity. <i>Medicina (Lithuania)</i> , 2022, 58, 209.	2.0	6
1700	Nivolumab induced hypophysitis in an advanced RCC patient. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 759-762.	0.9	3
1701	Immune checkpoint inhibitor-associated myocarditis. <i>Netherlands Heart Journal</i> , 2022, 30, 295-301.	0.8	8
1702	Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Therapy. <i>JAMA Dermatology</i> , 2022, 158, 189.	4.1	60
1703	Novel Mouse Models for Cancer Immunology. <i>Annual Review of Cancer Biology</i> , 2022, 6, 269-291.	4.5	9
1704	Emerging Treatment Options for Advanced or Recurrent Endometrial Cancer. <i>Journal of the Advanced Practitioner in Oncology</i> , 2022, 13, 45-59.	0.4	9

#	ARTICLE	IF	CITATIONS
1705	Indirect comparison of pembrolizumab monotherapy versus nivolumab+Âipilimumab in first-line metastatic lung cancer. <i>Immunotherapy</i> , 2022, 14, 295-307.	2.0	3
1706	Pro-BNP in the differential diagnosis of dyspnea in patients treated with immune-checkpoint inhibitors: Case Report. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 1239-1243.	0.9	1
1707	Immune-related adverse events are clinical biomarkers to predict favorable outcomes in advanced renal cell carcinoma treated with nivolumab plus ipilimumab. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 479-485.	1.3	8
1708	Squamous cell carcinoma of the lung: improving the detection and management of immune-related adverse events. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 203-213.	2.4	4
1709	An overview of the efficacy of phototherapy in oncodermatology. <i>Supportive Care in Cancer</i> , 2022, 30, 5591-5600.	2.2	3
1710	Biomarkers and risk factors for the early prediction of immune-related adverse events: a review. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-12.	3.3	11
1711	Immune-related adverse events in the treatment of non-Hodgkin lymphoma with immune checkpoint inhibitors. <i>Scientific Reports</i> , 2022, 12, 1753.	3.3	4
1712	Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial. <i>Lancet Oncology</i> , The, 2022, 23, 220-233.	10.7	106
1713	Immune checkpoint inhibitors rechallenge in urological tumors: An extensive review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 170, 103579.	4.4	10
1714	Immunotherapy-Induced Acute Hepatitis in the Elderly: The Case of a Patient with Urothelial Carcinoma and a Review of the Literature. <i>Forum of Clinical Oncology</i> , 2022, .	0.2	1
1715	Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance. <i>Cutaneous and Ocular Toxicology</i> , 2022, 41, 73-90.	1.3	31
1716	Resolving sticky relationships between platelets and lymphocytes in COVID-19: A role for checkpoint inhibitors?. <i>British Journal of Haematology</i> , 2022, 197, 247-249.	2.5	1
1717	Role of Corticosteroids in Drug-Induced Liver Injury. A Systematic Review. <i>Frontiers in Pharmacology</i> , 2022, 13, 820724.	3.5	22
1718	A Guide to Implementing Immune Checkpoint Inhibitors within a Cancer Program: Experience from a Large Canadian Community Centre. <i>Current Oncology</i> , 2022, 29, 869-880.	2.2	2
1719	Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy. , 2022, 10, e003625.		16
1720	Immune checkpoint inhibitors for the treatment of melanoma. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 563-576.	3.1	10
1721	Brief Communication PD1-related Nephrotoxicity: Optimizing Its Clinical Management Through Histopathologic Features. <i>Journal of Immunotherapy</i> , 2022, 45, 217-221.	2.4	5
1722	Oral Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors: Salivary Gland Dysfunction and Mucosal Diseases. <i>Cancers</i> , 2022, 14, 792.	3.7	8

#	ARTICLE	IF	CITATIONS
1723	Immune-Checkpoint Inhibitors in Advanced Bladder Cancer: Seize the Day. <i>Biomedicines</i> , 2022, 10, 411.	3.2	11
1724	Managing Metastatic Melanoma in 2022: A Clinical Review. <i>JCO Oncology Practice</i> , 2022, 18, 335-351.	2.9	91
1725	Checkpoint-Inhibitoren in der Onkologie: Rheumatologische Symptome beherrschen. , 0, , .		0
1726	Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial. <i>Lung Cancer</i> , 2022, 166, 84-93.	2.0	7
1727	Pericardial effusion with pembrolizumab. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 1664-1670.	0.9	3
1728	Celiac Disease After Administration of Immune Checkpoint Inhibitors: A Case Report. <i>Frontiers in Immunology</i> , 2021, 12, 799666.	4.8	5
1729	Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management. <i>Frontiers in Immunology</i> , 2021, 12, 800879.	4.8	54
1730	The Role of Immune Checkpoint Blockade in the Hepatocellular Carcinoma: A Review of Clinical Trials. <i>Frontiers in Oncology</i> , 2021, 11, 801379.	2.8	21
1731	Immunotherapy in esophagogastric cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2021, 19, 639-647.	0.3	5
1732	Pembrolizumab-induced Myasthenia Gravis Relapse after Immunosuppressive Therapy. <i>Internal Medicine</i> , 2022, 61, 3281-3285.	0.7	3
1733	Immune-related neuromuscular junction disorder after immune checkpoint inhibitor treatment. <i>Journal of Cancer Research and Practice</i> , 2022, 9, 22.	0.2	1
1734	Case Analysis of Immune-Related Myocarditis Induced by PD-1 Inhibitors. <i>Advances in Clinical Medicine</i> , 2022, 12, 1946-1953.	0.0	0
1735	Autoantibodies: A manifestation of immune related adverse events of cancer immunotherapy. <i>Revista Colombiana De ReumatologÃa (English Edition)</i> , 2022, 29, 3-8.	0.0	0
1736	Strategies to mitigate the toxicity of cancer therapeutics. <i>Advances in Cancer Research</i> , 2022, , 215-244.	5.0	5
1737	Neurologic complications of immune modulatory therapy. , 2022, , 537-551.		0
1738	Neurological complications of lung cancer. , 2022, , 243-276.		0
1739	Development of management strategies for immune-related adverse effects of immunotherapies used in oncological treatment. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2022, 9, 7-11.	1.6	1
1740	Pathophysiology roles and translational opportunities of miRNAs in cutaneous melanoma. , 2022, , 339-384.		0

#	ARTICLE	IF	CITATIONS
1741	Rheumatic side effects of cancer immunotherapy with immune checkpoint inhibitors. <i>Klinicka Farmakologie A Farmacie</i> , 2022, 35, 106-111.	0.2	0
1742	Anti-CD20â€œatezolizumabâ€œpolatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, , 1.	2.5	3
1743	Neurologic Toxicity of Immune Checkpoint Inhibitors: A Review of Literature. <i>Frontiers in Pharmacology</i> , 2022, 13, 774170.	3.5	15
1744	Vedolizumab Attenuates Immune-Checkpoint-Therapy-Induced Infliximab-Refractory Colitis. <i>Diagnostics</i> , 2022, 12, 480.	2.6	3
1745	Patient-Reported Outcomes During Checkpoint Inhibition: Insight into Symptom Burden in Daily Clinical Practice. <i>Journal of Pain and Symptom Management</i> , 2022, 63, 997-1005.	1.2	5
1746	Nivolumab-induced systemic lymphadenopathy occurring during treatment of malignant melanoma: a case report. <i>International Journal of Hematology</i> , 2022, 116, 302-306.	1.6	1
1747	Myasthenia gravis induced by pembrolizumab in a patient with metastatic Merkel cell carcinoma. <i>Annales De Dermatologie Et De Venereologie</i> , 2022, , .	1.0	2
1748	Rapid Improvement Following Receipt of Infliximab in Steroid-refractory Durvalumab-Associated Grade 3 Pneumonitis. <i>Cureus</i> , 2022, 14, e22295.	0.5	2
1749	Immune Checkpoint Inhibitors as a Threat to the Hypothalamusâ€œPituitary Axis: A Completed Puzzle. <i>Cancers</i> , 2022, 14, 1057.	3.7	4
1750	Neurotoxicity and safety of the rechallenge of immune checkpoint inhibitors: a growing issue in neuro-oncology practice. <i>Neurological Sciences</i> , 2022, 43, 2339-2361.	1.9	16
1751	Isolated Gastritis Secondary to Immune Checkpoint Inhibitors Complicated by Superimposed Cytomegalovirus Infection. <i>ACG Case Reports Journal</i> , 2022, 9, e00747.	0.4	5
1752	The Diagnosis and Management of Immune Checkpoint Inhibitor Cardiovascular Toxicity: Myocarditis and Beyond. <i>Vaccines</i> , 2022, 10, 304.	4.4	2
1753	Safety of Immune Checkpoint Inhibitor Resumption after Interruption for Immune-Related Adverse Events, a Narrative Review. <i>Cancers</i> , 2022, 14, 955.	3.7	9
1754	Applications of Model-Based Meta-Analysis in Drug Development. <i>Pharmaceutical Research</i> , 2022, 39, 1761-1777.	3.5	12
1755	Neurotoxicity: A Rare Side Effect of Programmed Cell Death 1 (PD-1) Inhibitors. <i>Cureus</i> , 2022, 14, e22584.	0.5	0
1756	Immune Checkpoint Inhibitorsâ€œAssociated Cardiotoxicity. <i>Cancers</i> , 2022, 14, 1145.	3.7	25
1757	Disease exacerbation is common in inflammatory bowel disease patients treated with immune checkpoint inhibitors for malignancy. <i>World Journal of Clinical Cases</i> , 2022, 10, 1787-1794.	0.8	5
1758	Review: A narrative review of predicting acute kidney injury induced by immune checkpoint inhibitors and the appropriate usage of ICI in chronic kidney disease patients. <i>Seminars in Oncology</i> , 2022, , .	2.2	2

#	ARTICLE	IF	CITATIONS
1759	Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era. <i>Cells</i> , 2022, 11, 770.	4.1	26
1760	Endocrine immune-related adverse events: Adrenal, parathyroid, diabetes insipidus, and lipoatrophy. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2022, 36, 101635.	4.7	10
1761	Nivolumab-related myasthenia gravis with myositis requiring prolonged mechanical ventilation: a case report. <i>Journal of Medical Case Reports</i> , 2022, 16, 61.	0.8	6
1762	A Rare Case of Large-Vessel Vasculitis following Checkpoint Inhibitor Therapy and Pegfilgrastim. <i>Case Reports in Oncological Medicine</i> , 2022, 2022, 1-5.	0.3	6
1763	Cardiotoxicity of Systemic Melanoma Treatments. <i>Current Treatment Options in Oncology</i> , 2022, 23, 240-253.	3.0	2
1764	The current state of acute oncology training for emergency physicians: a narrative review. , 2022, 1, .		4
1765	Immunotherapy Associated Neurotoxicity in Pediatric Oncology. <i>Frontiers in Oncology</i> , 2022, 12, 836452.	2.8	5
1766	Tumor necrosis factor alpha neutralization attenuates immune checkpoint inhibitor-induced activation of intermediate monocytes in synovial fluid mononuclear cells from patients with inflammatory arthritis. <i>Arthritis Research and Therapy</i> , 2022, 24, 43.	3.5	4
1767	Reduced FEV1 as Prognostic Factors in Patients With Advanced NSCLC Receiving Immune Checkpoint Inhibitors. <i>Frontiers in Medicine</i> , 2022, 9, 860733.	2.6	2
1768	Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology. <i>Current Oncology</i> , 2022, 29, 1828-1839.	2.2	72
1769	Patient and treatment characteristics of emergency presentations due to immune-mediated toxicities. <i>European Journal of Cancer</i> , 2022, 164, 62-69.	2.8	4
1770	Immune checkpoint inhibitor-induced myocarditis, myositis, myasthenia gravis and transaminitis: a case series and review. <i>Immunotherapy</i> , 2022, , .	2.0	4
1771	First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 499-514.	2.3	7
1772	Checkpoint-Inhibitoren beim malignen Melanom: Rheumatologische Symptome beherrschen. , 0, , .		0
1773	Review of Immune-Related Adverse Events (irAEs) in Non-Small-Cell Lung Cancer (NSCLC)â€”Their Incidence, Management, Multiorgan irAEs, and Rechallenge. <i>Biomedicines</i> , 2022, 10, 790.	3.2	17
1774	Hypersensitivity Reactions and Immune-Related Adverse Events to Immune Checkpoint Inhibitors: Approaches, Mechanisms, and Models. <i>Immunology and Allergy Clinics of North America</i> , 2022, 42, 285-305.	1.9	4
1775	Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View. <i>Cancers</i> , 2022, 14, 1760.	3.7	20
1776	A Case in which Mycophenolate Mofetil Administration Was Effective against Steroid-Refractory Liver Dysfunction Arising as a Nivolumab-Induced Immune-Related Adverse Event. <i>Nihon Jibi Inkoka Tokeibu Geka Gakkai Kaiho</i> , 2022, 125, 285-290.	0.1	0

#	ARTICLE	IF	CITATIONS
1777	Myasthenia Gravis: A Rare Neurologic Complication of Immune Checkpoint Inhibitor Therapy. <i>Journal of the Advanced Practitioner in Oncology</i> , 2022, 13, 151-157.	0.4	1
1778	Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events. <i>Frontiers in Immunology</i> , 2022, 13, 804597.	4.8	27
1779	Protective Effect of Crocin on Immune Checkpoint Inhibitors-Related Myocarditis Through Inhibiting NLRP3 Mediated Pyroptosis in Cardiomyocytes via NF- $\kappa$ B Pathway. <i>Journal of Inflammation Research</i> , 2022, Volume 15, 1653-1666.	3.5	15
1780	Current Understanding and Future Perspectives on Hyperprogressive Disease Highlight the Tumor Microenvironment. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 1059-1078.	2.0	0
1781	Validation of an online application to identify potential immune-related adverse events associated with immune checkpoint inhibitors based on the patient's symptoms. <i>PLoS ONE</i> , 2022, 17, e0265230.	2.5	0
1782	Immune-Related Adverse Events After Immune Checkpoint Inhibitors for Melanoma Among Older Adults. <i>JAMA Network Open</i> , 2022, 5, e223461.	5.9	16
1783	Incidence, Clinical Characteristics, and Predictors of Cardiovascular Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2022, 27, e410-e419.	3.7	9
1784	Eurasian clinical guidelines for cardiovascular complications of cancer treatments: diagnosis, prevention and treatment (2022). <i>Eurasian Heart Journal</i> , 2022, , 6-79.	0.8	6
1785	[Translated article] Characteristics, Management, and Prognostic Implications of Adverse Effects of Immune Checkpoint Inhibitors: A Systematic Review. <i>Actas Dermo-sifiliogrÁficas</i> , 2022, , .	0.4	2
1787	Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies. <i>Vaccines</i> , 2022, 10, 540.	4.4	8
1788	Immune Checkpoint Inhibitor-Induced Central Diabetes Insipidus: Looking for the Needle in the Haystack or a Very Rare Side-Effect to Promptly Diagnose?. <i>Frontiers in Oncology</i> , 2022, 12, 798517.	2.8	9
1789	PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases. <i>Frontiers in Pharmacology</i> , 2022, 13, 854967.	3.5	10
1790	Acute Kidney Injury in Critically Ill Patients with Cancer. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 1385-1398.	4.5	11
1791	Efficiency of Electronic Health Record Assessment of Patient-Reported Outcomes After Cancer Immunotherapy. <i>JAMA Network Open</i> , 2022, 5, e224427.	5.9	18
1792	Immunotherapy-Associated Hypothyroidism: Comparison of the Pre-Existing With De-Novo Hypothyroidism. <i>Frontiers in Endocrinology</i> , 2022, 13, 798253.	3.5	3
1793	Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)â€related interstitial lung disease/pneumonitisâ€”Focus on proactive monitoring, diagnosis, and management. <i>Cancer Treatment Reviews</i> , 2022, 106, 102378.	7.7	60
1794	Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment. <i>ESMO Open</i> , 2022, 7, 100404.	4.5	65
1795	Herpes zoster in patients with solid tumors treated with immune checkpoint inhibitors. <i>Immunotherapy</i> , 2022, 14, 389-393.	2.0	5



#	ARTICLE	IF	CITATIONS
1796	Endoscopic ultrasound guided interventions in the management of pancreatic cancer. <i>World Journal of Gastrointestinal Endoscopy</i> , 2022, 14, 191-204.	1.2	1
1797	Immune checkpoint inhibitor-related endocrinopathies. <i>Journal of Translational Internal Medicine</i> , 2022, 10, 9-14.	2.5	7
1798	Recurrent delayed immune-related pneumonitis after immune-checkpoint inhibitor therapy for advanced osteosarcoma. <i>Immunotherapy</i> , 2022, 14, 395-399.	2.0	3
1799	Cardiac Magnetic Resonance Imaging in Immune Check-Point Inhibitor Myocarditis: A Systematic Review. <i>Journal of Imaging</i> , 2022, 8, 99.	3.0	4
1800	Emergence of ocular toxicities associated with novel anticancer therapeutics: What the oncologist needs to know. <i>Cancer Treatment Reviews</i> , 2022, 105, 102376.	7.7	4
1801	Immune checkpoint inhibitor-induced neurologic toxicity: a case report and literature review. <i>Immunotherapy</i> , 2022, 14, 505-510.	2.0	3
1802	International society of oncology pharmacy practitioners (ISOPP) position statement: The role of oncology pharmacy practitioners in immunotherapy treatment with immune checkpoint inhibitors for malignant conditions. <i>Journal of Oncology Pharmacy Practice</i> , 2022, , 107815522210901.	0.9	0
1803	Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism. <i>Frontiers in Immunology</i> , 2022, 13, 830631.	4.8	28
1804	Immune checkpoint inhibitors for hepatocellular carcinoma – A game changer in treatment landscape. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 1371-1383.	1.7	3
1805	Immune checkpoint inhibitor-associated ophthalmic adverse events: current understanding of its mechanisms, diagnosis, and management. <i>International Journal of Ophthalmology</i> , 2022, 15, 646-656.	1.1	12
1806	Sacroiliitis as an immune-related adverse event of pembrolizumab treatment for melanoma. <i>Scandinavian Journal of Rheumatology</i> , 2022, , 1-2.	1.1	1
1807	Balancing the good and the bad: controlling immune-related adverse events versus anti-tumor responses in cancer patients treated with immune checkpoint inhibitors. <i>Immunotherapy Advances</i> , 2022, 2, .	3.0	5
1808	54-Year-Old Man With Acute Dyspnea on Exertion. <i>Mayo Clinic Proceedings</i> , 2022, 97, 1008-1013.	3.0	2
1809	Checkpoint Inhibitor Immune-Related Adverse Events: A Multimodality Pictorial Review. <i>Academic Radiology</i> , 2022, 29, 1869-1884.	2.5	3
1810	Emerging immunotherapy for HCC: A guide for hepatologists. <i>Hepatology</i> , 2022, 75, 1604-1626.	7.3	97
1811	Two cases with fulminant type 1 diabetes that developed long after cessation of immune checkpoint inhibitor treatment. <i>Journal of Diabetes Investigation</i> , 2022, 13, 1458-1460.	2.4	5
1812	Cardiovascular toxicity following immune checkpoint inhibitors: A systematic review and meta-analysis. <i>Translational Oncology</i> , 2022, 19, 101383.	3.7	4
1813	Toxicity profile of treatment with PD-1 inhibitors for lung cancer, melanoma and renal cell carcinoma: A real-world Brazilian study. <i>International Immunopharmacology</i> , 2022, 108, 108727.	3.8	1

#	ARTICLE	IF	CITATIONS
1814	Analysis of characteristics and predictive factors of immune checkpoint inhibitor-related adverse events. <i>Cancer Biology and Medicine</i> , 2021, 18, 1118-1133.	3.0	16
1815	Immunotherapy-Related Acute Kidney Injury. <i>Advances in Chronic Kidney Disease</i> , 2021, 28, 429-437.e1.	1.4	5
1816	Formation of necrotizing vasculitis in the patient with diffuse B-cell large cell lymphoma on immune checkpoint inhibitor (PD-1) therapy. <i>HERALD of North-Western State Medical University Named After I I Mechnikov</i> , 2021, 13, 83-90.	0.2	0
1817	The management of toxicities from immune, targeted and ADCs treatments in patients with urothelial cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2023, 41, 410-419.	1.6	3
1818	Immune Checkpoint Inhibitor Treatment and Ophthalmologist Consultations in Patients with Malignant Melanoma or Lung Cancer—A Nationwide Cohort Study. <i>Cancers</i> , 2022, 14, 49.	3.7	2
1819	Application of the Plan-Do-Check-Act Cycle for Managing Immune-Related Adverse Events. <i>Journal of Analytical Oncology</i> , 0, 10, 61-68.	0.1	0
1820	Treatment of acute kidney injury in cancer patients. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 873-884.	2.9	6
1821	Analysis of immune-mediated reactions in patients with non-small cell lung cancer treated with nivolumab and its association with effectiveness. <i>Journal of Oncology Pharmacy Practice</i> , 2023, 29, 290-298.	0.9	3
1822	Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors. <i>Frontiers in Immunology</i> , 2021, 12, 794099.	4.8	34
1823	Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 647-656.	2.5	6
1824	Infectious complications of immune checkpoint inhibitors in solid organ malignancies. <i>Cancer Medicine</i> , 2022, 11, 21-27.	2.8	15
1825	Humoral and cellular correlates of a novel immune-related adverse event and its treatment. , 2021, 9, e003585.		10
1826	Improvement of PD-1 Blockade Efficacy and Elimination of Immune-Related Gastrointestinal Adverse Effect by mTOR Inhibitor. <i>Frontiers in Immunology</i> , 2021, 12, 793831.	4.8	16
1827	Management of acute kidney injury in gastrointestinal tumor: An overview. <i>World Journal of Clinical Cases</i> , 2021, 9, 10746-10764.	0.8	0
1828	Case Report: Glucocorticoid Effect Observation in a Ureteral Urothelial Cancer Patient With ICI-Associated Myocarditis and Multiple Organ Injuries. <i>Frontiers in Immunology</i> , 2021, 12, 799077.	4.8	7
1829	Facts and Hopes in Prediction, Diagnosis, and Treatment of Immune-Related Adverse Events. <i>Clinical Cancer Research</i> , 2022, 28, 1250-1257.	7.0	11
1830	CANDIED: A Pan-Canadian Cohort of Immune Checkpoint Inhibitor-Induced Insulin-Dependent Diabetes Mellitus. <i>Cancers</i> , 2022, 14, 89.	3.7	5
1831	Current challenges of hematologic complications due to immune checkpoint blockade: a comprehensive review. <i>Annals of Hematology</i> , 2022, 101, 1-10.	1.8	23

#	ARTICLE	IF	CITATIONS
1832	Differential diagnosis and management of immune checkpoint inhibitor-induced colitis: A comprehensive review. <i>World Journal of Experimental Medicine</i> , 2021, 11, 79-92.	1.7	8
1833	Nivolumab-induced liver injury with a steroid-refractory increase in biliary enzymes, in a patient with malignant mesothelioma: An autopsy case report. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e05174.	0.5	1
1834	Myocarditis and diaphragmatic rhabdomyolysis with respiratory failure in a patient with metastatic melanoma treated with Nivolumab. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 750-753.	0.9	2
1835	Sintilimab-Induced Myocarditis Overlapping Myositis in a Patient With Metastatic Thymoma: A Case Report. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 797009.	2.4	6
1836	A Case of Lung Adenocarcinoma with Autoimmune Hemolytic Anemia Developing After Immune Checkpoint Inhibitor Treatment. <i>Japanese Journal of Lung Cancer</i> , 2021, 61, 975-978.	0.1	1
1837	Immunotherapy in non-small cell lung cancer: rationale, recent advances and future perspectives. <i>Precision Clinical Medicine</i> , 2021, 4, 258-270.	3.3	18
1838	Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in <scp>China</scp>. <i>Thoracic Cancer</i> , 2022, 13, 412-422.	1.9	19
1839	Management of immune-related adverse events in anti-PD-1-treated patients with advanced cutaneous squamous cell carcinoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 23-28.	2.4	8
1842	Immune checkpoint inhibitor-related interstitial lung disease in patients with advanced non-small cell lung cancer: systemic review of characteristics, incidence, risk factors, and management. <i>Journal of Thoracic Disease</i> , 2021, .	1.4	4
1843	Anti-GAD65 Antibody-Associated Autoimmune Encephalitis With Predominant Cerebellar Involvement Following Toripalimab Treatment: A Case Report of a Novel irAE of Toripalimab. <i>Frontiers in Immunology</i> , 2022, 13, 850540.	4.8	5
1844	Electrolyte Abnormalities Associated With The Use of Atezolizumab – A Systematic Review. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2022, 12, 35-44.	0.8	1
1845	PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism. <i>Frontiers in Pharmacology</i> , 2022, 13, 835510.	3.5	10
1846	The Role of Myeloid Cells in Hepatotoxicity Related to Cancer Immunotherapy. <i>Cancers</i> , 2022, 14, 1913.	3.7	7
1847	Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article. <i>Current Oncology</i> , 2022, 29, 2871-2886.	2.2	24
1848	Transition of the PD-1 occupancy of nivolumab on T cells after discontinuation and response of nivolumab re-challenge. <i>Molecular and Clinical Oncology</i> , 2022, 16, 104.	1.0	3
1849	Successful use of secukinumab in two melanoma patients with immune checkpoint inhibitor-induced inflammatory arthropathy. <i>Immunotherapy</i> , 2022, 14, 593-598.	2.0	15
1850	Frailty and checkpoint inhibitor toxicity in older patients with melanoma. <i>Cancer</i> , 2022, 128, 2746-2752.	4.1	12
1851	Severe immune-related hepatitis and myocarditis caused by PD-1 inhibitors in the treatment of triple-negative breast cancer: a case report. <i>Annals of Translational Medicine</i> , 2022, 10, 424-424.	1.7	7

#	ARTICLE	IF	CITATIONS
1852	Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 2018.	3.7	15
1853	Immune-Related Adverse Events (irAEs) in Cancer, with Inputs from a Nursing Expert: A Review. <i>Indian Journal of Medical and Paediatric Oncology</i> , 0, 43, .	0.2	0
1854	Epigenetic Alterations and Inflammation as Emerging Use for the Advancement of Treatment in Non-Small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 878740.	4.8	19
1855	Immune checkpoint inhibitor-related thyroid dysfunction. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2022, 36, 101660.	4.7	24
1856	Case Report: Thrombotic-Thrombocytopenic Purpura Following Ipilimumab and Nivolumab Combination Immunotherapy for Metastatic Melanoma. <i>Frontiers in Immunology</i> , 2022, 13, 871217.	4.8	7
1857	Prediction of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint inhibitors based on clinical and hematological markers: Real-world evidence. <i>Experimental Cell Research</i> , 2022, 416, 113157.	2.6	15
1901	Incidence of hepatotoxicity associated with addition of immune checkpoint blockade to systemic solid tumor therapy: a meta-analysis of phase 3 randomized controlled trials. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2837-2848.	4.2	5
1902	Paraneoplastic neurological syndrome: growing spectrum and relevance. <i>Neurological Sciences</i> , 2022, 43, 3583-3594.	1.9	4
1903	Transcriptional and post-transcriptional regulation of checkpoint genes on the tumour side of the immunological synapse. <i>Heredity</i> , 2022, 129, 64-74.	2.6	4
1904	Immunotherapy-induced Colitis. <i>Journal of Clinical Gastroenterology</i> , 2022, Publish Ahead of Print, .	2.2	5
1905	Hypereosinophilia is a predictive biomarker of immune checkpoint inhibitor-induced hypopituitarism in patients with renal cell carcinoma. <i>BMC Endocrine Disorders</i> , 2022, 22, 110.	2.2	7
1906	Recurrent autoimmune encephalitis related to immune checkpoint inhibitors. <i>Epileptic Disorders</i> , 2022, 24, 609-613.	1.3	1
1907	Grading Central Diabetes Insipidus Induced by Immune Checkpoint Inhibitors: A Challenging Task. <i>Frontiers in Endocrinology</i> , 2022, 13, 840971.	3.5	2
1912	Immuno-therapie. <i>Canadian Family Physician</i> , 2021, 67, e174-e177.	0.4	1
1913	An Unusual Case of Pericarditis. <i>Acta Cardiologica Sinica</i> , 2021, 37, 648-651.	0.2	0
1914	Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions. <i>Neuro-Oncology</i> , 2022, 24, 1613-1646.	1.2	39
1915	Autoimmune Polyendocrinopathy Induced by an Antibody (KN046) That Simultaneously Inhibits PD-L1 and CTLA-4: A Case Report and Literature Review. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2022, Volume 15, 1253-1260.	2.4	8
1916	Development and Validation of a Radiomics Nomogram Using Computed Tomography for Differentiating Immune Checkpoint Inhibitor-Related Pneumonitis From Radiation Pneumonitis for Patients With Non-Small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 870842.	4.8	13

#	ARTICLE	IF	CITATIONS
1917	Retreatment With Immune Checkpoint Inhibitors After a Severe Immune-Related Hepatitis: Results From a Prospective Multicenter Study. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 732-740.	4.4	19
1918	Effects of immune checkpoint inhibitor therapy resumption in patients with malignant tumors after moderate-to-severe immune-related adverse events. <i>PLoS ONE</i> , 2022, 17, e0267572.	2.5	5
1919	Feasibility of immunotherapy in cancer patients with persistent or past hepatitis B or C virus infection. <i>JGH Open</i> , 2022, 6, 309-316.	1.6	6
1920	Real-World Adherence to Toxicity Management Guidelines for Immune-Related Adverse Events. <i>Current Oncology</i> , 2022, 29, 3104-3117.	2.2	4
1921	Exploring the educational needs for severe immune-related adverse events of PD-1/PD-L1 inhibitors in advanced lung cancer: A single-center observational study. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2022, 9, 100076.	1.6	2
1922	The Many Faces of Immune Checkpoint Inhibitor-Associated Pneumonitis: 4 Case Reports. <i>American Journal of Case Reports</i> , 0, 23, .	0.8	2
1924	Advanced materials for management of immune-related adverse events induced by immune checkpoint inhibitors. <i>Materials and Design</i> , 2022, 219, 110738.	7.0	0
1925	Atypical Antiglomerular Basement Membrane Nephritis Following Immune Checkpoint Inhibitor. <i>Kidney International Reports</i> , 2022, 7, 1913-1916.	0.8	6
1926	Immune checkpoint inhibitor-related hypophysitis. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2022, 36, 101668.	4.7	11
1927	Cardio-oncology in Austria: cardiotoxicity and surveillance of anti-cancer therapies. <i>Wiener Klinische Wochenschrift</i> , 2022, 134, 654-674.	1.9	7
1928	Safety and potential increased risk of toxicity of radiotherapy combined immunotherapy strategy. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2023, 19, 35-50.	1.1	2
1929	Thyroid Dysfunction from Treatments for Solid Organ Cancers. <i>Endocrinology and Metabolism Clinics of North America</i> , 2022, 51, 265-286.	3.2	3
1930	Screening, Surveillance, and Management of Hepatocellular Carcinoma During the COVID-19 Pandemic: a Narrative Review. <i>Journal of Gastrointestinal Cancer</i> , 2023, 54, 408-419.	1.3	12
1931	Immune Checkpoint Inhibitor-Related Myositis Overlapping With Myocarditis: An Institutional Case Series and a Systematic Review of Literature. <i>Frontiers in Pharmacology</i> , 2022, 13, .	3.5	11
1932	Adverse and unconventional reactions related to immune checkpoint inhibitor therapy for cancer. <i>International Immunopharmacology</i> , 2022, 108, 108803.	3.8	5
1934	Mycophenolate mofetil for immune checkpoint inhibitor-related hepatotoxicity relapsing during dose reduction of corticosteroid: A report of two cases and literature review. <i>Cancer Reports</i> , 2022, 5, e1624.	1.4	7
1935	Mechanism and Management of Checkpoint Inhibitor-Related Toxicities in Genitourinary Cancers. <i>Cancers</i> , 2022, 14, 2460.	3.7	2
1936	Pembrolizumab-induced Myasthenia Gravis: Literature Review of Ocular Manifestations and a Refractory Case. <i>Journal of Immunotherapy</i> , 2022, Publish Ahead of Print, .	2.4	4

#	ARTICLE	IF	CITATIONS
1937	Risk factors for pneumonitis in advanced extrapulmonary cancer patients treated with immune checkpoint inhibitors. <i>BMC Cancer</i> , 2022, 22, 551.	2.6	4
1938	Effect of Atezolizumab plus Bevacizumab in Patients with Hepatocellular Carcinoma Harboring <i>CTNNB1</i> Mutation in Early Clinical Experience. <i>Journal of Cancer</i> , 2022, 13, 2656-2661.	2.5	6
1939	Role of Abdominal and Pelvic CT Scans in Diagnosis of Patients with Immunotherapy-Induced Colitis. <i>Journal of Immunotherapy and Precision Oncology</i> , 2022, 5, 32-36.	1.4	1
1940	Management of immune-related hepatitis in patients being treated with checkpoint inhibitors for metastatic melanoma, a review and case series. <i>Journal of Oncology Pharmacy Practice</i> , 2023, 29, 1163-1171.	0.9	3
1941	Paraneoplastic limbic encephalitis following treatment with single-agent pembrolizumab for advanced gastroesophageal adenocarcinoma. <i>BMJ Case Reports</i> , 2022, 15, e247676.	0.5	2
1942	Recent advances, patient selection & challenges in managing cancer patients undergoing treatment with immune checkpoint inhibitors. <i>Indian Journal of Medical Research</i> , 2022, .	1.0	0
1943	Cardiotoxicity of Biological Therapies in Cancer Patients: An In-depth Review. <i>Current Cardiology Reviews</i> , 2023, 19, .	1.5	3
1945	Non-bacterial Cystitis With Increased Expression of Programmed Cell Death Ligand 1 in the Urothelium: An Unusual Immune-Related Adverse Event After Atezolizumab Administration for Metastatic Breast Cancer. <i>Cureus</i> , 2022, , .	0.5	4
1947	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma. , 2022, 10, e003956.		16
1948	Chest Pain in the Cancer Patient. <i>European Cardiology Review</i> , 0, 17, .	2.2	3
1949	Nivolumab-Induced Peritonitis With Mesothelial Hyperplasia Mimicking Metastatic Mesothelioma. <i>AJSP Review and Reports</i> , 2022, 27, 98-102.	0.1	3
1950	Treatment of drug-induced immune thrombocytopenias. <i>Haematologica</i> , 2022, 107, 1264-1277.	3.5	17
1951	Clinical Presentation of Immune-Related Endocrine Adverse Events during Immune Checkpoint Inhibitor Treatment. <i>Cancers</i> , 2022, 14, 2687.	3.7	10
1952	Acupuncture Treatment of Guillain-Barré Syndrome After Using Immune Checkpoint Inhibitors: A Case Report. <i>Frontiers in Neurology</i> , 2022, 13, .	2.4	7
1953	Pembrolizumab-induced aseptic meningitis in a patient with non-small cell lung cancer: A case report and literature review of aseptic meningitis as an immune-related adverse event. <i>Molecular and Clinical Oncology</i> , 2022, 17, .	1.0	2
1954	Management of Steroid-Refractory Gastrointestinal Immune-Related Adverse Events. <i>Annals of Pharmacotherapy</i> , 0, , 106002802210943.	1.9	1
1955	A Prospective Study to Detect Immune Checkpoint Inhibitors Associated With Myocarditis Among Patients Treated for Lung Cancer. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, .	2.4	4
1956	Immune-related adverse events in older adults: Data mining of the FDA Adverse Event Reporting System. <i>Journal of Geriatric Oncology</i> , 2022, , .	1.0	2

#	ARTICLE	IF	CITATIONS
1957	Analysis of interactions of immune checkpoint inhibitors with antibiotics in cancer therapy. <i>Frontiers of Medicine</i> , 2022, 16, 307-321.	3.4	6
1958	Oncologic emergencies and urgencies: A comprehensive review. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 570-593.	329.8	18
1959	Sexual dysfunction among adolescent and young adult cancer patients: diagnostic and therapeutic approach. <i>Current Opinion in Supportive and Palliative Care</i> , 2022, 16, 83-91.	1.3	4
1960	Renal and urinary bladder cancer. , 2023, , 327-335.		0
1961	Cancer Immunotherapy and Uveitis: Balancing Anti-Tumor Immunity and Ocular Autoimmunity. <i>International Ophthalmology Clinics</i> , 2022, 62, 49-63.	0.7	6
1962	Fecal Microbiota Transplantation Effectively Cures a Patient With Severe Bleeding Immune Checkpoint Inhibitor-Associated Colitis and a Short Review. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	14
1963	Safety of sequential immune checkpoint inhibitors after prior immune therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 2375-2382.	2.5	2
1964	High Grade Dermatologic Adverse Events Associated With Immune Checkpoint Blockade for Cancer. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	7
1965	Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer. <i>Molecules</i> , 2022, 27, 3798.	3.8	29
1966	Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma. <i>Clinical Drug Investigation</i> , 0, , .	2.2	0
1967	Successful Treatment with Short-Term Steroid Against Severe Hepatitis Confirmed by Liver Biopsy in a Patient with Advanced Squamous-Cell Lung Cancer Receiving a Combination of Pembrolizumab, Carboplatin, and Nab-Paclitaxel: A Case Report. <i>OncoTargets and Therapy</i> , 0, Volume 15, 637-642.	2.0	2
1968	Role of cardiac <scp>MRI</scp> in the diagnosis of immune checkpoint inhibitor-associated myocarditis. <i>International Journal of Cancer</i> , 2022, 151, 1860-1873.	5.1	19
1969	PD-1/PD-L Axis in Neuroinflammation: New Insights. <i>Frontiers in Neurology</i> , 0, 13, .	2.4	16
1970	Safety and Immunogenicity of mRNA Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Lung Cancer Receiving Immune Checkpoint Inhibitors: A Multicenter Observational Study in Japan. <i>Journal of Thoracic Oncology</i> , 2022, 17, 1002-1013.	1.1	11
1971	Clinical Manifestations, Monitoring, and Prognosis: A Review of Cardiotoxicity After Antitumor Strategy. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	7
1972	Challenging Dermatologic Considerations Associated with Immune Checkpoint Inhibitors. <i>American Journal of Clinical Dermatology</i> , 0, , .	6.7	3
1973	Pharmacological Treatments Available for Immune-Checkpoint-Inhibitor-Induced Colitis. <i>Biomedicines</i> , 2022, 10, 1334.	3.2	5
1975	Moderate Colitis Not Requiring Intravenous Steroids Is Associated with Improved Survival in Stage IV Melanoma after Anti-CTLA4 Monotherapy, But Not Combination Therapy. <i>Oncologist</i> , 2022, 27, 799-808.	3.7	3

#	ARTICLE	IF	CITATIONS
1976	Immune Checkpoint Inhibitor Associated Autoimmune Encephalitis, Rare and Novel Topic of Neuroimmunology: A Case Report and Review of the Literature. <i>Brain Sciences</i> , 2022, 12, 773.	2.3	7
1977	Myocardial Dysfunction in Patients with Cancer. <i>Heart Failure Clinics</i> , 2022, 18, 361-374.	2.1	1
1978	Anti-4striational antibody-4positive myasthenia gravis and Guillain-4Barr-4 syndrome secondary to pembrolizumab administration for malignant melanoma : A case report. <i>Skin Cancer</i> , 2022, 37, 40-45.	0.0	0
1979	Neurologic Complications of Immune Checkpoint Inhibitors. <i>Touch Reviews in Neurology</i> , 2022, 18, 58.	0.2	0
1980	THYROID DYSFUNCTIONS INDUCED BY IMMUNE CHECK-POINT INHIBITORS. <i>Ek'sperimentuli Da Klinikuri Medic'ina</i> , 0, , .	0.0	0
1981	Effects of systemic targeted immunosuppressive therapy on ocular surface. <i>Current Opinion in Ophthalmology</i> , 2022, Publish Ahead of Print, .	2.9	1
1982	Hypophysitis. <i>Endocrine Practice</i> , 2022, 28, 901-910.	2.1	3
1983	Nivolumab-4plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. <i>Annals of Oncology</i> , 2022, 33, 1052-1060.	1.2	81
1985	Immune checkpoint inhibitor-4related liver toxicity. <i>Clinical Liver Disease</i> , 2022, 20, 93-96.	2.1	0
1986	Monitoring Endocrine Complications of Immunotherapy: A Screening Tool. <i>Cureus</i> , 2022, , .	0.5	3
1987	Pretreatment Modified Albumin-4Bilirubin Grade Is an Important Predictive Factor Associated with the Therapeutic Response and the Continuation of Atezolizumab plus Bevacizumab Combination Therapy for Patients with Unresectable Hepatocellular Carcinoma. <i>Current Oncology</i> , 2022, 29, 4799-4810.	2.2	8
1988	Ipilimumab- and nivolumab-induced myocarditis in a patient with metastatic cholangiocarcinoma: a case report. <i>Journal of Medical Case Reports</i> , 2022, 16, .	0.8	4
1989	Facing the Challenge of Drug-Induced Acute Interstitial Nephritis. <i>Nephron</i> , 2023, 147, 78-90.	1.8	12
1990	Multi-organ Immune-Related Adverse Event Is a Risk Factor of Immune Checkpoint Inhibitor-Associated Myocarditis in Cancer Patients: A Multi-center Study. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	9
1991	Thyroid Dysfunction as a Predictive Indicator in Camrelizumab of Advanced Esophageal Squamous Cell Carcinoma. <i>Journal of Immunology Research</i> , 2022, 2022, 1-8.	2.2	3
1992	An Interesting Case Report of Myasthenia Gravis Exacerbation Induced by Durvalumab. <i>Cureus</i> , 2022, , .	0.5	1
1993	Intrinsic Differences in Immune Checkpoint Inhibitor-Induced Myocarditis: A Retrospective Analysis of Real World Data. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	3
1994	A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma. <i>Therapeutics and Clinical Risk Management</i> , 0, Volume 18, 683-698.	2.0	2



#	ARTICLE	IF	CITATIONS
1996	Clinical Significance of Transient Asymptomatic Elevations in Aminotransferase (TAEAT) in Oncology. American Journal of Clinical Oncology: Cancer Clinical Trials, 0, Publish Ahead of Print, .	1.3	3
1997	Safety Implications of Switching Pembrolizumab Dosage From 200 mg Every 3 Weeks to 400 mg Every 6 Weeks in Patients With Advanced NSCLC. Journal of Thoracic Oncology, 2022, 17, 1227-1232.	1.1	10
1998	Circulating T Cell Activation and Exhaustion Markers Are Associated With Radiation Pneumonitis and Poor Survival in Non-Small-Cell Lung Cancer. Frontiers in Immunology, 0, 13, .	4.8	2
1999	Autoantibody positivity predicts severity of rheumatic immune-related adverse events to immune-checkpoint inhibitors. European Journal of Internal Medicine, 2022, 103, 95-99.	2.2	6
2000	Inhibition of IL-17A Protects against Thyroid Immune-Related Adverse Events while Preserving Checkpoint Inhibitor Antitumor Efficacy. Journal of Immunology, 2022, 209, 696-709.	0.8	14
2001	Esophagogastric Cancers: Integrating Immunotherapy Therapy Into Current Practice. Journal of Clinical Oncology, 2022, 40, 2751-2762.	1.6	27
2002	Imaging Mass Cytometry Analysis of immune Checkpoint Inhibitor-Related Pneumonitis: A Case Report. Frontiers in Immunology, 0, 13, .	4.8	2
2003	Two cases of ulcerative colitis that developed while using abatacept. Clinical Journal of Gastroenterology, 0, , .	0.8	1
2004	Diretriz de Miocardites da Sociedade Brasileira de Cardiologia 2022. Arquivos Brasileiros De Cardiologia, 2022, 119, 143-211.	0.8	14
2005	Leptomeningeal Metastases: New Opportunities in the Modern Era. Neurotherapeutics, 2022, 19, 1782-1798.	4.4	9
2006	Pembrolizumab-Induced Pancreatic Exocrine Insufficiency Complicated by Severe Hepatic Steatosis. Cureus, 2022, , .	0.5	0
2007	A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202). ESMO Open, 2022, 7, 100529.	4.5	23
2008	Applicability analysis of immunotherapy for lung cancer patients based on deep learning. Methods, 2022, 205, 149-156.	3.8	5
2009	Complications in the Oncologic Patient: Chest. , 2023, , 681-691.		0
2010	The Challenges of Novel Therapies in the Care of the Critically Ill Cancer Patient. , 2023, , 448-458.		0
2011	Newer Cancer Therapies and Perioperative Implications. , 2023, , 56-69.		0
2012	Immunotherapy-induced Hepatotoxicity: A Review. Journal of Clinical and Translational Hepatology, 2022, 000, 000-000.	1.4	3
2013	Therapeutic targeting of PD-1/PD-L1 blockade by novel small-molecule inhibitors recruits cytotoxic T cells into solid tumor microenvironment. , 2022, 10, e004695.		16

#	ARTICLE	IF	CITATIONS
2014	Checkpoint inhibitor-induced hepatotoxicity: Role of liver biopsy and management approach. <i>World Journal of Hepatology</i> , 2022, 14, 1269-1276.	2.0	6
2015	Atezolizumab-associated encephalitis in metastatic breast cancer: A case report. <i>Oncology Letters</i> , 2022, 24, .	1.8	4
2016	Interferon- $\beta$ predicts the treatment efficiency of immune checkpoint inhibitors in cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	2.5	1
2017	Type 3 autoimmune pancreatitis (immune checkpoint inhibitor-induced pancreatitis). <i>Current Opinion in Gastroenterology</i> , 2022, 38, 516-520.	2.3	8
2018	Proposed clinical phases for the improvement of personalized treatment of checkpoint inhibitor-related pneumonitis. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	7
2019	Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes. <i>Cells</i> , 2022, 11, 2249.	4.1	23
2020	Immune checkpoint inhibitor-associated new-onset primary adrenal insufficiency: a retrospective analysis using the FAERS. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 2131-2137.	3.3	10
2021	Non-specific symptoms as a prodrome of immune-related adverse events in patients with non-small cell lung cancer receiving nivolumab: a consecutive analysis of 200 patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 3185-3191.	2.5	1
2022	Subvalorizaço das Artralgias: Papel do Enfermeiro na detecço precoce da Imunotoxicidade. <i>Onco News</i> , 2021, , 56-62.	0.1	0
2023	VII. Diagnosis and Treatment of Autoimmune Encephalitis. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2021, 110, 1601-1610.	0.0	0
2024	Imaging features of toxicities associated with immune checkpoint inhibitors. <i>European Journal of Radiology Open</i> , 2022, 9, 100434.	1.6	6
2025	Immune Checkpoint Inhibitors Induced Hepatotoxicity; Gastroenterologists' Perspectives. <i>Middle East Journal of Digestive Diseases</i> , 2022, 14, 244-253.	0.4	1
2026	Immune-Checkpoint-Inhibitor-Related Lung Toxicity: A Multicentre Real-Life Retrospective Portrait from Six Italian Centres. <i>Life</i> , 2022, 12, 1149.	2.4	2
2027	Interstitial nephritis secondary to treatment with pembrolizumab, a rare complication in two patients with lung adenocarcinoma. <i>Monaldi Archives for Chest Disease</i> , 0, , .	0.6	1
2028	Clinical Outcomes after Immunotherapies in Cancer Setting during COVID-19 Era: A Systematic Review and Meta-Regression. <i>Reports</i> , 2022, 5, 31.	0.5	0
2029	Characteristics and usefulness of transabdominal ultrasonography in immune-mediated colitis. <i>Intestinal Research</i> , 2023, 21, 126-136.	2.6	1
2030	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer. , 2022, 10, e004434.		14
2031	Use of Glucocorticoids in Patients with Cancer: Potential Benefits, Harms, and Practical Considerations for Clinical Practice. <i>Practical Radiation Oncology</i> , 2022, , .	2.1	1

#	ARTICLE	IF	CITATIONS
2032	Immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: A review. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	5
2033	Reversible Tumor Progression Induced by a Dexamethasone Course for Severe COVID-19 during Immune Checkpoint Inhibitor Treatment. <i>Diagnostics</i> , 2022, 12, 1933.	2.6	1
2034	Pulmonary Lymphangitis Carcinomatosa Mimicking Immunotherapy-Related Interstitial Pneumonitis: A Case Report. <i>Case Reports in Oncology</i> , 0, , 732-737.	0.7	0
2035	PD-1 inhibitor-associated type 1 diabetes: A case report and systematic review. <i>Frontiers in Public Health</i> , 0, 10, .	2.7	10
2036	Effect of chronic stress on tumorigenesis and development. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, .	5.4	3
2037	Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instabilityâ€“High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study. <i>Journal of Clinical Oncology</i> , 2023, 41, 255-265.	1.6	98
2038	Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150. <i>Cancers</i> , 2022, 14, 3938.	3.7	8
2039	Pharmaceutical Prevention and Management of Cardiotoxicity in Hematological Malignancies. <i>Pharmaceuticals</i> , 2022, 15, 1007.	3.8	3
2040	Nivolumab plus ipilimumab induced endocrinopathy and acute interstitial nephritis in metastatic sarcomatoid renal-cell carcinoma: A case report and review of literature. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	5
2041	Regulatory T Cell Depletion Using a CRISPR Fc-Optimized CD25 Antibody. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8707.	4.1	3
2042	Immune-checkpoint inhibitor-associated grade 3 hepatotoxicity managed with enteric-coated budesonide monotherapy: A case report. <i>Medicine (United States)</i> , 2022, 101, e29473.	1.0	2
2043	2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>European Heart Journal Cardiovascular Imaging</i> , 2022, 23, e333-e465.	1.2	97
2044	Successful immune checkpoint inhibitor rechallenge after immune-related pericarditis: Clinical case series. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	2
2045	Risk of pneumonitis in non-small cell lung cancer patients with preexisting interstitial lung diseases treated with immune checkpoint inhibitors: a nationwide retrospective cohort study. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 591-598.	4.2	4
2046	Prospective screening for myocarditis in cancer patients treated with immune checkpoint inhibitors. <i>Journal of Cardiology</i> , 2023, 81, 63-67.	1.9	8
2047	Progression from early to advanced stage of immuneâ€“related cholangitis. <i>Hepatology Research</i> , 0, , .	3.4	1
2048	The role of kidney biopsy in immune checkpoint inhibitor nephrotoxicity. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	2
2049	Eosinophil as a biomarker for diagnosis, prediction, and prognosis evaluation of severe checkpoint inhibitor pneumonitis. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	3

#	ARTICLE	IF	CITATIONS
2050	Clinical course and management of insidious adrenal crisis manifested initially as hyperpyrexia secondary to pembrolizumab: Case reports and literature review. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	2
2051	2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>European Heart Journal</i> , 2022, 43, 4229-4361.	2.2	705
2052	Elevated TSH Level, TgAb, and Prior Use of Ramucirumab or TKIs as Risk Factors for Thyroid Dysfunction in PD-L1 Blockade. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e4115-e4123.	3.6	6
2053	The CURB65 score predicted 180-day mortality of non-small cell lung carcinoma patients with immune checkpoint inhibitor-associated pneumonitis: A pilot retrospective analysis. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	0
2054	The effects of glucocorticoids and immunosuppressants on cancer outcomes in checkpoint inhibitor therapy. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	16
2055	Nivolumabâ€“ipilimumab combination therapy-induced seronegative encephalitis; rapid response to steroid plus intravenous immunoglobulin (IVIG) treatment. <i>Journal of Oncology Pharmacy Practice</i> , 2023, 29, 760-763.	0.9	4
2056	Emerging Immunotherapy: Liver Cancer Microenvironment for Treatment. , 0, , .		0
2057	Research Progress on Radiotherapy Combined with Immunotherapy for Associated Pneumonitis During Treatment of Non-Small Cell Lung Cancer. <i>Cancer Management and Research</i> , 0, Volume 14, 2469-2483.	1.9	5
2058	Checkpoint Immunotherapy-Induced Myocarditis and Encephalitis Complicated With Complete AV Block. <i>JACC: Case Reports</i> , 2022, 4, 1032-1036.	0.6	7
2059	A Case of Systemic Severe Bullous Pemphigoid Caused by Long-Term Sintilimab Treatment for Renal Cell Carcinoma. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 0, Volume 15, 1611-1614.	1.8	4
2060	Immune checkpoint Inhibitorâ€“Induced diarrhea and Colitis: Incidence and Management. A systematic review and Meta-analysis. <i>Cancer Treatment Reviews</i> , 2022, 109, 102440.	7.7	28
2061	Pathophysiology of Immune Checkpoint Inhibitor-Induced Myocarditis. <i>Cancers</i> , 2022, 14, 4494.	3.7	16
2062	MRI techniques for immunotherapy monitoring. , 2022, 10, e004708.		5
2063	Fatal toxicity induced by anti-PD-1 immune checkpoint inhibitor in thymic epithelial tumor. <i>Immunotherapy</i> , 2022, 14, 1097-1107.	2.0	3
2064	Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study. <i>European Journal of Cancer</i> , 2022, 175, 224-235.	2.8	13
2065	A risk stratification model for toxicities in phase 1 immunotherapy trials. <i>European Journal of Cancer</i> , 2022, 175, 11-18.	2.8	0
2066	Pancreas and Gallbladder. , 2022, , 255-264.		0
2067	Hepatology (Liver and Bile Duct). , 2022, , 119-165.		0

#	ARTICLE	IF	CITATIONS
2068	Supportivtherapie in der Uroonkologie. Springer Reference Medizin, 2022, , 1-11.	0.0	0
2069	An autopsy case of immune-related severe colitis due to long-term use of nivolumab in a patient with non-small cell lung cancer. Respiratory Medicine Case Reports, 2022, 39, 101720.	0.4	1
2070	Rheumatology (Arthritis and Myositis). , 2022, , 301-313.		0
2071	Gastroenterology (GI). , 2022, , 81-96.		0
2072	Nephrology (Kidney). , 2022, , 197-214.		0
2073	Drug induced liver injury by immunotherapy. Revista Espanola De Enfermedades Digestivas, 2022, , .	0.3	1
2074	Management of Patients with Cardiac Toxicity: The Point of View of the Oncologist. Current Clinical Pathology, 2022, , 91-111.	0.0	0
2075	Cardiology (Heart). , 2022, , 7-27.		0
2077	Checkpoint Inhibitors in Non-small Cell Lung Cancer: Potentials and Challenges. , 2022, , .		0
2078	Diagnostic Methods of Cardiac Immunotherapy Damaging. Current Clinical Pathology, 2022, , 51-61.	0.0	0
2079	Emergencies in Idiopathic Inflammatory Myopathies. , 2022, , 283-317.		0
2080	Question 32. , 2022, , 71-72.		0
2082	Pulmonology (Lung). , 2022, , 275-299.		1
2083	Evaluation and Management of Acute High-Grade Immunotherapy-Related Neurotoxicity. SSRN Electronic Journal, 0, , .	0.4	0
2084	Immune checkpoint inhibitor-related gastrointestinal toxicity in patients with malignancy involving the luminal gastrointestinal tract and its impact on cancer outcomes. Annals of Gastroenterology, 2022, , .	0.6	2
2085	Endocrine. , 2022, , 59-79.		0
2087	Management of Patients with Cardiac Toxicity: The Point of View of the Cardiologist. Current Clinical Pathology, 2022, , 73-89.	0.0	0
2088	Multiple Choice Questions with explanations. , 2022, , 1-267.		0

#	ARTICLE	IF	CITATIONS
2089	Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy. <i>Diagnostics</i> , 2022, 12, 2091.	2.6	5
2090	A Case of Unresectable Advanced Esophageal Cancer with Tuberculosis and Immune Thrombocytopenic Purpura Due to Nivolumab. <i>Japanese Journal of Gastroenterological Surgery</i> , 2022, 55, 483-490.	0.1	0
2091	Severe Immune Checkpoint Inhibitor Toxicity Leading to ICU Admission in Patients With Solid Tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2022, 45, 403-404.	1.3	0
2092	Combination Intravenous Immune Globulin (IVIG) and High Dose Steroids for Treatment of Immune-Related Myelitis in a Non-Small Cell Lung Cancer Patient Treated With Pembrolizumab and Palliative Radiation Treatment: A Case Report. <i>Clinical Lung Cancer</i> , 2022, 23, e563-e567.	2.6	2
2093	Phase 2 Study of the PD-1 Inhibitor Serplulimab plus the Bevacizumab Biosimilar HLX04 in Patients with Previously Treated Advanced Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2023, 12, 116-128.	7.7	5
2094	DEGRO practical guideline for central nervous system radiation necrosis part 2: treatment. <i>Strahlentherapie Und Onkologie</i> , 2022, 198, 971-980.	2.0	7
2095	Severe Immune-Related Adverse Events: A Case Series of Patients Needing Hospital Admission in a Spanish Oncology Referral Center and Review of the Literature. <i>Diagnostics</i> , 2022, 12, 2116.	2.6	1
2096	Anti-PD-1 sintilimab-induced bilateral optic neuropathy in non-small cell lung cancer: A case report and literature review. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	1
2097	What does radiomics do in <sc>PD-1</sc> blockade therapy of <sc>NSCLC</sc> patients?. <i>Thoracic Cancer</i> , 2022, 13, 2669-2680.	1.9	2
2098	Immune checkpoint inhibitor-induced arthralgia is tightly associated with improved overall survival in cancer patients. <i>Rheumatology</i> , 2023, 62, 1451-1459.	1.9	1
2099	Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	5
2100	Permissive Cardiotoxicity. <i>JACC: CardioOncology</i> , 2022, 4, 302-312.	4.0	10
2101	A case of steroid-resistant cystitis as an immune-related adverse event during treatment with nivolumab for lung cancer, which was successfully treated with infliximab. <i>IJU Case Reports</i> , 0, .	0.3	4
2102	Immune Checkpoint Inhibitor-Induced Myositis/Myocarditis with Myasthenia Gravis-like Misleading Presentation: A Case Series in Intensive Care Unit. <i>Journal of Clinical Medicine</i> , 2022, 11, 5611.	2.4	5
2103	Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade. <i>Science Immunology</i> , 2022, 7, .	11.9	15
2104	Toxic epidermal necrolysis after immune checkpoint inhibition, case report, and review of the literature. <i>Acta Oncologica</i> , 2022, 61, 1295-1299.	1.8	2
2105	Rare and Insidious Toxicities from New Combination Therapies in Metastatic Renal Cell Cancer: Lessons Learned from Real-Practice. <i>Current Oncology</i> , 2022, 29, 6776-6786.	2.2	2
2106	Therapeutic plasma exchange in the management of immune checkpoint <sc>inhibitor-associated</sc> immune-related adverse effects: A review. <i>Transfusion</i> , 2022, 62, 2370-2390.	1.6	1

#	ARTICLE	IF	CITATIONS
2107	Case report: Pneumonia with clinical symptoms precedes imaging evidence after immune checkpoint inhibitors combined with radiotherapy in lung squamous cell cancer. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	0
2108	Current progress and future perspectives of neoadjuvant anti-PD-1/PD-L1 therapy for colorectal cancer. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	19
2109	Immune checkpoint inhibitors â€œ the revolutionary cancer immunotherapy comes with a cardiotoxic price. <i>Trends in Cardiovascular Medicine</i> , 2024, 34, 71-77.	4.9	6
2110	Immunotherapy-Associated Uveitis. , 0, , .		0
2111	A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma. <i>Nature Communications</i> , 2022, 13, .	12.8	26
2112	Safety and efficacy of infliximab and corticosteroid therapy in checkpoint inhibitorâ€nduced colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 1370-1382.	3.7	8
2113	Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10948.	4.1	8
2114	Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline. <i>European Journal of Endocrinology</i> , 2022, 187, G1-G21.	3.7	35
2115	Thyroid-related adverse events induced by immune checkpoint inhibitors. <i>Frontiers in Endocrinology</i> , 0, 13, .	3.5	9
2116	Pancreatic involvement due to immune checkpoint inhibitors: a proposed classification. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 895-901.	4.2	2
2117	Outcomes of immunotherapy-related hepatotoxicity from a multi-disciplinary toxicity team. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 877-883.	2.5	3
2118	PD-1 inhibitor therapy causes multisystem immune adverse reactions: a case report and literature review. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	4
2119	Application of artificial liver in immune-related liver injury induced by immune checkpoint inhibitor: Case reports and review of the literature. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	3
2120	Neurology of cancer immunotherapy. <i>Neurological Sciences</i> , 2023, 44, 137-148.	1.9	3
2121	Hope, Cure, and Adverse Effects in Immunotherapy: Atezolizumab-Associated Encephalitis in Metastatic Small Cell Lung Cancer â€œ A Case Report and Literature Review. <i>Case Reports in Neurology</i> , 2022, 14, 366-371.	0.7	2
2122	Cardiotoxicity induced by immune checkpoint inhibitor: The complete insight into mechanisms, monitoring, diagnosis, and treatment. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	4
2123	Thyroid Dysfunction in Nonâ€œSmall Cell Lung Cancer With Immune Checkpoint Inhibitors: A Metaâ€œAnalysis. <i>Journal of Clinical Pharmacology</i> , 0, , .	2.0	0
2124	Which cardiac parameters best predict the cardiovascular outcomes among patients with anti-PD-1 immunotherapy-induced myocardial injury?. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	1

#	ARTICLE	IF	CITATIONS
2125	Immune Checkpoint Inhibitor-Induced Hepatic Injury: A Clinicopathologic Review. , 2022, 000, 000-000.		1
2126	Drug-related immune-mediated myelopathies. <i>Frontiers in Neurology</i> , 0, 13, .	2.4	1
2127	Adoptive Cellular Therapy for Metastatic Melanoma: The Road to Commercialization and Treatment Guidelines for Clinicians. <i>Annals of Surgical Oncology</i> , 2023, 30, 589-601.	1.5	2
2128	Pancreatic injury following immune checkpoint inhibitors: A systematic review and meta-analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	5
2129	Case report: Anti-PLA2R positive membranous nephropathy associated with atezolizumab. <i>Journal of Onco-Nephrology</i> , 0, , 239936932211254.	0.6	2
2130	An exploratory cross-sectional study of immune checkpoint inhibitors and immuno-related adverse events: Knowledge and influencing factors among Japanese oncology nurses. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2023, 10, 100147.	1.6	3
2131	Research focus and theme trend on fulminant myocarditis: A bibliometric analysis. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	1
2132	Retrospective review of outcomes associated with metastatic melanoma patients treated with 1stâ€line <sc>BRAF</sc>â€targeted therapy. <i>Pigment Cell and Melanoma Research</i> , 2022, 35, 595-604.	3.3	2
2134	Molecular dynamics identifies semi-rigid domains in the PD-1 checkpoint receptor bound to its natural ligand PD-L1. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	4.1	2
2135	Association between the efficacy and immune-related adverse events of pembrolizumab and chemotherapy in non-small cell lung cancer patients: a retrospective study. <i>BMC Cancer</i> , 2022, 22, .	2.6	3
2137	Multiple Cranial Neuropathies Similar to Orbital Apex Syndrome Associated with Pembrolizumab: A Case Report. <i>Case Reports in Oncology</i> , 0, , 868-873.	0.7	1
2138	Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life. <i>European Journal of Cancer</i> , 2022, 176, 88-99.	2.8	18
2139	Clinical implications of the interaction between PD-1/PD-L1 and PI3K/AKT/mTOR pathway in progression and treatment of non-small cell lung cancer. <i>Journal of Cancer</i> , 2022, 13, 3434-3443.	2.5	16
2140	A case of pembrolizumab-induced hypopituitarism subsequent to hypothyroidism. <i>Japanese Journal of Head and Neck Cancer</i> , 2022, 48, 295-300.	0.1	1
2141	Cutaneous Reactions to Oncologic Immunotherapy. <i>Updates in Clinical Dermatology</i> , 2022, , 317-330.	0.1	0
2142	Risk of Cardiovascular Disease Death in Older Malignant Melanoma Patients: A Population-Based Study. <i>Cancers</i> , 2022, 14, 4783.	3.7	1
2143	Myasthenia Gravis in the Setting of Immune Checkpoint Inhibitor Therapy: Practical Considerations and Opinion-Based Approach to Acute Management. <i>Cureus</i> , 2022, , .	0.5	1
2144	Immunotherapy and Hepatocellular Carcinoma. , 0, , .		0



#	ARTICLE	IF	CITATIONS
2145	Immune checkpoint inhibition in early-stage triple-negative breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 1225-1238.	2.4	2
2146	Immune checkpoint inhibitors-induced diabetes mellitus: a growing clinical presentation requiring our attention. <i>Expert Opinion on Drug Safety</i> , 0, , 1-3.	2.4	0
2147	Emerging Trends in Radionuclide Imaging of Infection and Inflammation in Pediatrics: Focus on FDG PET/CT and Immune Reactivity. <i>Seminars in Nuclear Medicine</i> , 2023, 53, 18-36.	4.6	5
2149	Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12641.	4.1	6
2150	Update on Immune Checkpoint Inhibitor Enterocolitis. <i>Current Gastroenterology Reports</i> , 2022, 24, 171-181.	2.5	5
2151	Update on immune checkpoint therapy for melanoma. <i>Dermatological Reviews</i> , 0, , .	0.5	0
2152	A history of variceal bleeding is associated with furtherÂbleeding under atezolizumabâ€“bevacizumab in patients with <sc>HCC</sc>. <i>Liver International</i> , 2022, 42, 2843-2854.	3.9	8
2153	Quantitation of cardiac troponin I in cancer patients treated with immune checkpoint inhibitors: a case-control study. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, .	2.3	0
2154	Patient-Reported Financial Toxicity in a Population-Based Cohort of Oropharynx Cancer Survivors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, , .	0.8	2
2156	Perioperative considerations in patients with chemotherapy-induced cognitive impairment: a narrative review. <i>British Journal of Anaesthesia</i> , 2022, , .	3.4	1
2157	Phase I/II study of nedaplatin and nab-paclitaxel for patients with previously untreated advanced squamous cell lung cancer: Kanto Respiratory Disease Study Group (KRSG) 1302. <i>International Journal of Clinical Oncology</i> , 0, , .	2.2	0
2158	Clustering using unsupervised machine learning can stratify the risk of immuneâ€related liver injury. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 0, , .	2.8	2
2159	A case of <sc>HCC</sc> successfully treated with infliximabâ€steroid sequential therapy for small bowel perforation due to atezolizumab/bevacizumab combination therapy. <i>Cancer Reports</i> , 2022, 5, .	1.4	4
2160	A Case Report of Immune Checkpoint Inhibitor-Induced Aortitis Treated with Tocilizumab. <i>Case Reports in Immunology</i> , 2022, 2022, 1-3.	0.4	6
2161	Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2022, 33, 1217-1238.	1.2	204
2163	Immune checkpoint inhibitor related nephrotoxicity: Advances in clinicopathologic features, noninvasive approaches, and therapeutic strategy and rechallenge. , 0, 2, .		2
2165	Adverse events of immune checkpoint inhibitors for patients with digestive system cancers: A systematic review and meta-analysis. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	4
2166	A case of refractory immune checkpoint inhibitorâ€induced colitis with <i>Clostridioides difficile</i> infection. <i>DEN Open</i> , 2023, 3, .	0.9	0

#	ARTICLE	IF	CITATIONS
2167	Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial. <i>British Journal of Cancer</i> , 2022, 127, 2241-2248.	6.4	9
2168	Rapidly progressing dyspnea and retiform purpura. <i>JAAD Case Reports</i> , 2022, 30, 66-69.	0.8	1
2170	Progress in diagnosis and treatment of checkpoint inhibitor pneumonitis. <i>Current Opinion in Oncology</i> , 2023, 35, 31-36.	2.4	0
2171	Immune Checkpoint Inhibitors Related to Cardiotoxicity. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 378.	1.6	3
2172	Association between immune-mediated adverse events and efficacy in metastatic non-small-cell lung cancer patients treated with durvalumab and tremelimumab. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	1
2173	Immune checkpoint inhibitor monotherapy is associated with less cardiac toxicity than combination therapy. <i>PLoS ONE</i> , 2022, 17, e0272022.	2.5	4
2174	Cytokine Release Syndrome and Sepsis. <i>Infectious Disease Clinics of North America</i> , 2022, 36, 735-748.	5.1	4
2175	Immune checkpoint blockade in melanoma: Advantages, shortcomings and emerging roles of the nanoparticles. <i>International Immunopharmacology</i> , 2022, 113, 109300.	3.8	4
2176	Immunotherapy in gynecologic malignancies. , 2023, , 506-520.e7.		0
2177	Basic principles of chemotherapy and other systemic therapies. , 2023, , 443-463.e2.		0
2178	Recent Update on Immunotherapy and Its Combination With Interventional Therapies for Hepatocellular Carcinoma. <i>Clinical Medicine Insights: Oncology</i> , 2022, 16, 117955492211348.	1.3	2
2179	Immune Checkpoint Inhibitors in Hodgkin Lymphoma and Non-Hodgkin Lymphoma. , 0, , .		0
2180	Development of Novel Small Antitumor Compounds Inhibiting PD-1/PD-L1 Binding. <i>Anticancer Research</i> , 2022, 42, 5233-5247.	1.1	3
2181	Immune-related generalised oedema “ A new category of adverse events with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2023, 179, 28-47.	2.8	3
2182	Are anti-PD-1-associated immune related adverse events a harbinger of favorable clinical prognosis in patients with gastric cancer?. <i>BMC Cancer</i> , 2022, 22, .	2.6	2
2183	Pembrolizumab-Induced Autoimmune Grade 4 Neutropenia in a Patient With Advanced Bladder Cancer: A Case Report. <i>Cureus</i> , 2022, , .	0.5	3
2184	Nontuberculous mycobacterial infections during cancer therapy with immune checkpoint inhibitors: a systematic review. <i>ERJ Open Research</i> , 2022, 8, 00364-2022.	2.6	4
2185	Characterization of the Immune Microenvironmental Landscape of Lung Squamous Cell Carcinoma with Immune Cell Infiltration. <i>Disease Markers</i> , 2022, 2022, 1-15.	1.3	2

#	ARTICLE	IF	CITATIONS
2186	Effects of hirsuteine on MDA-MB-453 breast cancer cell proliferation. <i>Oncology Letters</i> , 2022, 25, .	1.8	2
2188	Characterization of immune checkpoint inhibitor-associated fulminant type 1 diabetes associated with autoantibody status and ethnic origin. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	5
2190	Immune-related keratitis is a rare complication associated with nivolumab treatment in a patient with advanced colorectal cancer: A case report. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	6
2191	Intensive care unit requirements in patients treated with immune checkpoint inhibitors. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2023, 116, 285-287.	0.5	4
2192	Association between skin immune-related adverse events (irAEs) and multisystem irAEs during PD-1/PD-L1 inhibitor monotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 1659-1666.	2.5	3
2193	Immune checkpoint inhibitors in esophageal cancer: Clinical development and perspectives. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	3.3	6
2194	Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course. <i>Cancer</i> , 2023, 129, 367-375.	4.1	4
2195	Onkodiabetológia III.. <i>Orvosi Hetilap</i> , 2022, 163, 1614-1628.	0.4	0
2197	Two cases of nivolumab plus ipilimumab therapy for dialysis patients with advanced bone metastasis from renal cell carcinoma. <i>CEN Case Reports</i> , 2023, 12, 237-241.	0.9	3
2199	A case of immune checkpoint inhibitor-related myocarditis induced by pembrolizumab for tongue cancer. <i>Nihon Koku Geka Gakkai Zasshi</i> , 2022, 68, 385-391.	0.0	0
2200	Immune checkpoint inhibitor-induced pure red cell aplasia: Case series and large-scale pharmacovigilance analysis. <i>International Immunopharmacology</i> , 2023, 114, 109490.	3.8	1
2201	Immune checkpoint inhibitors as neoadjuvant therapy in early triple-negative breast cancer: A systematic review and meta-analysis. <i>Journal of Cancer Research and Therapeutics</i> , 2022, 18, 1754.	0.9	3
2202	Hematologic and Oncologic Emergencies. <i>Critical Care Nursing Quarterly</i> , 2023, 46, 100-113.	0.8	0
2203	Characteristic cerebrospinal fluid findings in immune checkpoint inhibitor-related peripheral neuropathy: A case report. <i>Journal of Neuroimmunology</i> , 2023, 374, 578010.	2.3	2
2204	Immune Checkpoint Inhibitors. , 2022, , 233-251.		0
2205	An Updated Focus on Immune Checkpoint Inhibitors and Tubulointerstitial Nephritis. , 2023, , 157-184.		0
2207	Pacemakers and methylprednisolone pulse therapy in immune-related myocarditis concomitant with complete heart block. <i>Open Medicine (Poland)</i> , 2022, 17, 2109-2116.	1.3	6
2208	A Review of Neurotoxicities Associated with Immune Checkpoint Inhibitors. , 2022, , 1-16.		0

#	ARTICLE	IF	CITATIONS
2209	Immunotherapy for Cancer: Common Gastrointestinal, Liver, and Pancreatic Side Effects and Their Management. <i>American Journal of Gastroenterology</i> , 2022, 117, 1917-1932.	0.4	4
2210	Safety and efficacy of immunotherapy rechallenge following checkpoint inhibitor-related pneumonitis in advanced lung cancer patients: a retrospective multi-center cohort study. <i>Translational Lung Cancer Research</i> , 2022, 11, 2289-2305.	2.8	6
2211	The Flip of the Coin of Personalized Cancer Immunotherapy: A Focused Review on Rare Immune Checkpoint Related Adverse Effects. , 0, , .		0
2212	Immune thrombocytopenia in a small cell lung cancer patient treated with atezolizumab: a case report. <i>Translational Lung Cancer Research</i> , 2022, 11, 2346-2355.	2.8	0
2213	Successful treatment of <sc>PD</sc>â€1 inhibitorâ€induced psoriasis with infliximab. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2023, 37, .	2.4	4
2214	Multisystem immune-related adverse events due to toripalimab: Two cases-based review. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	3
2215	Anti-programmed death-1 inhibitor nivolumab-induced immune-related adverse events: hepatitis, renal insufficiency, myositis, vitiligo, and hypothyroidism: a case-based review. <i>Rheumatology International</i> , 2023, 43, 559-565.	3.0	1
2216	Immunogenomic correlates of immune-related adverse events for antiâ€programmed cell death 1 therapy. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	4
2217	Cutaneous adverse events in patients treated with PD-1/PD-L1 checkpoint inhibitors and their association with survival: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2022, 12, .	3.3	4
2218	Immune Checkpoints: The Rising Branch in Cancer Immunotherapy. , 0, , .		0
2219	Real-World Experience of Monitoring Practice of Endocrinopathies Associated with the Use of Novel Targeted Therapies among Patients with Solid Tumors. <i>Medical Sciences (Basel, Switzerland)</i> , 2022, 10, 65.	2.9	0
2220	Development and implementation of an immunotherapy unit in a urology department. <i>Actas UrolÃ³gicas EspaÃ±olas (English Edition)</i> , 2022, , .	0.2	0
2221	Activity of Immunotherapy Regimens on Primary Renal Tumours: A Systematic Review. <i>Kidney Cancer</i> , 2022, 6, 221-236.	0.4	1
2222	Clinical features, diagnosis, and management of pembrolizumab-induced myasthenia gravis. <i>Clinical and Experimental Immunology</i> , 0, , .	2.6	2
2224	Body composition parameters for predicting the efficacy of neoadjuvant chemotherapy with immunotherapy for gastric cancer. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	3
2225	Acetylcholine receptor binding antibodyâ€associated myasthenia gravis, myocarditis, and rhabdomyolysis induced by tislelizumab in a patient with colon cancer: A case report and literature review. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	4
2226	Anti-PD-1 immune-related adverse events are associated with high therapeutic antibody fixation on T cells. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	4
2227	Immune responses to SARS-CoV-2 in vaccinated patients receiving checkpoint blockade immunotherapy for cancer. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	4

#	ARTICLE	IF	CITATIONS
2228	Rare forms of inflammatory myopathies – part I, generalized forms. Expert Review of Clinical Immunology, 0, , 1-15.	3.0	1
2229	Immune Checkpoint Inhibitor Therapy in Oncology. JACC: CardioOncology, 2022, 4, 579-597.	4.0	25
2231	Safety and efficacy of immune checkpoint inhibitors in advanced cancer patients with autoimmune disease: A meta-analysis. Human Vaccines and Immunotherapeutics, 2022, 18, .	3.3	8
2232	Immune Checkpoint Inhibitors and Endocrine Disorders: A Position Statement from the Korean Endocrine Society. Endocrinology and Metabolism, 2022, 37, 839-850.	3.0	3
2233	Simultaneous development of pneumonitis and autoimmune diabetes secondary to immune checkpoint inhibitor treatment with durvalumab in an advanced small cell lung cancer patient: A case report. Medicine (United States), 2022, 101, e32076.	1.0	2
2234	Refining personalized diagnosis, treatment and exploitation of hypothyroidism related to solid nonthyroid cancer. Personalized Medicine, 0, , .	1.5	0
2235	Fecal Transplant Sustained Colitis Remission on Immunotherapy Resumption. , 2022, 1, .		1
2236	Skin rash after camrelizumab and sorafenib in a patient with advanced hepatocellular carcinoma. The International Journal of Gastroenterology and Hepatology Diseases, 2022, 02, .	0.2	0
2237	Pre-Existing Autoimmune Disease Increases the Risk of Cardiovascular and Noncardiovascular Events After Immunotherapy. JACC: CardioOncology, 2022, 4, 660-669.	4.0	7
2238	Treatment of rheumatic adverse events of cancer immunotherapy. Best Practice and Research in Clinical Rheumatology, 2022, 36, 101805.	3.3	9
2239	Immune checkpoint inhibitor induced nephrotoxicity: An ongoing challenge. Frontiers in Medicine, 0, 9, .	2.6	1
2240	Estimated Costs of the Ipilimumab–Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma. Cancers, 2023, 15, 31.	3.7	1
2241	Immune-related adverse events: A bibliometric analysis. Frontiers in Immunology, 0, 13, .	4.8	10
2242	Neurologic complications of breast cancer. Cancer, 0, , .	4.1	0
2243	Prognostic Significance of the Severity of Immune-Related Adverse Events in Advanced Cancer Patients Treated with PD-1/PD-L1 Inhibitors: A Real-World Data Analysis. Targeted Oncology, 2023, 18, 147-158.	3.6	2
2245	Association between increased peripheral blood CD86-positive plasmacytoid dendritic cells and immune-related adverse events in patients with non-small cell lung cancer. Global Health & Medicine, 2022, 4, 301-308.	1.4	0
2246	Severe neuromuscular immune-related adverse events of immune checkpoint inhibitors at national cancer center in Korea. Journal of Cancer Research and Clinical Oncology, 2023, 149, 5583-5589.	2.5	6
2249	Imunoterapia em oncologia: implicações para a prática de enfermagem. , 2022, 22, 177-185.		0

#	ARTICLE	IF	CITATIONS
2250	Pembrolizumab Induced Calcitriol-Mediated Hypercalcemia. Case Reports in Nephrology, 2023, 2023, 1-3.	0.4	1
2252	Drugs and Pituitary Function. , 2022, , 413-427.		0
2253	Risk Factors for Refractory Immune Checkpoint Inhibitor-related Pneumonitis in Patients With Lung Cancer. Journal of Immunotherapy, 2023, 46, 64-73.	2.4	4
2254	Clinical best practices in optimal monitoring, early diagnosis, and effective management of antibodyâ€drug conjugate-induced interstitial lung disease or pneumonitis: a multidisciplinary team approach in Singapore. Expert Opinion on Drug Metabolism and Toxicology, 2022, 18, 805-815.	3.3	3
2255	Checkpoint inhibitor immune-related adverse events: A focused review on autoantibodies and B cells as biomarkers, advancements and future possibilities. Frontiers in Immunology, 0, 13, .	4.8	6
2256	Pembrolizumab induced remission of recurrent and metastatic sinonasal squamous cell carcinoma after overcoming checkpointâ€inhibitor pneumonitis: A case report and literature review. Cancer Reports, 0, , .	1.4	3
2257	The threat of triple M and autoimmune overlap syndromes with immune checkpoint inhibitors - A series of case reports. Autoimmunity Reviews, 2023, , 103269.	5.8	1
2259	Configuring Therapeutic Aspects of Immune Checkpoints in Lung Cancer. Cancers, 2023, 15, 543.	3.7	8
2260	New developments and concepts in the diagnosis and management of diabetes insipidus (AVPâ€deficiency) Tj ETQg0,0 0 rgBJ /Overlock	2.6	0
2261	Immune checkpoint inhibitor-induced myocarditis and myositis in liver cancer patients: A case report and literature review. Frontiers in Oncology, 0, 12, .	2.8	1
2262	Immuneâ€related aseptic meningitis diagnosed by Cube <sc>FLAIR</sc> on enhanced magnetic resonance imaging for a lung cancer patient administered atezolizumab: A case report. Respiriology Case Reports, 2023, 11, .	0.6	0
2263	Lateâ€onset immune checkpoint inhibitorâ€related pneumonitis after cessation of sintilimab: A case report and literature review. Experimental and Therapeutic Medicine, 2023, 25, .	1.8	1
2264	Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States. Journal of Experimental and Clinical Cancer Research, 2023, 42, .	8.6	12
2265	Combined diabetic ketoacidosis and hyperosmolar hyperglycemic state in type 1 diabetes mellitus induced by immune checkpoint inhibitors: Underrecognized and underreported emergency in ICIs-DM. Frontiers in Endocrinology, 0, 13, .	3.5	1
2267	Nintedanib in an elderly non-small-cell lung cancer patient with severe steroid-refractory checkpoint inhibitor-related pneumonitis: A case report and literature review. Frontiers in Immunology, 0, 13, .	4.8	3
2269	Disproportionality analysis of acetaminophen-induced hepatic disorders with and without immune checkpoint inhibitors. International Journal of Clinical Pharmacy, 0, , .	2.1	0
2270	Factors associated with liver injury and prognosis in advanced cancer patients treated with immune checkpoint inhibitors. Hepatology Research, 2023, 53, 450-459.	3.4	2
2271	The value of the multidisciplinary team in metastatic renal cell carcinoma: Paving the way for precision medicine in toxicities management. Frontiers in Oncology, 0, 12, .	2.8	3

#	ARTICLE	IF	CITATIONS
2272	Ponatinib Drives Cardiotoxicity by S100A8/A9-NLRP3-IL-1 $\beta$ Mediated Inflammation. <i>Circulation Research</i> , 2023, 132, 267-289.	4.5	8
2273	Immunopathogenesis of Immune Checkpoint Inhibitor Induced Myocarditis: Insights from Experimental Models and Treatment Implications. <i>Biomedicines</i> , 2023, 11, 107.	3.2	4
2274	The Current status of steroid-refractory immune-checkpoint-inhibitor-related hepatotoxicity. <i>Translational Oncology</i> , 2023, 28, 101619.	3.7	8
2275	Dietary Considerations for Inflammatory Bowel Disease Are Useful for Treatment of Checkpoint Inhibitor-Induced Colitis. <i>Cancers</i> , 2023, 15, 84.	3.7	1
2276	Long Non-Coding RNAs as Epigenetic Regulators of Immune Checkpoints in Cancer Immunity. <i>Cancers</i> , 2023, 15, 184.	3.7	3
2277	The Role of Immune Checkpoint Inhibitors in Cancer Therapy. <i>Clinics and Practice</i> , 2023, 13, 22-40.	1.4	14
2278	Use of fluocinolone acetonide intravitreal implant to manage chronic panuveitis for long-term inflammatory control without interfering with systemic immunity. <i>Digital Journal of Ophthalmology: DJO</i> , 2022, 28, 119-125.	0.6	1
2279	Cardio-Oncology Recommendations for Pediatric Oncology Patients. , 2022, 1, 100155.		4
2280	Immune checkpoint inhibitor-related pneumonitis and COVID-19: a case-matched comparison of CT findings. <i>Radiologia Medica</i> , 2023, 128, 212-221.	7.7	2
2281	Impact of Immune-Related Adverse Events on Immune Checkpoint Inhibitors Treated Cancer Patients's Survival: Single Center Experience and Literature Review. <i>Cancers</i> , 2023, 15, 888.	3.7	5
2282	Association of immune-related adverse events and efficacy in advanced non-small-cell lung cancer: a systematic review and meta-analysis. <i>Immunotherapy</i> , 2023, 15, 209-220.	2.0	5
2283	A Review of Bullous Dermatologic Adverse Events Associated with Anti-Cancer Therapy. <i>Biomedicines</i> , 2023, 11, 323.	3.2	1
2284	Pulmonary Side Effects of Immunotherapy. , 2023, , 1-13.		0
2285	Drug-induced liver injury: An overview and update. , 2023, , .		0
2287	Immune-Related Adverse Events of the Gastrointestinal System. <i>Cancers</i> , 2023, 15, 691.	3.7	1
2288	Immune checkpoint inhibitors as first-line therapy for non-small cell lung cancer: A systematic evaluation and meta-analysis. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	3.3	3
2289	Association between <sc>PD</sc> inhibitor-related adverse events and frailty assessed by frailty index in lung cancer patients. <i>Cancer Medicine</i> , 0, , .	2.8	1
2290	Immune-related thyroid dysfunction is associated with improved long-term prognosis in patients with non-small cell lung cancer treated with immunotherapy: a systematic review and meta-analysis. <i>Journal of Thoracic Disease</i> , 2023, 15, 690-700.	1.4	1

#	ARTICLE	IF	CITATIONS
2291	Cardiovascular, Renal and Pulmonary Toxicity of Immune Checkpoint Inhibitors in Cancer: What the GP Should Know. <i>Praxis</i> , 2023, 112, 160-171.	0.4	1
2292	A text-mining approach to study the real-world effectiveness and potentially fatal immune-related adverse events of PD-1 and PD-L1 inhibitors in older patients with stage III/IV non-small cell lung cancer. <i>BMC Cancer</i> , 2023, 23, .	2.6	0
2293	Immune checkpoint inhibitor-induced hypophysitis: clinical and biochemical features. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 7925-7932.	2.5	2
2294	Clinical characteristics and therapeutic effects of checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer. <i>BMC Cancer</i> , 2023, 23, .	2.6	5
2295	Ophthalmic immune-related adverse events associated with immune checkpoint inhibitors. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	6
2296	Combination immunomodulation for immune-checkpoint-inhibitor-associated myocarditis. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 427-428.	27.6	3
2297	Nivolumab plus ipilimumab combination therapy in cancer: Current evidence to date. <i>International Immunopharmacology</i> , 2023, 117, 109881.	3.8	8
2298	Drug-Induced Liver Injury due to Biologics and Immune Check Point Inhibitors. <i>Medical Clinics of North America</i> , 2023, 107, 623-640.	2.5	0
2299	Management, risk factors and prognostic impact of checkpoint-inhibitor pneumonitis (CIP) in lung cancer – A multicenter observational analysis. <i>Lung Cancer</i> , 2023, 179, 107184.	2.0	3
2300	Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: A multi-institutional cohort study. <i>Journal of the American Academy of Dermatology</i> , 2023, 88, 1024-1032.	1.2	12
2301	Combined radiation- and immune checkpoint-inhibitor-induced pneumonitis – The challenge to predict and detect overlapping immune-related adverse effects from evolving laboratory biomarkers and clinical imaging. <i>Neoplasia</i> , 2023, 39, 100892.	5.3	1
2302	Immunoglobulins as a treatment modality for corticosteroid-refractory pemetrexed-induced interstitial lung disease, case report. <i>Respiratory Medicine and Research</i> , 2023, 83, 101000.	0.6	1
2303	Symptoms, symptom clusters and associated factors among cancer patients receiving immune checkpoint inhibitor therapy: A cross-sectional survey. <i>European Journal of Oncology Nursing</i> , 2023, 63, 102288.	2.1	0
2305	Immune checkpoint inhibitor-induced aplastic anaemia: Case series and large-scale pharmacovigilance analysis. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	1
2306	Nebenwirkungen und deren Management. , 2022, , 121-146.		0
2307	Melanome der Haut und Schleimhaut. , 2022, , 205-236.		0
2308	Recommendations on the use of item libraries for patient-reported outcome measurement in oncology trials: findings from an international, multidisciplinary working group. <i>Lancet Oncology</i> , The, 2023, 24, e86-e95.	10.7	13
2310	Steroid hormone regulation of immune responses in cancer. <i>Immunometabolism</i> , 2022, 4, e00012.	1.6	3



#	ARTICLE	IF	CITATIONS
2311	A Novel Workflow to Create a Checkpoint Inhibitor Pneumonitis Patient Registry. <i>Cureus</i> , 2023, , .	0.5	0
2312	Boosting Checkpoint Immunotherapy with Biomaterials. <i>ACS Nano</i> , 2023, 17, 3225-3258.	14.6	20
2313	A Rare Case of Pembrolizumab-Associated Gravesâ€™ Disease. <i>Cureus</i> , 2023, , .	0.5	1
2314	Clinicopathological Features of Kidney Injury Related to Immune Checkpoint Inhibitors: A Systematic Review. <i>Journal of Clinical Medicine</i> , 2023, 12, 1349.	2.4	1
2315	Outcome of Nivolumab-Induced Vogtâ€™Koyanagiâ€™Harada Disease-Like Uveitis in a Patient Managed without Intravenous Methylprednisolone Therapy. <i>Case Reports in Ophthalmological Medicine</i> , 2023, 2023, 1-8.	0.5	0
2316	Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients. <i>Hepatology International</i> , 2023, 17, 709-719.	4.2	17
2317	Immune-related adverse events after immune checkpoint inhibitor exposure in adult cancer patients with pre-existing autoimmune diseases. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 6341-6350.	2.5	10
2318	Immunotherapy for hepatocellular carcinoma: Current status and future perspectives. <i>World Journal of Gastroenterology</i> , 0, 29, 1054-1075.	3.3	18
2319	Association of Clinical and Radiological Features with Disease Severity of Symptomatic Immune Checkpoint Inhibitor-Related Pneumonitis. <i>Diagnostics</i> , 2023, 13, 691.	2.6	1
2320	Radiation Recall Pneumonitis: The Open Challenge in Differential Diagnosis of Pneumonia Induced by Oncological Treatments. <i>Journal of Clinical Medicine</i> , 2023, 12, 1442.	2.4	0
2321	Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature. <i>ESMO Open</i> , 2023, 8, 100791.	4.5	3
2322	Evaluation and management of acute high-grade immunotherapy-related neurotoxicity. <i>Heliyon</i> , 2023, 9, e13725.	3.2	0
2324	Efficacy and safety of mycophenolate mofetil in treating immuneâ€™related hepatitis induced by immune checkpoint inhibitor use: A retrospective study. <i>JGH Open</i> , 2023, 7, 87-97.	1.6	4
2325	Effectiveness and safety of lenvatinib plus antiâ€™programmed deathâ€™1 antibodies in patients with hepatocellular carcinoma: A <sc>realâ€™world</sc> cohort study. <i>Cancer Medicine</i> , 2023, 12, 9202-9212.	2.8	3
2326	Case report: Electrocardiographic changes in pembrolizumab-induced fatal myocarditis. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	2
2327	Emerging treatment strategies in hepatobiliary cancer. <i>Expert Review of Anticancer Therapy</i> , 2023, 23, 243-256.	2.4	1
2328	The Changing Landscape of Immunotherapy for Advanced Renal Cancer. <i>Urologic Clinics of North America</i> , 2023, 50, 335-349.	1.8	2
2329	Cutaneous manifestations associated with immune checkpoint inhibitors. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	12

#	ARTICLE	IF	CITATIONS
2330	Case series: Immune checkpoint inhibitor-induced transverse myelitis. <i>Frontiers in Neurology</i> , 0, 14, .	2.4	1
2331	Advances in immune checkpoint inhibitors induced-cardiotoxicity. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	2
2332	Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis. <i>Cancer Discovery</i> , 2023, 13, 1100-1115.	9.4	40
2333	Endocrine Consequences Following Immune Checkpoint Inhibitors Therapy. , 2023, , 1-32.		0
2334	The need for kidney biopsy in the management of side effects of target and immunotherapy. , 0, 3, .		0
2335	Hematological toxicities of immune checkpoint inhibitors and the impact of blood transfusion and its microbiome on therapeutic efficacy and recipient's safety and survival outcome:A systematic narrative appraisal of where we are now!. <i>Transfusion and Apheresis Science</i> , 2023, 62, 103685.	1.0	1
2336	Antithymocyte globulin for aplastic anemia secondary to pembrolizumab: a case report and review of literature. <i>Immunotherapy</i> , 2023, 15, 323-333.	2.0	3
2337	A real-world retrospective study of incidence and associated factors of endocrine adverse events related to PD-1/PD-L1 inhibitors. <i>Annals of Translational Medicine</i> , 2023, 11, 164-164.	1.7	0
2338	Endocrine and Neurological Toxicities of Immunotherapies. <i>Praxis</i> , 2023, 112, 178-183.	0.4	1
2339	Alanine aminotransferase assay biosensor platform using silicon nanowire field effect transistors. , 2023, 2, .		2
2340	Side Effects of Cancer Immunotherapies: Dermatologic and Rheumatologic Toxicities. <i>Praxis</i> , 2023, 112, 184-188.	0.4	1
2341	Expert Consensus on the Diagnosis and Treatment of Anticancer Drug-Induced Interstitial Lung Disease. <i>Current Medical Science</i> , 2023, 43, 1-12.	1.8	1
2342	Analysis of the clinical characteristics of pembrolizumab-induced bullous pemphigoid. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	1
2343	Role and mechanism of PIM family in the immune microenvironment of diffuse large B cell lymphoma. <i>World Journal of Surgical Oncology</i> , 2023, 21, .	1.9	2
2344	Stuttering as a signal of encephalopathy associated with toripalimab in a pancreatic ductal adenocarcinoma patient: a case report. <i>BMC Neurology</i> , 2023, 23, .	1.8	1
2345	An Immunological Perspective on the Mechanism of Drug Induced Liver Injury: Focused on Drugs for Treatment of Hepatocellular Carcinoma and Liver Transplantation. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5002.	4.1	6
2346	PD-L1 expression as biomarker of efficacy of PD-1/PD-L1 checkpoint inhibitors in metastatic triple negative breast cancer: A systematic review and meta-analysis. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	7
2347	Neoadjuvant immunotherapy for colorectal cancer: Right regimens, right patients, right directions?. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	7

#	ARTICLE	IF	CITATIONS
2348	Current landscape and tailored management of immune-related adverse events. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	1
2349	Baseline risk factors associated with immune related adverse events and atezolizumab. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	3
2350	Executive summary of the consensus document on hypophysitis of the Neuroendocrinology Area of Knowledge of the Spanish Society of Endocrinology and Nutrition. <i>Endocrinología y Nutrición (English Ed)</i> , 2023, 70, 116-125.	0.2	0
2351	Treatment and outcomes of immune checkpoint inhibitors-associated colitis/diarrhea: A systematic review and meta-analysis. <i>Digestive and Liver Disease</i> , 2023, 55, 1621-1631.	0.9	1
2352	Multiple Autoimmune Complications After a Single Dose of Pembrolizumab. <i>Cureus</i> , 2023, , .	0.5	0
2353	JCS 2023 Guideline on the Diagnosis and Treatment of Myocarditis. <i>Circulation Journal</i> , 2023, 87, 674-754.	1.6	14
2354	Unresectable Hepatocellular Carcinoma: A Review of New Advances with Focus on Targeted Therapy and Immunotherapy. <i>Livers</i> , 2023, 3, 121-160.	1.9	2
2355	Rheumatic Immune-Related Adverse Events due to Immune Checkpoint Inhibitorsâ€”A 2023 Update. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5643.	4.1	7
2356	Acute rejection was observed in a combination therapy of CTLA-4 and PD-1 inhibitors before liver transplantation: A case report and literature review. , 2023, , .		0
2357	Lung cancer patients receiving immune checkpoint inhibitors: safety and immunogenicity of MRNA-covid-19 vaccination. <i>Journal of Lung, Pulmonary &amp; Respiratory Research</i> , 2023, 10, 15-16.	0.3	0
2358	Immuneâ€related adverse events in hepatitis treated with thiopurineâ€based immunosuppressants: A case report. <i>Thoracic Cancer</i> , 0, , .	1.9	2
2359	Adverse events and clinical outcomes in patients treated with PD-(L)1 blockade for advanced non-small-cell lung cancer. <i>Future Oncology</i> , 2022, 18, 4509-4523.	2.4	2
2360	Immunotherapies for advanced hepatocellular carcinoma. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	4
2361	Characterization of immunomodulatory factors and cells in bronchoalveolar lavage fluid for immune checkpoint inhibitor-related pneumonitis. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	2.5	0
2362	Immune checkpoint inhibitor-related thyroid dysfunction. <i>Annales D'Endocrinologie</i> , 2023, 84, 346-350.	1.4	2
2363	Infliximab for Steroid-Refractory Immune Checkpoint Inhibitor-Induced Acute Pancreatitis. <i>ACG Case Reports Journal</i> , 2023, 10, e01018.	0.4	0
2364	Immune checkpoint inhibitors break whose heart? Perspectives from cardio-immuno-oncology. <i>Genes and Diseases</i> , 2024, 11, 807-818.	3.4	4
2365	The predictive value of <sc>PDâ€L1</sc> expression in patients with advanced hepatocellular carcinoma treated with <sc>PD</sc>â€1/<sc>PDâ€L1</sc> inhibitors: A systematic review and metaâ€analysis. <i>Cancer Medicine</i> , 2023, 12, 9282-9292.	2.8	8

#	ARTICLE	IF	CITATIONS
2366	Position statement on the management of the immune checkpoint inhibitor-induced colitis via multidisciplinary modified Delphi consensus. <i>European Journal of Cancer</i> , 2023, 187, 36-57.	2.8	1
2367	Clinicopathological classification of immune checkpoint inhibitor-associated myocarditis: possible refinement by measuring macrophage abundance. <i>Cardio-Oncology</i> , 2023, 9, .	1.7	1
2368	Pituitary hypoadrenocorticism and hypothyroidism after immunochemotherapy followed by salvage surgery for lung cancer: a case report. , 2023, 2, .		0
2369	Immune Checkpoint Inhibitors-Related Myocarditis: A Review of Reported Clinical Cases. <i>Diagnostics</i> , 2023, 13, 1243.	2.6	9
2370	Toxicitatea cardiacă a inhibitorilor punctelor de control (IPC) utilizate în imunoterapia cancerului. <i>Oncolog-Hematolog Ro</i> , 2023, 1, 23.	0.0	0
2371	The role of the neurologist in the diagnosis and treatment of brain metastases and carcinomatous meningitis. <i>Revue Neurologique</i> , 2023, , .	1.5	0
2372	Anti-cancer immune checkpoint inhibitor tolerability: summon up of savoir faire in 2023. <i>Annales D'Endocrinologie</i> , 2023, , .	1.4	0
2373	Clinical characteristics, treatment and outcome of nivolumab-induced myasthenia gravis. <i>Investigational New Drugs</i> , 0, , .	2.6	0
2374	Inflammatory biomarkers in assessing severity and prognosis of immune checkpoint inhibitor-associated cardiotoxicity. <i>ESC Heart Failure</i> , 2023, 10, 1907-1918.	3.1	3
2375	Demyelinating polyneuropathy combined with brachial plexopathy after nivolumab therapy for hodgkin lymphoma: a case report. <i>BMC Neurology</i> , 2023, 23, .	1.8	1
2376	Actionable Genetic Screens Unveil Targeting of AURKA, MEK, and Fatty Acid Metabolism as an Alternative Therapeutic Approach for Advanced Melanoma. <i>Journal of Investigative Dermatology</i> , 2023, 143, 1993-2006.e10.	0.7	0
2377	Rheumatological adverse events secondary to immune checkpoint inhibitors. <i>ReumatologÃa ClÃnica (English Edition)</i> , 2023, 19, 215-222.	0.3	0
2379	NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2023, 21, 340-350.	4.9	70
2380	Immune-related pulmonary toxicities of checkpoint inhibitors in non-small cell lung cancer: Diagnosis, mechanism, and treatment strategies. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	3
2381	Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue. <i>Journal of Clinical Apheresis</i> , 2023, 38, 77-278.	1.3	81
2382	Solid Organ Transplantation: Rejection, Immunosuppression, and Tolerance. , 2023, , 1128-1145.		0
2384	Immune Responses to Solid Tumors and Immune Checkpoint Therapy. , 2023, , 1028-1041.		0
2385	Recent advances and future challenges of tumor vaccination therapy for recurrent glioblastoma. <i>Cell Communication and Signaling</i> , 2023, 21, .	6.5	7

#	ARTICLE	IF	CITATIONS
2386	Immediate hypersensitivity reactions to antineoplastic agents – A practical guide for the oncologist. <i>Cancer Treatment Reviews</i> , 2023, 116, 102559.	7.7	1
2387	A case of subclinical immune checkpoint inhibitor-associated myocarditis in non-small cell lung cancer. <i>BMC Pulmonary Medicine</i> , 2023, 23, .	2.0	3
2388	Cardiotoxicity of lung cancer-related immunotherapy versus chemotherapy: a systematic review and network meta-analysis of randomized controlled trials. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
2389	Polymyalgia rheumatica during combination therapy with atezolizumab plus bevacizumab for advanced hepatocellular carcinoma. <i>Clinical Journal of Gastroenterology</i> , 2023, 16, 567-571.	0.8	1
2390	Gastrointestinal injury induced by immunomodulators: A review article. <i>Therapeutic Advances in Gastroenterology</i> , 2023, 16, 175628482311585.	3.2	0
2391	ICU admission for solid cancer patients treated with immune checkpoint inhibitors. <i>Annals of Intensive Care</i> , 2023, 13, .	4.6	4
2392	Immune-Related Colitis Induced by Camrelizumab: A Case Report. <i>Journal of Inflammation Research</i> , 0, Volume 16, 1727-1731.	3.5	1
2393	Mortality associated with the development of acute liver failure after a single dose of nivolumab. <i>Clinical Journal of Gastroenterology</i> , 0, , .	0.8	1
2394	Permanent hypothyroidism following immune checkpoint inhibitors induced thyroiditis may be associated with improved survival: results of an explanatory study. <i>Frontiers in Endocrinology</i> , 0, 14, .	3.5	0
2395	Immune-related adverse events following checkpoint inhibitor treatment in head and neck cancers: A comprehensive review. , 2023, 6, 100036.		4
2396	Hepatocellular carcinoma (HCC) immunotherapy by anti-PD-1 monoclonal antibodies: A rapidly evolving strategy. <i>Pathology Research and Practice</i> , 2023, 247, 154473.	2.3	1
2397	Immune checkpoint inhibitor-associated myocarditis: from pathophysiology to rechallenge of therapy – a narrative review. <i>Future Cardiology</i> , 2023, 19, 91-103.	1.2	6
2398	Risk of Thyroid Dysfunction in PD-1 Blockade Is Stratified by the Pattern of TgAb and TPOAb Positivity at Baseline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2023, 108, e1056-e1062.	3.6	4
2399	A Concerted Vision to Advance the Knowledge of Diabetes Mellitus Related to Immune Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7630.	4.1	1
2400	Extensive CardioVascular Characterization and Follow-Up of Patients Receiving Immune Checkpoint Inhibitors: A Prospective Multicenter Study. <i>Pharmaceuticals</i> , 2023, 16, 625.	3.8	1
2401	Predictive factors and prognosis of immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer patients. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	1
2402	Cohort study on immune checkpoint inhibitor-associated acute kidney injury: Incidence, risk factors, and management strategies. <i>Journal of Oncology Pharmacy Practice</i> , 0, , 107815522311710.	0.9	0
2403	Gastrointestinal treatment-related adverse events of combined immune checkpoint inhibitors: a meta-analysis. <i>Immunotherapy</i> , 2023, 15, 773-786.	2.0	1

#	ARTICLE	IF	CITATIONS
2404	Penpulimab-induced complete atrioventricular block in a patient with metastatic renal cancer. <i>HeartRhythm Case Reports</i> , 2023, 9, 451-455.	0.4	1
2405	Patient-reported outcome (PRO)-based symptom assessment in patients with advanced lung cancer receiving first-line combination immunotherapy: a protocol for a multicenter, prospective, observational study. <i>BMC Pulmonary Medicine</i> , 2023, 23, .	2.0	0
2406	Sequential administration of PD-1 inhibitor and cetuximab causes pneumonia. <i>Oncology Letters</i> , 2023, 26, .	1.8	0
2407	Targeting ferroptosis as a cell death pathway in Melanoma: From molecular mechanisms to skin cancer treatment. <i>International Immunopharmacology</i> , 2023, 119, 110215.	3.8	4
2408	Immune mediated colitis: a surgical perspective. <i>ANZ Journal of Surgery</i> , 2023, 93, 1495-1502.	0.7	1
2409	Characteristics of Immune Checkpoint Inhibitor-Induced Colitis: A Systematic Review. <i>Kurume Medical Journal</i> , 2021, 68, 43-52.	0.1	1
2410	Immune checkpoint inhibitor-associated central nervous system autoimmunity. <i>European Journal of Neurology</i> , 2023, 30, 2418-2429.	3.3	3
2411	First-in-human phase I/II study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors. <i>Journal of Hematology and Oncology</i> , 2023, 16, .	17.0	11
2412	The safety profile of nivolumab plus ipilimumab combination therapy in Japanese patients with renal cell carcinoma: results from post-marketing surveillance. <i>Japanese Journal of Clinical Oncology</i> , 0, , .	1.3	1
2413	: SEVERE AND REFRACTORY GASTROINTESTINAL TOXICITY DUE TO IMMUNE CHECKPOINT INHIBITORS: CLINICAL EXPERIENCE IN A TERTIARY REFERRAL HOSPITAL. <i>Revista Espanola De Enfermedades Digestivas</i> , 2023, , .	0.3	3
2415	Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs). <i>Oncolimmunology</i> , 2023, 12, .	4.6	6
2416	Uncovering the Burden of Immune-Related Adverse Events in Immunotherapy: Insights from a Nationally Representative Sample. <i>Targeted Oncology</i> , 2023, 18, 451-461.	3.6	0
2417	Immune Checkpoint Inhibitor Toxicity Management in Non-muscle-invasive Bladder Cancer: What Urologists Need To Know. <i>European Urology Focus</i> , 2023, 9, 579-581.	3.1	2
2418	Checkpoint Inhibitor-Induced Colitis: An Update. <i>Biomedicines</i> , 2023, 11, 1496.	3.2	5
2419	Impact of Selective Immunosuppressive Therapy on Subsequent Immune-Related Adverse Events After Immune Checkpoint Inhibitor-Induced Colitis Treatment. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 0, Publish Ahead of Print, .	1.3	0
2420	The Feasibility, Acceptability, and Effectiveness of Electronic Patient-Reported Outcome Symptom Monitoring for Immune Checkpoint Inhibitor Toxicities: A Systematic Review. <i>JCO Clinical Cancer Informatics</i> , 2023, , .	2.1	1
2421	Drug therapy for myocarditis induced by immune checkpoint inhibitors. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	3
2422	High intramuscular adipose tissue content was a favorable prognostic factor in patients with advanced gastric cancer treated with nivolumab monotherapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2023, 38, 1760-1767.	2.8	1

#	ARTICLE	IF	CITATIONS
2423	The clinical application of immuno-therapeutics. , 2024, , 237-288.e7.		0
2424	Histological Characteristics and Management of Hepatitis on Immune Checkpoint Inhibitors: A Retrospective Descriptive Study. <i>Journal of Clinical Medicine</i> , 2023, 12, 3751.	2.4	1
2425	Current immune therapeutic strategies in advanced or metastatic non-small-cell lung cancer. <i>Chinese Medical Journal</i> , 0, Publish Ahead of Print, .	2.3	1
2426	A case of acute myocarditis induced by PD-1 inhibitor (sintilimab) in the treatment of large cell neuroendocrine carcinoma. <i>Heliyon</i> , 2023, 9, e16874.	3.2	0
2427	Nivolumab-induced lichen planus responsive to dupilumab treatment in a patient with stageÂIII C melanoma. <i>JAAD Case Reports</i> , 2023, 38, 23-26.	0.8	2
2428	Immune-related adverse effects of checkpoint immunotherapy and implications for the treatment of patients with cancer and autoimmune diseases. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	6
2429	Cardiac monitoring of neoadjuvant chemotherapy in a patient with breast cancer. <i>Kardiologiya I Serdechno-Sosudistaya Khirurgiya</i> , 2023, 16, 309.	0.3	0
2430	Atezolizumab-associated myositis in a patient with unresectable hepatocellular carcinoma. <i>Journal of Oncology Pharmacy Practice</i> , 2023, 29, 1757-1761.	0.9	2
2431	Pneumonitis with combined immune checkpoint inhibitors and chemoradiotherapy in locally advanced non-small-cell lung cancer: a systematic review and meta-analysis. <i>Future Oncology</i> , 0, , .	2.4	1
2432	Computed tomography findings of hepatobiliary systems in patients with immune checkpoint inhibitor-induced liver injury. <i>Abdominal Radiology</i> , 0, , .	2.1	0
2433	Checkpoint inhibitors in older patients with advanced non-small cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 188, 104056.	4.4	0
2434	Pancreatic adverse events of immune checkpoint inhibitors therapy for solid cancer patients: a systematic review and meta-analysis. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	3
2435	Integrative analysis of risk factors for immune-related adverse events of checkpoint blockade therapy in cancer. <i>Nature Cancer</i> , 2023, 4, 844-859.	13.2	6
2436	latrogenic Conditions. , 2023, , 871-905.		0
2437	Immune Checkpoint Inhibitor-Induced Colitis: How Long Does the Threat Last?. <i>Cureus</i> , 2023, , .	0.5	0
2438	Evaluating Survival After Hospitalization Due to Immune-Related Adverse Events From Checkpoint Inhibitors. <i>Oncologist</i> , 0, , .	3.7	1
2439	Construction and Evaluation of Clinical Prediction Model for Immunotherapy-related Adverse Events and Clinical Benefit in Cancer Patients Receiving Immune Checkpoint Inhibitors Based on Serum Cytokine Levels. <i>Journal of Immunotherapy</i> , 2023, 46, 310-322.	2.4	1
2440	Temporary Severe Neutropenia during Administration of Atezolizumab: A Novel Case Report. <i>Case Reports in Oncology</i> , 0, , 387-392.	0.7	2

#	ARTICLE	IF	CITATIONS
2441	Infectious complications in patients with non-small cell lung cancer treated with immune checkpoint inhibitors. <i>Clinical Lung Cancer</i> , 2023, , .	2.6	1
2442	Balancing benefits and risks in lung cancer therapies: patient preferences for lung cancer treatment alternatives. <i>Frontiers in Psychology</i> , 0, 14, .	2.1	0
2443	3 i/4Žă...ç-«ăfă,šăffă,ăfă,ăfăf^é»ă³è-ăă%ă1/2œç”ç®iç†. <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , 2023, , .		
2444	Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitis. , 2023, 11, e007195.		0
2445	Predictors for the development of neurological immune-related adverse events of immune checkpoint inhibitors and impact on mortality. <i>European Journal of Neurology</i> , 2023, 30, 3221-3227.	3.3	3
2446	Cystatin C is glucocorticoid responsive, directs recruitment of Trem2+ macrophages, and predicts failure of cancer immunotherapy. <i>Cell Genomics</i> , 2023, , 100347.	6.5	2
2447	Nivolumab-induced tumour-like gastritis: A case report. <i>World Journal of Clinical Cases</i> , 0, 11, 4350-4359.	0.8	2
2448	Acute Liver Failure Guidelines. <i>American Journal of Gastroenterology</i> , 2023, 118, 1128-1153.	0.4	10
2449	Chapter 1: Evaluation of kidney function in patients undergoing anticancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022. <i>International Journal of Clinical Oncology</i> , 2023, 28, 1259-1297.	2.2	5
2450	Neurological adverse events associated with PD-1/PD-L1 immune checkpoint inhibitors. <i>Frontiers in Neuroscience</i> , 0, 17, .	2.8	1
2451	Risk factors for cardiovascular adverse events from immune checkpoint inhibitors. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
2452	Management and prediction of immune-related adverse events for PD1/PDL-1 immunotherapy in colorectal cancer. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	1
2453	Immune Checkpoint Inhibitor-Associated AKI: Debates in Diagnosis, Management, and Rechallenge. <i>Seminars in Nephrology</i> , 2022, 42, 151346.	1.6	1
2454	Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: An integrative review. <i>Journal of Oncology Pharmacy Practice</i> , 0, , 107815522311718.	0.9	0
2455	Endocrine side effects of immune checkpoint inhibitors. <i>Frontiers in Endocrinology</i> , 0, 14, .	3.5	7
2456	Acute respiratory distress syndrome and severe pneumonitis after atezolizumab plus bevacizumab for hepatocellular carcinoma treatment: A case report. <i>World Journal of Gastrointestinal Oncology</i> , 0, 15, 892-901.	2.0	2
2458	Functionally Masked Antibody to Uncouple Immune-Related Toxicities in Checkpoint Blockade Cancer Therapy. <i>ACS Nano</i> , 2023, 17, 10065-10077.	14.6	4
2459	Progress and Challenges of Immune Checkpoint Inhibitor-Induced Hypophysitis. <i>Journal of Clinical Medicine</i> , 2023, 12, 3468.	2.4	0



#	ARTICLE	IF	CITATIONS
2460	Clinical Characters and Influence Factors of Immune Checkpoint Inhibitor-related Thyroid Dysfunction. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2023, 108, 2916-2923.	3.6	1
2461	Immune checkpoint inhibitor-related myocarditis in thymic epithelial tumors: Recent progress and perspectives. , 2023, 2, .		0
2462	Translation and validation of chinese version of MDASI immunotherapy for early-phase trials module: a cross-sectional study. <i>BMC Nursing</i> , 2023, 22, .	2.5	0
2463	Safety profile of immune checkpoint inhibitors according to cancer type. <i>Bulletin Du Cancer</i> , 2023, 110, 825-835.	1.6	1
2464	Predicting response and toxicity to immune checkpoint inhibitors in lung cancer using antibodies to frameshift neoantigens. <i>Journal of Translational Medicine</i> , 2023, 21, .	4.4	3
2466	Pembrolizumab induced-C3 glomerulonephritis and RBC cast nephropathy: a case report. <i>BMC Nephrology</i> , 2023, 24, .	1.8	2
2467	Nivolumab-Induced Pneumonitis in a Patient With Urothelial Cancer. <i>Cureus</i> , 2023, , .	0.5	0
2468	Immune Checkpoint Inhibitor Rechallenge in a Patient With Previous Fulminant Myocarditis. <i>American Journal of Cardiology</i> , 2023, 199, 33-36.	1.6	1
2469	Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity. <i>Brain Communications</i> , 2023, 5, .	3.3	10
2470	Targeting the Interplay of Independent Cellular Pathways and Immunity: A Challenge in Cancer Immunotherapy. <i>Cancers</i> , 2023, 15, 3009.	3.7	2
2471	Role of Underlying Liver Pathology in the Development of Immune-Related Hepatitis: A Caseâ€“Control Study. <i>Targeted Oncology</i> , 2023, 18, 601-610.	3.6	0
2472	Pembrolizumab-Induced Adrenal Insufficiency Presenting Eight Months After Cessation of Treatment. <i>Cureus</i> , 2023, , .	0.5	0
2473	Side Effects of Biologic and Immunologic Therapies of Pediatric Cancer Management. , 2023, , 1-19.		0
2474	Analyzing fulminant myocarditis research trends and characteristics using the follower-leading clustering algorithm (FLCA): A bibliometric study. <i>Medicine (United States)</i> , 2023, 102, e34169.	1.0	7
2475	Treatment of Refractory Checkpoint-Inhibitor-Induced Hepatitis with Tacrolimus: A Case and Review of the Literature. <i>International Journal of Translational Medicine</i> , 2023, 3, 274-285.	0.4	0
2476	Rational design of PD-1-CD28 immunostimulatory fusion proteins for CAR T cell therapy. <i>British Journal of Cancer</i> , 2023, 129, 696-705.	6.4	2
2477	Tocilizumab in grade 4 hepatitis secondary to immune checkpoint inhibitor: a case report and review of the literature. <i>Immunotherapy</i> , 2023, 15, 1125-1132.	2.0	3
2478	Immune Checkpoint inhibitors in ovarian cancer. <i>Kazan Medical Journal</i> , 2023, 104, 584-589.	0.2	0

#	ARTICLE	IF	CITATIONS
2479	Managing Adverse Effects of Novel Therapeutic Agents in Gynecologic Malignancies. <i>SN Comprehensive Clinical Medicine</i> , 2023, 5, .	0.6	0
2480	A nomogram model for predicting the risk of checkpoint inhibitor-related pneumonitis for patients with advanced non-small-cell lung cancer. <i>Cancer Medicine</i> , 2023, 12, 15998-16010.	2.8	1
2481	Acid suppressants reduce the therapeutic effect of immune checkpoint inhibitors and increase the risk of acute kidney injury: a meta-analysis. <i>International Journal of Clinical Oncology</i> , 2023, 28, 1343-1353.	2.2	1
2482	Cutaneous immune-related adverse events to immune checkpoint inhibitors: from underlying immunological mechanisms to multi-omics prediction. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	1
2483	Bilateral Optic Neuritis and Hypophysitis With Diabetes Insipidus 1 Month After COVID-19 mRNA Vaccine: Case Report and Literature Review. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2023, 11, .	0.6	3
2484	Single-cell profiling reveals unique features of diabetogenic T cells in anti-PD-1-induced type 1 diabetes mice. <i>Journal of Experimental Medicine</i> , 2023, 220, .	8.5	4
2485	Editorial: Assessment and management of adverse drug reactions in oncology. <i>Frontiers in Allergy</i> , 0, 4, .	2.8	0
2486	Challenges for optimal care in onconephrology. <i>Nephrology Dialysis Transplantation</i> , 0, , .	0.7	0
2487	Immune checkpoint inhibitors promising role in cancer therapy: clinical evidence and immune-related adverse events. , 2023, 40, .		4
2488	Immunotherapy in combination with neoadjuvant anthracycline-free chemotherapy for triple-negative early breast cancer: A case report. <i>Oncology Letters</i> , 2023, 26, .	1.8	0
2489	Molecular Mechanisms of Cutaneous Immune-Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitors. <i>Current Oncology</i> , 2023, 30, 6805-6819.	2.2	3
2490	Prospective Clinical Trials to Advance the Study of Immune Checkpoint Inhibitor Toxicity. <i>Current Oncology</i> , 2023, 30, 6862-6871.	2.2	2
2491	Development of an eHealth-enhanced model of care for the monitoring and management of immune-related adverse events in patients treated with immune checkpoint inhibitors. <i>Supportive Care in Cancer</i> , 2023, 31, .	2.2	2
2492	Immunological mechanisms underlying clinical phenotypes and noninvasive diagnosis of immune checkpoint inhibitor-induced kidney disease. <i>Immunological Reviews</i> , 2023, 318, 61-69.	6.0	1
2493	Real-world adherence to toxicity management guidelines for immune checkpoint inhibitor-induced diabetes mellitus. <i>Frontiers in Endocrinology</i> , 0, 14, .	3.5	1
2494	Supportivtherapie in der Uroonkologie. <i>Springer Reference Medizin</i> , 2023, , 1281-1291.	0.0	0
2497	Six-week oral prednisolone therapy for immune-related pneumonitis: a single-arm phase II study. , 2023, 11, e007056.		1
2498	Evans syndrome during pembrolizumab therapy for upper urinary tract cancer. <i>IJU Case Reports</i> , 0, , .	0.3	0

#	ARTICLE	IF	CITATIONS
2499	A Systematic Review of Myocarditis Induced by Immune Checkpoint Inhibitors: How Concerning Is the Most Common Cardiotoxicity of Immune Checkpoint Inhibitors?. <i>Cureus</i> , 2023, , .	0.5	1
2500	Time-Course Progression of Whole Transcriptome Expression Changes of Trigeminal Ganglia Compared to Dorsal Root Ganglia in Rats Exposed to Nerve Injury. <i>Journal of Pain</i> , 2024, 25, 101-117.	1.4	0
2501	How detection of immune-related adverse events fails during transfer of patients between medical sectors. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	2.5	0
2502	Thrombotic risk of platinum combination chemotherapy with and without immune checkpoint inhibitors for advanced non-small cell lung cancer: a nationwide inpatient database study. <i>Cancer Immunology, Immunotherapy</i> , 0, , .	4.2	0
2503	Pulmonary sarcoidosis-like reactions induced by sintilimab in esophageal cancer: A case report. <i>Medicine (United States)</i> , 2023, 102, e34432.	1.0	1
2504	Autoimmunity in immune checkpoint inhibitor-induced immune-related adverse events: A focus on autoimmune skin toxicity and pneumonitis. <i>Immunological Reviews</i> , 2023, 318, 37-50.	6.0	2
2505	Immune checkpoint inhibitor-associated adrenal insufficiency in Chinese cancer patients: a retrospective analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 14113-14123.	2.5	1
2506	Endocrine Side Effects in Patients Treated with Immune Checkpoint Inhibitors: A Narrative Review. <i>Journal of Clinical Medicine</i> , 2023, 12, 5161.	2.4	3
2507	Cardiothoracic complications of immune checkpoint inhibitors. <i>Clinical Imaging</i> , 2023, 102, 98-108.	1.5	0
2508	Atezolizumab-induced encephalitis with subdural hemorrhage and subarachnoid hemorrhage in a patient with hepatocellular carcinoma. <i>Journal of the Formosan Medical Association</i> , 2023, , .	1.7	1
2509	Immune-related adverse events and outcomes among pan-cancer patients receiving immune checkpoint inhibitors: A monocentric real-world observational study. <i>Cancer Medicine</i> , 2023, 12, 18491-18502.	2.8	1
2510	Burden of grade 3 or 4 liver injury associated with immune checkpoint inhibitors. <i>JHEP Reports</i> , 2023, 5, 100880.	4.9	1
2511	T-cell tolerant fraction as a predictor of immune-related adverse events. , 2023, 11, e006437.		1
2512	Immune checkpoint inhibitor-associated myocarditis and fulminant type I diabetes in a patient with metastatic non-small cell lung cancer. <i>BMJ Case Reports</i> , 2023, 16, e255698.	0.5	1
2513	An Uncommon Case of Myocarditis Secondary to Durvalumab Plus Tremelimumab. <i>Cureus</i> , 2023, , .	0.5	0
2515	Imaging Assessment of Tumoral Response After Immunotherapy. , 2023, , 1-19.		0
2516	Update on Immunotherapy Cardiotoxicity: Checkpoint Inhibitors, CAR T, and Beyond. <i>Current Treatment Options in Oncology</i> , 0, , .	3.0	0
2517	Glucocorticoid Effect in Cancer Patients. <i>Methods in Molecular Biology</i> , 2023, , 339-352.	0.9	0

#	ARTICLE	IF	CITATIONS
2518	Role of echocardiography in patients treated with immune checkpoints inhibitors. <i>Journal of Echocardiography</i> , 0, .	0.8	0
2519	Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2023, 9, .	5.2	0
2520	Immune-Checkpoint Inhibitor-Related Myocarditis: Where We Are and Where We Will Go. <i>Angiology</i> , 0, .	1.8	0
2521	Radiological assessment of immunotherapy effects and immune checkpoint-related pneumonitis for lung cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2024, 28, .	3.6	1
2522	Pembrolizumab-Induced Rhabdomyolysis in a Clear Cell Renal Cell Carcinoma Patient: A Case Report. <i>Case Reports in Oncology</i> , 2023, 16, 728-733.	0.7	1
2523	Immune checkpoint inhibitor-associated myocarditis: a systematic analysis of case reports. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	1
2524	Ocular toxicities associated with antibody drug conjugates and immunotherapy in oncology: clinical presentation, pathogenesis, and management strategies. <i>Expert Opinion on Drug Safety</i> , 2023, 22, 921-928.	2.4	3
2525	A qualitative evaluation of a multi-modal cancer prehabilitation programme for colorectal, head and neck and lung cancers patients. <i>PLoS ONE</i> , 2023, 18, e0277589.	2.5	2
2526	HLA-DRB1*04:05 is involved in the development of Vogt-Koyanagi-Harada disease-like immune-related adverse events in patients receiving immune checkpoint inhibitors. <i>Scientific Reports</i> , 2023, 13, .	3.3	5
2527	Hematologic and Oncologic Aspects of Sarcoidosis. <i>Clinics in Chest Medicine</i> , 2024, 45, 119-129.	2.1	0
2528	Cardiovascular Toxicity Associated With Immune Checkpoint Inhibitor Therapy: A Comprehensive Review. <i>Critical Pathways in Cardiology</i> , 2023, 22, 69-82.	0.5	1
2529	Case Report: Immune checkpoint inhibitor-induced multiorgan vasculitis successfully treated with rituximab. , 0, 3, .		0
2530	Case Report: Keratoacanthoma and type I diabetes secondary to treatment with PM8001, a bifunctional fusion protein targeting TGF- $\beta$ 2 and PD-L1. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	2
2531	T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy. , 2023, 11, e007236.		3
2533	Myositis, myasthenia gravis, polyneuropathy and myocarditis: A life-threatening tetrad due to pembrolizumab. , 2023, 1, 100002.		0
2535	The Revolution of Lung Cancer Therapeutics. , 2023, , 235-249.		0
2536	Anti-PD-1/PD-L1 and anti-CTLA-4 associated checkpoint inhibitor pneumonitis in non-small cell lung cancer: Occurrence, pathogenesis and risk factors (Review). <i>International Journal of Oncology</i> , 2023, 63, .	3.3	0
2537	Pembrolizumab-Induced Myasthenia Gravis and Peripheral Neuropathy: A Case Series. <i>Cureus</i> , 2023, , .	0.5	0

#	ARTICLE	IF	CITATIONS
2538	Antineoplastic drugs inducing cardiac and vascular toxicity – An update. <i>Vascular Pharmacology</i> , 2023, 153, 107223.	2.1	2
2539	Pre-Existing Interstitial Lung Abnormalities in Patients with Head and Neck Squamous Cell Carcinoma and Their Follow Up after Therapy. <i>Diagnostics</i> , 2023, 13, 2908.	2.6	0
2540	Serious immune-related upper gastrointestinal toxicity of immune checkpoint inhibitors: a multicenter case series. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2023, 38, 2104-2110.	2.8	2
2541	Clinical characteristics and treatment efficacy of immune checkpoint inhibitors (ICIs) in patients with ICIs-induced Adrenal insufficiency. <i>Translational Oncology</i> , 2023, 38, 101787.	3.7	1
2542	A Case of Delayed Immune Checkpoint Inhibitor Hepatitis in a Patient with Malignant Melanoma. <i>Galician Medical Journal</i> , 0, , .	0.3	0
2543	Immunotherapy for Non-small Cell Lung Cancer. , 2023, , 1-25.		0
2544	The role of corticosteroids in the palliation of dyspnea in cancer patients: an evidence-based review. <i>Current Opinion in Supportive and Palliative Care</i> , 2023, 17, 270-276.	1.3	0
2545	Immune checkpoint inhibitors in bone metastasis: Clinical challenges, toxicities, and mechanisms. <i>Journal of Bone Oncology</i> , 2023, 43, 100505.	2.4	1
2546	Prognostic Impact of Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab: A Multicenter Retrospective Study. <i>Clinical Genitourinary Cancer</i> , 2024, 22, 76-83.	1.9	1
2547	Focus on Immune Checkpoint Inhibitors-related Intestinal Inflammation: From Pathogenesis to Therapeutical Approach. <i>Inflammatory Bowel Diseases</i> , 0, , .	1.9	1
2549	Uveitis associated with immune checkpoint inhibitors or BRAF/MEK inhibitors in patients with malignant melanoma. <i>Melanoma Research</i> , 0, , .	1.2	0
2550	Concurrent Nivolumab-Induced Gastritis and Cholangitis Accompanied by Biliary Tract Hemorrhage in a Patient With Stage IV Lung Adenocarcinoma. <i>Cureus</i> , 2023, , .	0.5	0
2552	Onset of Psoriasis with Immune Checkpoint Inhibitor Therapy: A Systematic Review. <i>Journal of the American Academy of Dermatology</i> , 2023, , .	1.2	0
2553	ΔjΔμÑ€ΔμÑ†Δ½Δ¾-ÑΔ¾ÑÑfΔ,ÑÑ,Ñ<Δμ Δ¾Ñ»Δ¾Δ½ΔμΔ½Δ,Ñ•Δ¾¼Δ¾¼ÑfΔ½Δ¾¼Ñ,ΔμÑ€ΔμΔ¿Δ¿,Δ¼ΔμΔ¾¼Δ°Ñ,Δ¾¼Δ¾¾»		
2554	ATP protects anti-PD-1/radiation-induced cardiac dysfunction by inhibiting anti-PD-1 exacerbated cardiomyocyte apoptosis, and improving autophagic flux. <i>Heliyon</i> , 2023, 9, e20660.	3.2	0
2557	Shedding light on the side effects of immunotherapies used for leukemia: an updated review of the literature. <i>Expert Review of Anticancer Therapy</i> , 2023, 23, 1193-1204.	2.4	0
2559	Successful treatment of refractory checkpoint inhibitor-induced hepatitis with quadruple therapy including extracorporeal photopheresis and infliximab. , 2024, 3, 317-320.		0
2560	Drug-induced liver injury: diagnosis of exclusion. <i>Terapevticheskie Arkhiv</i> , 2023, 95, 611-620.	0.8	0

#	ARTICLE	IF	CITATIONS
2561	Thyroid Storm and Type 1 Diabetes Mellitus Induced by Combined Ipilimumab and Nivolumab Immunotherapy: A Case Report. <i>Cureus</i> , 2023, , .	0.5	0
2562	The Prevalence and Patterns of Toxicity With Immune Checkpoint Inhibitors in Solid Tumors: A Real-World Experience From a Tertiary Care Center in Oman. <i>Cureus</i> , 2023, , .	0.5	0
2563	A phase 1a/1b first-in-human study (COMPASSION-01) evaluating cadonilimab in patients with advanced solid tumors. <i>Cell Reports Medicine</i> , 2023, 4, 101242.	6.5	3
2564	Immune-related adverse events of anti-PD-1 immune checkpoint inhibitors: a single center experience. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
2565	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0. , 2023, 11, e006947.		1
2566	Patterns for modeling process variability in a healthcare context. <i>Business Process Management Journal</i> , 0, , .	4.2	0
2567	Biopsy-proven acute tubulointerstitial nephritis in patients treated with immune checkpoint inhibitors: a pooled analysis of case reports. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	1
2568	The colitis may be microscopic, but the diarrhea is not: update on the treatment of microscopic colitis and immune checkpoint inhibitor colitis. <i>Current Opinion in Gastroenterology</i> , 0, , .	2.3	0
2569	The need for ambulatory emergency oncology: exemplified by the management of immune checkpoint inhibitor toxicity. <i>Supportive Care in Cancer</i> , 2023, 31, .	2.2	0
2570	Clinically Approved Monoclonal Antibodiesâ€‘based Immunotherapy: Association With Glycemic Control and Impact Role of Clinical Pharmacist for Cancer Patient Care. <i>Clinical Therapeutics</i> , 2024, 46, e29-e44.	2.5	1
2571	Pulmonary Toxicity Associated with Immune Checkpoint Inhibitors-Based Therapy: Current Perspectives and Future Directions. <i>Drug Safety</i> , 2023, 46, 1313-1322.	3.2	1
2572	Guillainâ€‘Barre syndrome in children. <i>Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova</i> , 2023, 123, 20.	0.7	0
2573	Immune Checkpoint Inhibitors and Their Cardiovascular Adverse Effects. <i>Oncology Reviews</i> , 0, 17, .	1.8	1
2574	Safety of Immunomodulatory Systemic Therapies Used in the Management of Immune-Related Cutaneous Adverse Events. <i>Pharmaceuticals</i> , 2023, 16, 1610.	3.8	0
2575	How to recognize and manage skin toxicities associated with immune checkpoint inhibitors: a practical approach. <i>British Journal of Dermatology</i> , 2023, 189, i3-i10.	1.5	0
2576	A case of successful treatment with eltrombopag for severe immune-related thrombocytopenia induced by atezolizumab:Case report. <i>Journal of Medical Investigation</i> , 2023, 70, 516-520.	0.5	1
2577	Immune checkpoint inhibitors as potential therapy for reverting T-cell exhaustion and reverting HIV latency in people living with HIV. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	1
2578	Clinical characteristics and potential biomarkers of thyroid and pituitary immune-related adverse events. <i>Endocrine Journal</i> , 2023, , .	1.6	0

#	ARTICLE	IF	CITATIONS
2579	The Role of Antibody-Based Therapies in Neuro-Oncology. <i>Antibodies</i> , 2023, 12, 74.	2.5	0
2580	A comprehensive review on immune checkpoint inhibitors induced cardiotoxicity characteristics and associated factors. <i>European Journal of Medical Research</i> , 2023, 28, .	2.2	0
2581	Evidence to Date: Clinical Utility of Tremelimumab in the Treatment of Unresectable Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 10, 1911-1922.	3.7	0
2582	Impact of Immune Checkpoint Inhibitor Therapy on Quality of Life in Patients With Advanced Melanoma. <i>Cancer Nursing</i> , 0, , .	1.5	0
2583	Survival Among Veterans Receiving Steroids for Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy. <i>JAMA Network Open</i> , 2023, 6, e2340695.	5.9	1
2584	Optimizing outcomes for high-risk, non-muscle-invasive bladder cancer: The evolving role of PD-(L)1 inhibition. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2023, 41, 461-475.	1.6	0
2585	Registry study of immune-related adverse events using electronic patient-reported outcome in patients with cancer receiving immune checkpoint inhibitors: protocol for a multicentre cohort study. <i>BMJ Open</i> , 2023, 13, e073724.	1.9	0
2586	The association between aspirin use and immune-related adverse events in specific cancer patients receiving ICIs therapy: analysis of the FAERS database. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	1
2587	Clinical characteristics and outcomes of patients with primary liver cancer and immune checkpoint inhibitor-associated adrenal insufficiency: A retrospective cohort study. <i>International Immunopharmacology</i> , 2024, 127, 111337.	3.8	0
2588	Neurological complications of cancer immunotherapy. <i>Neurologie Pro Praxi</i> , 2023, 24, 354-358.	0.1	0
2589	Effects of Early Short-Course Corticosteroids on Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors. <i>Oncology</i> , 0, , 1-9.	1.9	0
2590	Efficacy and Safety of Atezolizumab Monotherapy or Combined Therapy with Chemotherapy in Patients with Metastatic Triple-negative Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials. <i>Current Pharmaceutical Design</i> , 2023, 29, 2461-2476.	1.9	1
2591	Effects of glucocorticoid use on survival of advanced non-small-cell lung cancer patients treated with immune checkpoint inhibitors. <i>Chinese Medical Journal</i> , 2023, 136, 2562-2572.	2.3	0
2593	Sintilimab-related diabetes mellitus and psoriasis: A case report and literature review. <i>Medicine (United States)</i> , 2023, 102, e35946.	1.0	1
2594	Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours. <i>Journal of Hepatology</i> , 2024, 80, 431-442.	3.7	1
2595	Eosinophil may be a predictor of immune-related adverse events induced by different immune checkpoint inhibitor types: A retrospective multidisciplinary study. <i>Cancer Medicine</i> , 0, , .	2.8	0
2596	Adverse renal effects of check-point inhibitors (ICI) in cancer patients: Recommendations of the Onco-nephrology Working Group of the Spanish Society of Nephrology. <i>Nefrologia</i> , 2023, 43, 622-635.	0.4	0
2597	Programmed Death Ligand 1 Expressing Macrophages and Their Protective Role in the Joint During Arthritis. <i>Arthritis and Rheumatology</i> , 0, , .	5.6	1





#	ARTICLE	IF	CITATIONS
2616	Immune Checkpoint Inhibitors-Associated Myocarditis: Diagnosis, Treatment and Current Status on Rechallenge. <i>Journal of Clinical Medicine</i> , 2023, 12, 7737.	2.4	0
2617	Hypopituitarism induced by pembrolizumab plus axitinib in the treatment of metastatic renal cell carcinoma: A case report. <i>Oncology Letters</i> , 2023, 27, .	1.8	1
2618	Immunotherapy-associated symptoms, distress, financial toxicity and unmet supportive care needs of patients with cancer. <i>European Journal of Oncology Nursing</i> , 2024, 68, 102486.	2.1	0
2619	Successful Rechallenge of Trastuzumab Deruxtecan After Drug-Induced Interstitial Lung Disease in a NSCLC With HER2 Mutation: A Case Report. <i>JTO Clinical and Research Reports</i> , 2024, 5, 100628.	1.1	0
2620	Immune Checkpoint Inhibition. , 2024, , 1-91.		0
2621	Seasonal patterns of toxicity in melanoma patients treated with combination anti-PD-1 and anti-CTLA-4 immunotherapy. <i>European Journal of Cancer</i> , 2023, , 113506.	2.8	0
2622	Nephrotoxicity in the Age of Immune Checkpoint Inhibitors: Mechanisms, Diagnosis, and Management. <i>International Journal of Molecular Sciences</i> , 2024, 25, 414.	4.1	0
2623	Immune checkpoint inhibitor-induced epidermal necrolysis: A narrative review evaluating demographics, clinical features, and culprit medications. <i>Journal of Dermatology</i> , 2024, 51, 3-11.	1.2	0
2624	Concentrations of S100B and neurofilament light chain in blood as biomarkers for checkpoint inhibitor-induced CNS inflammation. <i>EBioMedicine</i> , 2024, 100, 104955.	6.1	1
2625	Immunotherapy in hepatocellular carcinoma: an overview of immune checkpoint inhibitors, drug resistance, and adverse effects. <i>Oncology</i> , 2024, 26, 9-25.	0.7	0
2626	Refining mutanome-based individualised immunotherapy of melanoma using artificial intelligence. <i>European Journal of Medical Research</i> , 2024, 29, .	2.2	0
2627	Protective effect of low-intensity pulsed ultrasound on immune checkpoint inhibitor-related myocarditis via fine-tuning CD4+ T-cell differentiation. <i>Cancer Immunology, Immunotherapy</i> , 2024, 73, .	4.2	0
2628	Management of Paraneoplastic Syndromes in the Era of Immune Checkpoint Inhibitors. <i>Current Treatment Options in Oncology</i> , 2024, 25, 42-65.	3.0	0
2629	Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH-AEG-SEPD-SEOM-GETECCU. <i>Revista Espanola De Enfermedades Digestivas</i> , 2024, , .	0.3	0
2630	Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH-AEG-SEPD-SEOM-GETECCU. <i>GastroenterologÃa Y HepatologÃa</i> , 2024, 47, 401-432.	0.5	0
2631	Gut microbiota influences the efficiency of immune checkpoint inhibitors by modulating the immune system (Review). <i>Oncology Letters</i> , 2024, 27, .	1.8	0
2632	Health-related quality of life and its influencing factors among lung cancer patients receiving immune checkpoint inhibitors: A cross-sectional study. <i>European Journal of Oncology Nursing</i> , 2024, 68, 102507.	2.1	0
2633	Association between immune checkpoint inhibitor medication and uveitis: a population-based cohort study utilizing TriNetX database. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0

#	ARTICLE	IF	CITATIONS
2634	Combined Stereotactic Body Radiation Therapy and Immune Checkpoint Inhibition for Liver Metastases: Safety and Outcomes in a Pooled Analysis of 3 Phase 1 Trials. <i>International Journal of Radiation Oncology Biology Physics</i> , 2024, 118, 1519-1530.	0.8	0
2635	Pan-cancer assessment of antineoplastic therapy-induced interstitial lung disease in patients receiving subsequent therapy immediately following immune checkpoint blockade therapy. <i>Respiratory Research</i> , 2024, 25, .	3.6	0
2636	Immunotherapy Combined with Radiation in Malignant Melanoma without BRAF Mutations Brain Metastasesâ€”Favorable Response after Immunotherapy Continued beyond Progression. <i>Journal of Personalized Medicine</i> , 2024, 14, 86.	2.5	0
2637	Adrenal crisis mainly manifested as recurrent syncope secondary to tislelizumab: a case report and literature review. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	1
2638	Immunosuppression management for refractory checkpoint inhibitor-related hepatotoxicity. <i>Clinical Liver Disease</i> , 2024, 23, .	2.1	0
2639	Clinicopathological features of kidney injury in patients receiving immune checkpoint inhibitors (ICPi) combined with anti-vascular endothelial growth factor (anti-VEGF) therapy. <i>Journal of Clinical Pathology</i> , 0, , jcp-2023-209173.	2.0	0
2640	Primary multiple endocrine insufficiency during immune checkpoint inhibitor treatment: A case report. <i>Medicine (United States)</i> , 2024, 103, e36998.	1.0	1
2641	Advances and challenges of first-line immunotherapy for non-small cell lung cancer: A review. <i>Medicine (United States)</i> , 2024, 103, e36861.	1.0	0
2642	Cardiac magnetic resonanceâ€”based layerâ€”specific strain in immune checkpoint inhibitorâ€”associated myocarditis. <i>ESC Heart Failure</i> , 2024, 11, 1061-1075.	3.1	0
2643	Steroid hormones and infection and immunity. , 2024, , 79-105.		0
2644	Cancer immunotherapy-associated endocrine complications and treatment strategies. , 2024, , 199-221.		0
2645	Orofacial complications from immune checkpoint inhibitors: A retrospective analysis from two academic medical centers. <i>Head and Neck</i> , 0, , .	2.0	0
2646	Clinical characteristics, diagnosis and management of nivolumab-induced myocarditis. <i>Investigational New Drugs</i> , 2024, 42, 116-126.	2.6	0
2647	How to deal with renal toxicities from immune-based combination treatments in metastatic renal cell carcinoma. A nephrological consultation for Oncologists. <i>Cancer Treatment Reviews</i> , 2024, 125, 102692.	7.7	0
2648	Distinguishing immune checkpoint inhibitor-related pneumonitis from radiation pneumonitis by CT radiomics features in non-small cell lung cancer. <i>International Immunopharmacology</i> , 2024, 128, 111489.	3.8	0
2649	Immune Checkpoint Inhibitor-Associated Myocarditis: A Literature Review. <i>Cureus</i> , 2024, , .	0.5	0
2651	Detection and evaluation of signals for immune-related adverse events: a nationwide, population-based study. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
2652	Dynamic immune signatures of patients with advanced nonâ€”small-cell lung cancer for infection prediction after immunotherapy. <i>Frontiers in Immunology</i> , 0, 15, .	4.8	0

#	ARTICLE	IF	CITATIONS
2654	Multidisciplinary insight for managing immune checkpoint inhibitor-related myocarditis: a case report. <i>Medical Biological Science and Engineering</i> , 2024, 7, 47-50.	0.2	0
2655	Predictors of persistence of post-chemotherapy symptoms among survivors of solid tumor cancers. <i>Quality of Life Research</i> , 2024, 33, 1143-1155.	3.1	0
2657	Diagnosing and Managing Uveitis Associated with Immune Checkpoint Inhibitors: A Review. <i>Diagnostics</i> , 2024, 14, 336.	2.6	0
2658	Immune checkpoint inhibitors associated cardiovascular immune-related adverse events. <i>Frontiers in Immunology</i> , 0, 15, .	4.8	0
2660	A case of eosinophilic gastroenteritis developed during administration of nivolumab for a patient with platinum-resistant head and neck cancer. <i>Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology</i> , 2024, , .	0.3	0
2661	Thyroid disorders induced by immune checkpoint inhibitors. <i>Endocrine</i> , 0, , .	2.3	0
2662	Achillesâ€™ Heel of currently approved immune checkpoint inhibitors: immune related adverse events. <i>Frontiers in Immunology</i> , 0, 15, .	4.8	0
2663	Tumor- und therapieassoziierte NotfÄlle. , 2024, , 305-329.		0
2664	Immune checkpoint inhibitor-related pneumonitis: research advances in prediction and management. <i>Frontiers in Immunology</i> , 0, 15, .	4.8	0
2665	Pembrolizumab-induced secondary adrenal insufficiency due to adrenocorticotrophic hormone deficiency in a patient with non-small-cell lung carcinoma: a case report. <i>Journal of Pharmaceutical Health Care and Sciences</i> , 2024, 10, .	1.0	0
2666	Treatment patterns and outcomes of high-grade immune checkpoint inhibitor-related pneumonitis in an oncology hospitalist service. <i>Supportive Care in Cancer</i> , 2024, 32, .	2.2	0
2667	Nivolumab Toxicity Meets Leptomeningeal Carcinomatosis: A Case Report. <i>Journal of Medical Clinical Case Reports</i> , 0, , .	0.0	0
2668	Diagnosis and management of immune mediated liver injury from checkpoint inhibitors. <i>Current Opinion in Gastroenterology</i> , 2024, 40, 164-171.	2.3	0
2669	New strategies in the diagnosis and treatment of immune-checkpoint inhibitor-mediated colitis. <i>World Journal of Clinical Cases</i> , 0, 12, 1050-1062.	0.8	0
2670	Immune checkpoint inhibitors and acute kidney injury. <i>Frontiers in Immunology</i> , 0, 15, .	4.8	0
2671	Bilateral keratitis associated with afatinib therapy. <i>Taiwan Journal of Ophthalmology</i> , 2024, 14, 121-124.	0.7	0
2672	Infusion-Related Reactions Induced by Cadonilimab (PD-1/CTLA-4 Bispecific Antibody): Seven Case Reports. <i>Case Reports in Oncology</i> , 2024, 17, 361-369.	0.7	0
2673	Effectiveness and Safety of Immune Checkpoint Inhibitors in Older Cancer Patients. <i>Journal of Personalized Medicine</i> , 2024, 14, 278.	2.5	0

#	ARTICLE	IF	CITATIONS
2674	Immune checkpoint inhibitors in high-grade upper tract urothelial carcinoma: Paradigm shift emphasizing organ preservation. <i>BJUI Compass</i> , 0, , .	1.3	0
2676	Anterior Uveitis Secondary to Avelumab and Pembrolizumab in a Patient with Metastatic Renal Cell Carcinoma—A Case Report. <i>Reports</i> , 2024, 7, 19.	0.5	0
2677	New advances in the study of PD-1/PD-L1 inhibitors-induced liver injury. <i>International Immunopharmacology</i> , 2024, 131, 111799.	3.8	0
2679	Knowledge domains and emerging trends in immune-related adverse events from immune checkpoint inhibitors: A bibliometrics and visualized analysis. <i>Heliyon</i> , 2024, 10, e27832.	3.2	0
2680	Enterocolitis and other immunotherapy and targeted therapy-related gastrointestinal manifestations: A review for gastroenterologist. <i>Revista De Gastroenterología De México (English Edition)</i> , 2024, 89, 89-105.	0.2	0
2681	Immune-mediated hepatitis: Basic concepts and treatment. <i>Revista De Gastroenterología De México (English Edition)</i> , 2024, 89, 106-120.	0.2	0
2682	Immune-Related Adverse Event-Related Adrenal Insufficiency Mediates Immune Checkpoint Inhibitors Efficacy in Cancer Treatment. <i>Cancer Management and Research</i> , 0, Volume 16, 151-161.	1.9	0
2683	Hematologic malignancies and hematopoietic stem cell transplantation. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2024, , 419-429.	1.8	0
2684	Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer. <i>British Journal of Cancer</i> , 0, , .	6.4	0
2685	Analysis of disulfidptosis and cuproptosis-related LncRNAs in modulating the immune microenvironment and chemosensitivity in colon adenocarcinoma. <i>IET Systems Biology</i> , 2024, 18, 55-75.	1.5	0
2686	Fertility and reproductive concerns related to the new generation of cancer drugs and the clinical implication for young individuals undergoing treatments for solid tumors. <i>European Journal of Cancer</i> , 2024, 202, 114010.	2.8	0
2687	Acute kidney injury in patients treated with immune checkpoint inhibitors: a single-center retrospective study. <i>Renal Failure</i> , 2024, 46, .	2.1	0
2688	Univariable and multivariable Mendelian randomization study identified the key role of gut microbiota in immunotherapeutic toxicity. <i>European Journal of Medical Research</i> , 2024, 29, .	2.2	0
2689	The role of immune checkpoint inhibitors in the development and treatment of infectious processes. <i>Journal of Clinical Practice</i> , 2024, 15, 91-106.	0.6	0
2690	Colitis due to cancer treatment with immune check-point inhibitors – review of literature and presentation of clinical cases. <i>Radiology and Oncology</i> , 2024, .	1.7	0
2691	Severe autoimmune hemolytic anemia following immunotherapy with checkpoint inhibitors in two patients with metastatic melanoma: a case report. <i>Frontiers in Immunology</i> , 0, 15, .	4.8	0